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Zussamenfassung 
Ilona Bułyszko 
Studien zu Ansamycin Antibiotika: Mutasynthetischer Ansatz zu neuen Rifamycin-
Derivaten und Totalsynthese von Progeldanamycin-Derivaten 
Schlagworte: Rifamycin, Geldanamycin, Totalsynthese, Mutasynthese, Polyketidsynthase 
Die Ansamycin Antibiotika sind Makrolactampolyketide, bestehend aus einer aliphatischen 
Brücke (lat. ansa = Henkel), welche in zwei nicht-benachbarten Positionen Benzyl- und 
Naphthylgruppen enthalten. Naphthalen enthaltene Ansamycine (z. B. Rifamycin) weisen 
überwiegend antimikrobielle Aktivitäten auf, während Benzol enthaltene Ansamycine (z. B. 
Geldanamycin) antikanzerogene Eigenschaften besitzen. Beide Vertreter der Ansamycin 
Antibiotika, Rifamycin und Geldanamycin, werden über eine Typ I Polyketidsynthase (PKS), 
ausgehend von 3-Amino-5-hydroxybenzoesäure (AHBA), biosynthetisiert. 
Im ersten Teil dieser Doktorarbeit wurde, unter Verwendung des Konzepts der Mutasynthese, 
das synthetische Potential der (AHBA)-Blockmutante A. mediterranei HGF003, welche 
Rifamycin B produziert, untersucht. Dreißig, verschieden substituierte und funktionalisierte 
Benzoesäuren, wurden der Blockmutante supplementiert, wobei dreizehn Tetraketide gebildet 
und isoliert wurden. Obwohl die isolierten 2H-Pyran-2-on-Derivate keine biologischen 
Aktivitäten aufweisen, können einige von ihnen als chirale Bausteine für die Synthese von 
komplexeren Intermediaten verwendet werden. Die Resultate offenbaren eine hohe Toleranz 
der Rifamycin Ladungsdomäne für unnatürliche Benzoesäuren und eine hohe 
Substratspezifität der bei der Naphthalenbildung beteiligten Enzyme. Zusätzlich enthüllen die 
Fütterungsexperimente mit Azid- und Nitroanaloga von AHBA, die einzigartigen reduktiven 
Eigenschaften von A. mediterranei bezogen auf Arylazide und Nitroarene. Dies ist bisher erst 
die zweite literaturbekannte mikrobielle Quelle, welche reduktive Eigenschaften besitzt. 
Im zweiten Teil dieser Arbeit wurden Untersuchungen zur Synthese von vier seco-
Progeldanamycinsäure-Derivaten vorgestellt, von denen ein seco-Progeldanamycin 
erfolgreich dargestellt werden konnte. Dieses Derivat wird als Substrat für Studien zur 
Flexibilität der Amidsynthase (GdmF), einem Schlüsselenzym in der Geldanamycin 
Biosynthese, welcher für die Makrolactamisierung zuständig ist, benutzt werden, um die 
Toleranz und die biosynthetische Umwandlung des Enzyms zu untersuchen. Zusätzlich 
konnten auch die SNAc-Ester zu einem Knockout Stamm von S. hygroscopicus var. geldanus 
(K-390-61-1) supplementiert werden, um neue Geldanamycin-Derivate zu erhalten. 
 
 
  
 
 
Abstract 
Ilona Bułyszko 
Studies on Ansamycin Antibiotics: Mutasynthetic Approach Towards  
New Rifamycin Derivatives and Total Synthesis of Progeldanamycin Derivatives 
Keywords: rifamycin, geldanamycin, total synthesis, mutasynthesis, polyketide synthase 
The ansamycin antibiotics are macrolactam polyketides consisting of an aliphatic bridge 
linking two non-adjacent positions of a benzenic or naphthalenic moiety (from the Latin ansa 
means a handle). Naphthalenic ansamycins (e.g. rifamycins) exhibit mainly antimicrobial 
activities, while benzenic ansamycins (e.g. geldanamycin) display anticancer properties. Both 
representatives of the ansamycin antibiotics, rifamycin and geldanamycin, are synthesized by 
type I polyketide synthase (PKS) assembled from 3-amino-5-hydroxybenzoic acid (AHBA). 
In the first part of this doctoral thesis the synthetic potential of the AHBA(−) mutant strain of  
A. mediterranei HGF003, the producer of rifamycin B, has been evaluated using the concept 
of mutasynthesis. Thirty differently substituted and functionalized benzoic acids were fed to 
the mutant strain resulting in the formation and the isolation of thirteen tetraketides. Although 
the isolated 2H-pyran-2-one derivatives do not display any biological activity, some of them 
can be employed as chiral building blocks in the synthesis of more advanced intermediates. 
These results revealed high tolerance of the rifamycin loading domain to unnatural benzoic 
acids and high substrate specificity of the enzymes involved in naphthalene formation. 
Additionally, feeding experiments with azido- and nitro analogues of AHBA unveiled unique 
reductive properties of A. mediterranei towards aryl azides and nitroarenes. It has been the 
second microbial source possessing reductive properties towards azidoarenes reported so far 
in the literature. 
In the second part of this work the synthesis of four seco-progeldanamycin acid derivatives 
was studied, out of which one seco-progeldanamycin acid derivative has been successfully 
synthesized. It will be used as a substrate in the studies on the flexibility of the amide 
synthase (GdmF), a key enzyme in the geldanamycin biosynthesis responsible for the 
macrolactamization, to investigate the tolerance and biosynthetic transformation by the 
enzyme. Additionally, the prepared SNAc ester could be fed to a knockout strain of  
S. hygroscopicus var. geldanus (K-390-61-1) to obtain new geldanamycin derivative. 
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1 Rifamycins 
1.1 Introduction 
The ansamycins comprise a class of macrolactam polyketides which exhibit a broad spectrum 
of antimicrobial activity against Gram-positive and some Gram-negative bacteria and are used 
as antibiotics, anticancer agents and enzyme inhibitors.
[1]
 The name of ansamycins has an 
origin in the latin word ansa which means “a handle” – in this case represented by an aliphatic 
bridge linking two non-adjacent positions of a benzenic or naphthalenic moiety  
(Figure 1).
[2–4]
 Naphthalenic ansamycins (rifamycins, streptovaricins, naphthomycins) display 
mainly antimicrobial activities, while benzenic ansamycins (geldanamycin, ansamitocin, 
ansatrienine) demonstrate anticancer properties.
[1,4]
 
 
Figure 1. Structures of ansamycin antibiotics. 
A structural component typical of all ansamycin antibiotics is the so-called mC7N unit 
consisting of a six-membered carbocycle, usually aromatic or quinoid, bearing extra carbon 
and nitrogen atom in a meta arrangement.
[3,5–7]
 Studies on the biosynthesis of rifamycins 
carried out independently by two research groups in 1981 revealed 3-amino-5-
hydroxybenzoic acid (AHBA, 7) as a specific precursor of the mC7N unit. 
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Scheme 1. The shikimate pathway and the aminoshikimate pathway of AHBA formation.[3] 
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In 1981 Ghisalba and Nüesch published the results of the feeding experiments with the use of 
a mutant of Amycolatopsis mediterranei blocked in an early step of the rifamycin 
biosynthesis.
[8]
 They found that supplementation with the compound 7 restored rifamycin 
production in the mutant strain. In the same year the Rickards group performed feeding 
experiments with 
14
C and 
13
C-labeled AHBA which showed that compound 7 was efficiently 
incorporated into the mC7N unit of actamycin, rifamycin, ansamitocin and mitomycin.
[9–11]
 In 
the following years the incorporation of AHBA into the benzenic ansamycins was 
reported.
[12–14]
 However, all the published results did not explain the formation of 3-amino-5-
hydroxybenzoic acid in the shikimate pathway (Scheme 1). The key question was whether the 
nitrogen atom present in AHBA was attached to C-3 or C-5 of the cyclic shikimate pathway 
intermediates. According to the work of Hornemann and co-workers,
[15]
 the origin of the 
AHBA related to the aminoshikimate pathway was proposed. Erythrose-4-phosphate (E4P) 
was suggested to react with the ammonia generated in situ by hydrolysis of glutamine, to form 
an imine which is condensed with phosphoenolpyruvate (PEP) to give aminoDAHP - a key 
intermediate in the synthesis of AHBA. Cyclization to aminoDHQ and the following 
dehydration were proposed to provide aminoDHS which is aromatized to AHBA. The 
aminoshikimate pathway was proven by the preparation of the three postulated intermediates 
which were used for incubation with cell-free extracts of the rifamycin producer − A. 
mediterranei. The observed conversion of all of these compounds to AHBA (aminoDAHP 
45%, aminoDHQ 41%, aminoDHS 100%) and no conversion of DAHP supported the 
hypothetical aminoshikimate pathway.
[5]
 
The complete pathway of AHBA formation was published by Floss and co-workers in  
2011 (Scheme 1).
[3]
 Studies on the gene clusters of AHBA synthesis revealed that kanosamine 
is a nitrogenous precursor. This compound is then phosphorylated and converted by a set of 
enzymes into 1-deoxy-1-imino-erythrose-4-phosphate – a substrate for the aminoDAHP 
formation. The further steps from the stage of aminoDAHP to AHBA in the aminoshikimate 
pathway were validated. 
1.1.1 General Information about Rifamycins 
The rifamycins belong to the group of naphthalenic ansamycins and were first isolated in 
1957 from a fermentation culture of Amycolatopsis mediterranei (previously classified as 
Streptomyces mediterranei or Nocardia mediterranei) by Sensi and co-workers at the 
laboratory of Gruppo Lepetit in Milan, Italy, as a mixture of several congeners. In 1973 White 
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and co-workers established the biosynthetic origin of rifamycin S and proposed a general 
scheme for the ansamycin biogenesis based on NMR studies with 
13
C-enriched precursors.
[16]
 
 
Scheme 2. Conversion of rifamycin B to rifamycin SV and examples of clinically used rifamycin 
derivatives.[2] 
The rifamycins display antimicrobial activity against Gram-positive bacteria, particularly 
mycobacteria and some Gram-negative bacteria. Rifamycin B (1) which is the main product 
of the commercial fermentation and exhibits only slight activity can be converted chemically, 
enzymatically or by biotransformation to the active rifamycin SV (10, Scheme 2), the first 
clinically used rifamycin.  
 
Figure 2. Clinically used rifamycin derivatives. 
Another compound with enhanced activity against Gram-positive bacteria is rifampicin (11) 
almost always used along with other antibiotics. It displays good activity also against Gram-
negative bacteria and excellent oral bioavailability. Deemed one of the most in-demand 
medications nowadays, rifampicin is used in the treatment of tuberculosis, leprosy, 
Legionnaire’s disease and AIDS-associated microbacterial infections called Mycobacterium 
avium complex (MAC).
[17]
 The antibiotic 11 is also known for its ability to inhibit multidrug 
resistance by enhancing the anticancer drug’s accumulation in cancer cells.[18,19] Following 
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the clinical introduction of rifamycin SV and rifampicin other rifamycin derivatives: 
rifabutine (12) and rifapentine (13, Figure 2) were successfully tested and brought to the 
market.
[2]
 
1.1.2 Mechanism of Action 
The rifamycins display their activity through inhibition of DNA-dependent RNA polymerases 
of prokaryotes. Simultaneously, they exhibit very low activity against eukaryotic RNA 
polymerases which renders them effective and safe drugs. This mechanism was found to be 
common for all antimicrobially active rifamycins.
[2]
 
 
Figure 3. Interaction of rifampicin with amino acids of Thermus aquaticus DNA-dependent RNA 
polymerase (modified from the ref.[20]). 
The DNA-dependent RNA polymerase is a complex enzyme producing primary transcript 
RNA and constists of five subunits: αI, αII, β, β’ and ω. Studies on the interaction of the 
enzyme from Thermus aquaticus with rifampicin (11) provided a detailed functional model 
for rifampicin’s mode of action.[20,21] It validated the earlier work done by Hartmann and Nitta 
who observed that rifampicin acts only in an early stage of the RNA synthesis by a physical 
interruption of the growing oligonucleotide chain after the first or the second elongation 
step.
[22,23]
 The binding site for rifampicin has been found at the subunit β which is encoded by 
the rpoB gene. The connection to the enzyme involves hydrogen bonding interactions 
between the four hydroxyl groups (at C-1, C-8, C-21 and C-23) as well as the carbonyl 
oxygen of the C-25 acetoxy group in rifampicin and amino acid residues R409, S411, Q393, 
H406, D396 and F394 in RNA polymerase (Figure 3). 
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The lower activity of rifamycins against Gram-negative bacteria is most likely caused by 
weaker penetration of the antibiotics through the cell membrane. Additionally, the β subunit 
of the DNA-dependent RNA polymerase is susceptible to mutational alterations which 
increase the resistance of M. tuberculosis and other pathogens to rifamycins. Therefore, 
rifampicin is usually used along with other antibiotics. The transport and the resistance 
problems can be partially solved by structural modifications. However, because of the 
complex structure of the rifamycins the modifications have been limited mainly to the C-3 or 
C-4 positions of the aromatic unit. 
1.1.3 The Biosynthesis of Rifamycin 
The biosynthesis of rifamycins has been extensively studied by classical feeding experiments 
with isotopically labeled precursors, mutagenesis approaches and complementary genetic and 
biochemical experiments.
[8,24–26]
 All the reported studies demonstrated that rifamycins are 
synthesized by type I polyketide synthase (PKS) assembled from AHBA (7) as a starting 
building block through chain extension by eight propionate and two acetate units (Scheme 3). 
 
Scheme 3. Proposed biosynthesis of rifamycin B (1) in A. mediterranei[2] (AD = adenylation/thiolation 
didomain; KS = ketosynthase; AT = acyltransferase; DH = dehydratase; KR = ketoreductase; ACP = 
acyl carrier protein; *not active domain). 
3-Amino-5-hydroxybenzoic acid (7) is recognized by a loading module which was identified 
as a didomain homologous to adenylation/thiolation domain (AD) of a non-ribosomal peptide 
synthetase (NRPS). The type I rif-PKS comprises ten modules arranged in five 
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multifunctional proteins which are encoded by the rifA-rifE genes. The product of the rifF 
gene - an amide synthase, releases a linear undecaketide from the PKS and catalyzes an 
intramolecular amide formation to give the macrocyclic lactam 14.
[2]
 Proansamycin X (14) is 
then processed to rifamycin B in a few steps which is described in the second part of this 
section. 
Studies on the disruption of the rifF gene resulted in the isolation of a series of different chain 
length polyketides ranging from the tetra- to decaketides.
[27–29]
 The deactivation of the rifD 
gene in module 8 and the rifE in modules 9 and 10 also revealed the formation of such linear 
ketides. These experiments provided clear evidence that the rif-PKS operates in a processive 
manner. Additionally, the structures of the isolated compounds suggested that the oxidative 
cyclization from a benzenoid to a naphthalenic structure must occur between the third and the 
fourth chain extension steps (Scheme 4). 
 
Scheme 4. Proposed mechanism of the oxidative cyclization from a benzenoid to a naphthalenic 
structure between the third and the fourth chain extension steps. 
Whereas the tetraketide 15 bears an unmodified benzenoid structure, the penta- to decaketides 
have undergone a ring closure to the naphthoquinones. This transformation requires an 
enzymatic oxidation of the compound 15 to the hydroquinone 16 which is further oxidized to 
the quinone 17a. The intramolecular Michael addition initiated by the deprotonation of the 
1,3-diketo moiety, followed by reoxidation yields the dihydronaphthoquinone 18 which is 
processed to pentaketide 19 in the module 4. 
Floss and co-workers investigated a number of genes which could be involved in this 
sequence of steps and indicated rif-orf19 as a gene implicated in the formation of the 
naphthalene ring.
[30]
 It encodes a protein homologous to 3-(3-hydroxyphenyl)propionate 
hydoxylases – flavoproteins which catalyze the hydroxylation of phenol molecules. Similar 
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genes have been reported in the biosynthesis of many natural products, for example 
geldanamycin (4). The deactivation of rif-orf19 in a mutant strain resulted in a disruption of 
rifamycin B production and release of either the tetraketide P8/1-OG (20a) or its lactone form 
20b (Scheme 5), first isolated by Ghisalba in 1981.
[8]
 Floss proposed that Rif-Orf19 acts as a 
separate protein interacting with the rif-PKS by introduction of a hydroxyl group into the 
ACP-bound tetraketide.  
 
Scheme 5. Formation and release of the tetraketide 20 after premature polyketide chain termination in 
the mutant strain. 
The naphthalene ring formation is unprecedented in polyketide biosynthesis. In the literature 
no examples of an oxidation domain located in the PKS system or oxidation reactions taking 
place during the polyketide assembly have been reported so far. 
Proansamycin X (14) is the first macrocyclic product released from the rif-PKS. However, the 
structure of the earliest cyclic intermediate in rifamycin B biosynthesis has been investigated 
over the years. Based on the results of feeding experiments Ghisalba and Nüesch proposed 
protorifamycin I (21) as the first released product - a naphthoquinone lacking the 8-hydroxyl 
group.
[31]
 This theory was refuted by Rickards in 1989 and reexamined by Floss in 1999.
[27,32]
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Rickards and co-workers carried out feeding experiments using [carboxy-
13
C, 
14
C, 
18
O2]-
AHBA and proved that the C-8 carbon atom and C-8 phenolic hydroxyl group originate from 
the carboxyl group of AHBA. Additionally, fermentation of A. mediterranei was carried out 
under an artificial atmosphere containing N2 and 
18
O2 providing clear evidence that the 
bacteria utilize atmospheric oxygen to introduce the C-1 oxygen function and the C-29 vinyl 
ether group. A few years later Floss and co-workers investigated whether the  
8-hydroxynaphthoquinone structure in the rifamycin core is formed from the 8-hydroxy-7,8-
dihydronaphthoquinone unit by dehydration followed by hydroxylation at C-8 or by a direct 
dehydrogenation to give the 7,8-double bond (Scheme 6). Feeding with protorifamycin I (21) 
to a mutant strain carrying all the downstream-processing genes resulted in no formation of 
rifamycin B (1). Therefore, the results obtained by Floss and Rickard support a pathway 
involving the dehydrogenation of proansamycin X (14) in the rifamycin biosynthesis. 
 
Scheme 6. Possible routes from proansamycin X (14) to rifamycin W (24), the precursor of rifamycin 
B (1). 
In 2002 Traber and co-workers isolated and characterized proansamycin B (22) which was 
converted to protorifamycin I (21), but the following transformation to rifamycin B (1) was 
not observed.
[33]
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Scheme 7. The role of individual rif genes in the rifamycin biosynthesis.[2] 
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However, the compound 21 was processed to 8-deoxyrifamycin B which suggests the 
presence of a minor shunt pathway in A. mediterranei alongside of the “normal” biosynthesis 
of rifamycin B. 
The proposed biosynthetic pathway from proansamycin X (14) to rifamycin B (1) and the role 
of individual rif genes are depicted in Scheme 7. In the first steps proansamycin X (14) is 
converted to rifamycin W (24) by dehydrogenation to form the 7,8-double bond and the 
following oxidation at C-34a. Transformation of rifamycin W (24) to rifamycin SV 
(10)/rifamycin S (9) involves a number of oxidation steps, as well as acetylation and 
methylation. However, only limited information about the role of individual genes has been 
collected so far. 
The role of the suggested rif biosynthetic genes has been deduced on the basis of sequence 
similarity analyses with other bacteria species which revealed a series of putative post-PKS 
modifying genes. It was found that the rif cluster contains genes homologous to  
P450-dependent monooxygenases, several regulatory genes and a group of genes encoding 
the formation of sugar nucleotides.
[2]
 In 2003 Floss and co-workers isolated and characterized 
27-O-demethylrifamycin SV methyltransferase, an enzyme encoded by the gene rif orf14 and 
able to catalyze the O-methylation at C-27 of 27-O-demethylrifamycin SV (DMRSV, 29) to 
give rifamycin SV (10).
[34]
 The studies on the substrate specificity revealed that  
27-O-demethylrifamycin SV methyltransferase converts only DMRSV, but not its quinone 27 
nor its 25-O-deacetyl derivative DMDARSV (28). Additionally, the deactivation of the rif 
orf14 gene supressed the ability to produce rifamycin B and resulted in accumulation of 
DMRSV. The gene encoding acetyltransferase which promotes a C-25-selective acetylation of 
the compound 28 to 29 could not be identified in the set of rif genes which suggests that it is 
not related to the rif biosynthetic gene cluster. 
In 2011 the Zhao group published the results of their genetic studies on the rif15 and rif16 
genes which were found to encode a transketolase and a P450 monooxygenase respectively, 
both of which are essential for the conversion of rifamycin SV (10) to rifamycin B (1).
[35,36]
 
The expression of these two genes in a mutant of A. mediterranei U32 producing rifamycin 
SV in the wild form
[37]
 resulted in the conversion of the compound 10 to the desired product 
1. However, heterologous expression of rif15 and rif16 in Streptomyces coelicolor and 
Mycobacterium smegmatis failed to convert rifamycin SV to rifamycin B. These results may 
suggest that some other genes specific for A. mediterranei are involved in this transformation. 
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It is interesting to note that in 2007 Fenical and co-workers isolated a new group of bicyclic 
polyketides from the marine organism Salinispora arenicola called saliniketals which display 
striking structural similarities and identical stereochemistry to the ansa chain of the rifamycins 
(Figure 4).
[38]
 They are used in the cancer chemoprevention as inhibitors of ornithine 
decarboxylase induction. Saliniketals A and B (30-31) and rifamycins (1, 10, 28, 29)  
co-occurred in the fermentation mixture which together with genetic studies suggested the 
horizontal transfer of the rif genes between A. mediterranei S699 and S. arenicola. The 
biosynthetic similarity between these two groups of compounds was investigated by carrying 
out bioinformatic studies, mutagenesis experiments, studies with isotope-labeled precursors 
and chemical analyses. As a result, the saliniketals were found as the unexpected byproducts 
of the rif pathway diverging at the stage of 34a-deoxy-rifamycin W (23). The primary amide 
is formed in a retro-Michael cleavage of the C-N bond in one of the further steps. 
 
Figure 4. Structures of the rifamycin B (1) and the saliniketals isolated from S. arenicola CNS-205. 
1.1.4 Stereospecificity of the Ketoreductase and Dehydratase Domains of Rifamycin 
Polyketide Synthase 
Ketoreductases (KR) are one of the most versatile type I PKS enzymes which catalyze the 
reduction of the β-keto group in 2-methyl-3-ketoacyl acyl carrier protein (ACP) substrates to 
form an alcohol and in some cases also epimerization of the 2-methyl group.
[39]
 
There have been only very few ketoreductases characterized in the literature so far.
[40–43]
 In 
2013 Cane and co-workers published the results of their studies on two KRs from the rif-PKS: 
RifKR7 from the module 7 and RifKR10 from the module 10. Incubation of (2R)-2-methyl-3-
ketopentanoyl-EryACP6 as a model substrate with RifKR7 and NADPH resulted in the 
predominant formation of (2S,3S)-2-methyl-3-hydroxycyl-ACP product. A similar experiment 
with RifKR10 provided a product with the same stereochemistry as in the example mentioned 
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above. These results show that both enzymes catalyze the stereospecific epimerization of the  
2-methyl group providing the (2S,3S)-2-methyl-3-hydroxycyl-ACP products 33 and 35, 
respectively (Scheme 8).
[44]
 
 
Scheme 8. Reactions catalyzed by RifKR7 and RifKR10 in the rifamycin biosynthesis. 
Complementary studies have been carried out on the RifDH10 domain which uses the 
RifKR10-generated product as the substrate. Dehydratases (DH) are the PKS domains which 
catalyze elimination of the β-hydroxyl group and the α-proton to form an α,β-enoyl double 
bond. So far only two PKS DH domains have been experimentally determined by both 
obtaining the protein structure and investigation of the stereospecificity of the dehydration 
reaction. These are DHs from the erythromycin PKS (EryDH4)
[45]
 and RifDH10 from the rif-
PKS.
[46]
 
RifDH10 is the dehydratase located in the terminal module 10 of the rif-PKS which was 
reported to catalyze the diastereospecific dehydration of RifACP10-bound (2S,3S)-2-methyl-
3-hydroxyacyl undecaketide 35 resulting in the exclusive formation of (E)-2-methyl- 2-enoyl 
undecaketide 36a (Scheme 9). Isomerization of the double bond to the cis configuration, 
characteristic of proansamycin X (14) and the final biosynthetic product rifamycin B (1), 
probably occurs during the macrolactamization step catalyzed by the amide synthase RifF. 
To prove this hypothesis Cane and co-workers used four diastereomeric RifACP10-bound 
diketide thioesters as model substrates in recombination experiments. They demonstrated that 
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RifDH10 catalyzes dehydration of only one of them – (2S,3S)-2-methyl-3-hydroxypentenoyl-
RifACP10 to give exclusively (E)-2-methyl-2-pentenoyl thioester product. This result 
highlights the stereospecific dehydration and substrate diastereoselectivity of RifDH10 in the 
acceptance and further processing of the ACP-bound undecaketide.  
 
Scheme 9. Dehydration of a RifACP10-bound (2S,3S)-2-methyl-3-hydroxyacyl undecaketide 35 by 
RifDH10 and following macrolactamization of the linear product to proansamycin X (14), the 
rifamycin B (1) precursor. 
Surprisingly, the substrate specificity of RifDH10 is reversed when the substrate is attached to 
a non-native acyl carrier protein, e.g. EryACP6 or the corresponding N-acetylcysteamine or 
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pantetheine thioester analogues resulting in dehydration of (2R,3R)-2-methyl-3-
hydroxypentenoyl thioesters. 
In spite of many structural similarities to EryDH4 and other characterized DH domains, the 
RifDH10 is unique in the sense of displaying strict specificity towards (2S,2S)-2-methyl-3-
hydroxypentenoyl-RifACP10 substrate and catalyzing the dehydration of it. The opposite 
substrate specificity when RifDH10 is tethered to non-cognate ACP is also unusual and 
constitutes the first example published in the literature. 
As it was shown in this section the rifamycins can be distinguished from other polyketides by 
a few unique features, including a naphthalene ring formation, a macrolactam ring and a 
trisubstituted cis double bond. Among over 2000 known polyketides carrying one or more 
double bonds, most of which have trans geometry, only a minor part contains one or more cis 
configured double bonds. Furthermore, in most PKSs the linear ketide is released from PKS 
by thioesterase (TE) which is replaced in the rif-PKS by the separately encoded amide 
synthase, RifF. 
1.1.5 Mutasynthesis 
Mutational biosynthesis or, in short, mutasynthesis is an attractive technique, alternative to 
semi- or total synthesis approaches, for the preparation of complex natural products with 
enhanced or unique biological activity. It combines the power of chemical synthesis with 
metabolic engineering and can be applied for creation of secondary metabolites libraries.
[47–50]
 
Mutasynthesis often complements semisynthesis and with respect to total synthesis it can be 
regarded as a biosynthetic shortcut. 
The concept of mutasynthesis was first theoretically thought by Birch in 1963
[51]
 and named 
by Rinehart in 1977 who defined it as a generation of a mutant strain of a producer organism 
which is blocked in the formation of a biosynthetic building unit of the target natural product. 
Feeding with chemically modified analogues of these building blocks, called mutasynthons, 
results in the production of new metabolites which are evaluated in terms of their biological 
activities (Scheme 10).
[52]
 
Ansamycin antibiotics are perfectly suited for mutasynthetic studies as it has been shown by a 
few groups over the last ten years.
[53–66]
 The libraries of new ansamycin antibiotics modified 
in the aromatic unit have been prepared by feeding AHBA analogues to the AHBA(−) 
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blocked mutants of Streptomyces hygroscopicus, the geldanamycin (4) producer
[53,54]
, and 
Actinosynnema pretiosum which produces the ansamitocins.
[55–64]
 
 
Scheme 10. A general concept of mutasynthesis and semisynthesis (a-d = enzymes, A = starting 
material, B-D = biosynthetic intermediates, E = natural product, B* = mutasynthon, C*-D* - new 
intermediates, E*, F* = generated derivatives of natural product).[47] 
In spite of its advantages, mutasynthetic approach has a few clear limitations. First of all, 
feeding with modified building blocks to a mutant strain requires a broad substrate flexibility 
of all catalytic domains including the first enzyme loading the substrate onto the PKS. Some 
of the produced secondary metabolites lack structural complexity and in such cases the semi- 
or total synthesis approach can be considered. On the other hand, employing more complex 
substrates may hamper the acceptance by the producer organism and/or the transport through 
the cell membrane. Additionally, the technique cannot be applied for the mutants blocked in 
the biosynthesis of natural precursors when the starter unit is essential for the growth of the 
producer organism. Some of these problems may be solved by means of metabolic 
engineering, namely the relocation of enzymes to heterologous organisms. The substrate 
specificity may be widened by changing the respective modules to their analogues from other 
gene clusters which display a broader spectrum of selectivity. The yield and growth of the 
producer strain can be improved by optimization of the fermentation procedures. 
17 
 
1.2 Purpose of the Project: Mutasynthetic Approach Towards New Rifamycin 
Derivatives 
The aim of the first project is to obtain and identify new rifamycin derivatives using an 
AHBA(−) blocked mutant of Amycolatopsis mediterranei HGF003 and AHBA analogues as 
the substrates. These mutasynthetic studies are a continuation of the previous work on AHBA 
mutants of Streptomyces hygroscopicus, a geldanamycin producer and Actinosynnema 
pretiosum, an ansamitocin P3 producer.  
 
Scheme 11. Planned feeding experiments with AHBA analogues and AHBA(−) blocked mutant of  
A. mediterranei HGF003. 
 
Scheme 12. Reductive properties of A. mediterranei planned to be tested with nitro and azido 
analogues of AHBA. 
 
18 
 
Aromatic building blocks are planned to be supplemented to the mutant strain HGF003 in 
order to evaluate its synthetic potential, the scope of tolerance and limitations. The 
mutasynthons are divided into two groups: substituted m-hydroxybenzoic acids and 
substituted aminobenzoic acids bearing electron-withdrawing groups (Scheme 11). 
Additionally, the reductive properties of A. mediterranei HGF003 will be investigated. In 
order to do that, a few nitro and azido analogues of AHBA will be fed to the mutant strain 
(Scheme 12). 
1.3 Discussion and Results 
1.3.1 Previous Work on Structure Elucidation of the Stereochemistry at C-6 and C-7 
in Tetraketides 
Stereogenic centers generated in module 1 are also present in tetraketide 20b but disappear 
during processing in the rif-PKS. Determination of the absolute configuration of both 
stereogenic centers at C-6 and C-7 in tetraketides has been reported by Khosla and  
co-workers.
[67]
 They prepared four diastereomers of a biosynthetic substrate (37-40) for 
module 2 of the rif-PKS in form of their SNAc esters which were fed to the blocked mutant of 
A. mediterranei (Scheme 13). HPLC and LC-MS analyses with rifamycin B (1) as a reference 
revealed that only the substrate 37 was transformed into the compound 1. 
In the Kirschning group bromotetraketide 42 has been chosen for the determination of the 
absolute configuration of both stereogenic centers at C-6 and C-7.
[68,69]
 The pyranone 42 was 
obtained in the yield of 19 mg/L after feeding with 3-amino-4-bromobenzoic acid 41 to the 
mutant strain and subsequently transformed into Mosher esters 44a and 44b (Scheme 14). The 
stereogenic center at C-7 was determined to be S on the basis of 
1
H NMR analyses, while the 
configuration at C-6 was established to be R by carrying out computational analyses of 
conformational energies using SPARTAN ’08 (Wavefunction, Inc., Irvine, CA, USA). The 
latter analysis was based on the relationship between the H-H coupling (J = 8.7 Hz) of the 
vicinal protons at C6 and C-7, as observed in the 
1
H NMR spectrum, and the torsion angle 
(179.4°). Both stereochemical assignments - at C-6 and C-7 are in agreement with the results 
reported by Khosla.
[67]
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Scheme 13. In vivo transformations with four diketide analogues. 
 
Scheme 14. Stereochemical assignment of C6 and C7 after Mosher esterification.[68] Reaction 
conditions: a) Boc2O, Et3N, dioxane/water, RT, 12 h, 49%; b) (S)-(+)-MTPA-Cl or (R)-(−)-MTPA-Cl, 
Et3N, DMAP, CH2Cl2, RT, 24 h, 50%. 
1.3.2 Synthesis of Mutasynthons 
The synthesis of 3-hydroxy-5-(hydroxymethyl)benzoic acid (48) was first reported by Simone 
Eichner
[70]
 and modified using 5-hydroxyisophthalic acid (45) as a starting material (Scheme 
15). The compound 45 was transformed into a methyl ester 46 under standard esterification 
conditions employing methanol and concentrated sulfuric acid. The reaction was carried out 
under refluxing conditions for 20 h and provided the compound 46 in 97% yield. 
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Scheme 15. Synthesis of 3-hydroxy-5-(hydroxymethyl)benzoic acid (48). Reaction conditions:  
a) MeOH, conc. H2SO4, reflux, 20 h, 97%; b) LiAlH4, THF, 0 °C → RT, 3.5 h, 44%; c) LiOH (1 M in 
H2O), MeOH, RT, 2 h, 96%. 
One of the ester groups of dimethyl 5-hydroxyisophthalate (46) was then reduced using 1 M 
solution of LiAlH4 in THF according to the Portnoy’s procedure
[71]
 to give the corresponding 
benzyl alcohol 47 in 44% yield. The last step was saponification carried out in MeOH with 
the use of a 1 M aqueous solution of LiOH providing the desired benzoic acid 48 in 96% 
yield. 
The next mutasynthon, 3-(aminomethyl)-5-hydroxybenzoic acid (53) was prepared using the 
above described methyl 3-hydroxy-5-(hydroxymethyl) benzoate (47) or 3-hydroxy-5-
(hydroxymethyl)benzoic acid (48) as starting materials (Scheme 16). 
Esterification of 48 with methanol in the presence of sulfuric acid provided the compound 47 
in quantitative yield. The subsequent Appel reaction yielded methyl 3-(bromomethyl)-5-
hydroxybenzoate (49) which was protected in the next step with TBDPSCl providing the 
compound 50 in 97% yield. The following step - substitution with phthalimide potassium salt 
was expected to give the compound 51 but unexpectedly yielded the TBDPS-deprotected 
product 52 which was directly obtained from benzyl bromide 49 in one of the previous 
experiments. The compound 52 had to be protected with TBDPSCl again due to troublesome 
work-ups in the next steps and submitted to the second part of the Gabriel synthesis involving 
hydrolysis with hydrazine monohydrate and work-up by acidic hydrolysis to give the desired 
benzoic acid 53 in quantitative yield. 
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Scheme 16. Synthesis of 3-(aminomethyl)-5-hydroxybenzoic acid (53). Reaction conditions: a) 
MeOH, conc. H2SO4, reflux, 24 h, quant.; b) CBr4, PPh3, CH2Cl2, RT, 3 h, 90%; c) Phthalimide 
potassium salt, K2CO3, DMF, RT, 3 h, 60%; d) Imidazole, DMAP, TBDPSCl, CH2Cl2, RT, 5 h, 
quant.; e) NH2NH2·H2O, EtOH, reflux, 3 h; f) conc. HCl, reflux, 2 h; quant.; g) Imidazole, DMAP, 
TBDPSCl, CH2Cl2, RT, 5 h, 97%; h) Phthalimide potassium salt, K2CO3, DMF, RT, 3 h, quant. to 52. 
The synthesis of 3-amino-2-fluorobenzoic acid (55) from 2-fluoro-3-nitrobenzoic acid (54) 
has been already published in the literature by Baell and co-workers.
[72]
 However, after 
loading of the substrate into the ThalesNano H-Cube® with a 10% Pd/C CatCart® they were 
not able to separate the obtained product 55 from a small residual amount of the substrate. 
 
Scheme 17. Synthesis of 3-amino-2-fluorobenzoic acid (55). Reaction conditions: 10% Pd/C, TES, 
EtOH, RT, 1 h, 97%. 
In this approach 2-fluoro-3-nitrobenzoic acid (54) was reduced to the desired 3-amino-2-
fluorobenzoic acid (55) using molecular hydrogen generated in situ by addition of 
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triethylsilane to 10% Pd/C (Scheme 17). This simple approach has been developed by 
McMurray in 2007 and successfully employed in the reduction of azides, imines, nitro groups 
and multiple bonds, as well as in deprotection of benzyl and allyl groups.
[73]
 
The syntheses of 3-amino-2-hydroxybenzoic acid (61) and 3-azido-2-hydroxybenzoic acid 
(63) were conducted using methyl 2-hydroxy-3-nitrobenzoate (59) which was prepared 
according to the procedure reported by Zeng (Scheme 18).
[74]
 
 
Scheme 18. Syntheses of 3-amino-2-hydroxybenzoic acid (61) and 3-azido-2-hydroxybenzoic acid 
(63). Reaction conditions: a) HNO3 (65%), conc. H2SO4, CH2Cl2, 0 °C, 30 min; b) MeOH, conc. 
H2SO4, reflux, 48 h, 47%.; c) 10% Pd/C, TES, EtOH, RT, 1 h, 94%; d) LiOH (1 M in H2O), MeOH, 
40 °C, 2 h, 88%; e) HCl (2 M), NaNO2/H2O, 0 °C; f) NaN3, NaOAc, 0 °C, 2 h, quant.; g) LiOH (1 M 
in H2O), MeOH, 40 °C, 2 h, 90%. 
Nitration of salicylic acid (56) led to a mixture of benzoic acids 57 and 58 which were used in 
the following esterification step without further purification. The nitro compound 59 was 
obtained after purification by flash chromatography in 47% yield and subsequently reduced to 
the amine 60 in 94% yield using triethylsilane and 10% Pd/C. The following saponification 
with 1 M aqueous solution of LiOH provided 3-amino-2-hydroxybenzoic acid (61) in 88% 
yield. The compound 60 was converted in situ to a diazonium salt, following by treatment 
with sodium azide to yield the compound 62 quantitatively. The subsequent saponification of 
62 provided the desired aryl azide 63 in 90% yield. 
The remaining substrates used for the feeding experiments were either commercially available 
or prepared according to the known literature procedures (details described in the section 3.4). 
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1.3.3 Mutasynthetic Approach with a Blocked Mutant of Amycolatopsis mediterranei 
HGF003 
The feeding experiments were carried out using AHBA(−) mutant of A. mediterranei 
HGF003 generated by a knockout of RifK activity (Figure 5) responsible for the 
aromatization of the AHBA precursor, 5-deoxy-5-amino-3-dehydroshikimic acid (Scheme 1). 
When AHBA (or some of its analogues as described in the further part of this thesis) is added 
to the production medium, the ability to biosynthesize the rifamycins is restored. 
 
Figure 5. Biosynthetic gene cluster of rif-PKS and flanking genes encoding proteins and DNA-
dependent RNA polymerase. 
To analyze the flexibility of the loading domain in the rif-PKS, a series of benzoic acid 
derivatives has been supplemented to the mutant strain. Intramolecular cyclization of the  
β-ketothioester leading to dihydronaphthalenes, similar to the one presented in Scheme 4 
(Section 1.1.3), was sought to be achieved by appropriate choice of either phenols, which 
could be oxidized to hydroquinones (like 15 → 16) or electron-withdrawing groups (NO2, 
CN, CF3, halides, ester group).  
Every fermentation process was conducted with an additional flask containing AHBA 
(positive control) and with no substrate added (zero control) to monitor the productivity of the 
bacterial strain and exclude a false-positive result, respectively. 
1.3.4 Mutasynthetic Experiments with Substituted m-Hydroxybenzoic Acids 
The first feeding experiment with A. mediterranei HGF003 was conducted using the natural 
starter unit, AHBA (7) to optimize the fermentation conditions and to control the productivity 
of the strain. As expected, cultivation of the strain in the presence of AHBA resulted in 
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restoration of rifamycins biosynthesis. When fermentation was carried out in liquid medium, 
rifamycin B (1) and rifamycin S (9) were isolated in the amounts of 20 mg/L and 1.1 mg/L, 
respectively (Table 1). Additionally, traces of the released tetraketide 20b were detected by 
UPLC-MS. Cultivation on solid agar medium for the same period of time resulted in the 
production of rifamycin S (2.4 mg/L) and rifamycin W (12.8 mg/L).
[69]
 The extension of the 
fermentation period could presumably lead to the production of rifamycin B or rifamycin S 
but this hypothesis was not investigated. 
 
Substrate 
Rifamycin B 1 
(mg/L) 
Rifamycin S 9 
(mg/L) 
Rifamycin W 24 
(mg/L) 
Pyranone (mg/L) 
7 20
[a] 
1.1[a] 
2.4[b] 
12.8[b] 20b[c] 
64 − − − 67 (118) 
65 − − − 68 (4.2) 
48 − − − 69 (chemically labile) 
53 − − − not formed 
66 − − − not formed 
Table 1. Products isolated after supplementation of AHBA(−) blocked mutant of A. mediterranei with 
different m-hydroxybenzoic acids. [a] fermentation was carried out in liquid medium; [b] fermentation 
was carried out on solid agar medium; [c] Detected by UPLC-MS: m/z: [M+H]+ calcd for 
[C15H18NO5]
+: 292.1185, found: 292.1182. 
Mutasynthetic approach with A. mediterranei HGF003 strain has been reported in the 
literature with the use of only two AHBA analogues: 3-hydroxybenzoic acid (64) and 3,5-
dihydroxybenzoic acid (65).
[75]
 These experiments were repeated resulting in the formation of 
the known 2H-pyran-2-ones 67 and 68. The tetraketide 67 was isolated in preparatively 
excellent yield (118 mg/L) which makes it useful as a chiral building block in further 
synthesis of more complex molecules. Unfortunately, hydroxylation and the following 
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hydroquinone or naphthoquinone formation were not observed. It remains unknown whether 
the release of the tetraketide from the module 3 is a result of a spontaneous liberation due to 
the presence of the labile diketo carbonyl system or its enols forms or if there is an enzyme 
which presents a blockade to the polyketide chain elongation. It seems that oxidation and 
hence cyclization, as well as the presence of an aromatic amino group are the necessary 
conditions for further processing by the enzymes of the rif-PKS.
[69]
 
The next mutasynthons employed in the feeding experiments were the benzyl alcohol 48 and 
the benzylamine 53. This approach was based on the results observed in the geldanamycin 
producer, S. hygroscopicus which was able to process the alcohol 48 to ring-enlarged 
macrolactones.
[76]
 In this case, the supplementation of AHBA(−) mutant of A. mediterranei 
with the compound 48 led to the formation of the chemically labile pyranone 69. The 
corresponding benzylamine 53 was not processed and only the detoxification products could 
be detected (the amino group was N-acylated). Also was the aryl hydrazinium chloride 66 not 
tolerated by the bacteria and no products could be found in the crude fermentation mixture.
[69]
 
1.3.5 Mutasynthetic Experiments with Substituted Aminobenzoic Acids 
The studies on the flexibility of the loading domain in the rif-PKS have been extended to 
differently substituted and functionalized benzoic acids (Figure 6).
[69]
 In the first group of the 
aminobenzoic acids fed to the mutant strain has neither anthranilic acid (70) nor its nitro-
substituted derivatives 71-72 been accepted by bacteria. Except for the compound 70 these 
results are in agreement with the kinetic data collected for the loading module by Khosla and 
co-workers.
[77]
 They expressed and purified adenylation-thiolation didomain and carried out 
kinetic measurements for the covalent loading of the A-T didomain by different unnatural 
substituted benzoic acids. The rate constants for the T domain arylation were measured 
relative to the T domain arylation by benzoic acid. 
4-Aminobenzoic acids 73-74 were also not processed by the mutant strain of A. mediterranei. 
Subsequently, a series of differently functionalized 3-aminobenzoic acids has been prepared 
and used in the further feeding experiments. The 2-hydroxysubstituted mutasynthon 61 was 
not loaded onto the rif-PKS resulting in the formation of the detoxification products, while 3-
amino-2-flurobenzoic acid (55) was processed to the pyranone 87 in unexpectedly good yield 
of 25 mg/L (Figure 7). 
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Figure 6. Aminobenzoic acids used for supplementation of AHBA(−) blocked mutant of  
A. mediterranei. X, Y = different substituents; n.a. = not accepted but detoxification products were 
detected (benzamides and acetylated amines listed in the section 4.2). 
Similarly, 3-amino-4-nitrobenzoic acid (76) was not consumed by the mutant strain, whereas 
4-fluoro- and 4-bromosubstituted compounds 75 and 40 were accepted and transformed into 
the tetraketides 88 and 42, isolated in the satisfying amounts of 20 mg/L and 19 mg/L, 
respectively. 
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Figure 7. Products isolated after supplementation of AHBA(−) blocked mutant of A. mediterranei 
with aminobenzoic acids. X, Y = different substituents. 
Interestingly, the 3-aminobenzoic acids with a third substituent located at position 5, as in 
mutasynthons 77-82, are processed preferentially with good yields. These results are in 
accordance with the already mentioned kinetic data.
[77]
 The 5-azidomethyl- and 5-
fluropyranones 89-90 were isolated in the amount of 2.5 mg/L. Contrary to expectations, the 
presence of electron-deficient functionalities, that is a trifluoromethyl group in the 
mutasynthon 79 and a nitrile group in the compound 80, did not promote cyclization to the 
corresponding dihydronaphthalenes. However, the substrates were processed to the stage of 
the tetraketides isolated subsequently in the yields of 1.5 mg/L and 7 mg/L, respectively, 
before their release from the rif-PKS. The last two mutasynthons from this group: the 
compound 81 with an ester group and the benzyl alcohol 82 were not accepted by the mutant 
strain. 
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Additionally, it is worth emphasising that all the fluorine-bearing mutasynthons 55, 75 and 
83, which contain a substitution pattern (functionalizations in the positions 2-, 4- and 6-) not 
favored in the active site of the loading domain (ATL-ACPL) are transformed into the 
corresponding 2H-pyran-2-ones 87, 88 and 93, respectively. Presumably, the fluorine atom is 
sufficiently small atom to occupy the aromatic ring in the binding site of the ATL-ACPL, 
similarly to the unsubstituted 3-aminobenzoic acid
[77]
 or 3-hydroxybenzoic acid (64) (Table 
1). Additionally, fluorine-containing compounds are very promising for the medicinal 
chemistry as the fluorine atom has been reported to improve drug properties.
[78]
 
1.3.6 Studies on the Reductive Properties of Amycolatopsis mediterranei 
Mutasynthetic studies on the geldanamycin producer, S. hygroscopicus, revealed its unique 
and unprecedented reductive properties towards aryl azides, a few examples of which were 
transformed into the corresponding anilines.
[57]
 The A. mediterranei HGF003 was found to be 
another bacterial strain able to reduce the azido group, not only to the amino group but also to 
the nitro group.
[69]
 
After feeding of the AHBA(−) blocked mutant of A. mediterranei with 3-azido-5-
hydroxybenzoic acid (94) a 2H-pyran-2-one derivative 96 was isolated as the main product in 
the amount of 47 mg/L (Table 2).  
 
Mutasynthon Rifamycin B 1 (mg/L) Rifamycin S 9 (mg/L) Pyranone 96 (mg/L) 
94 2.0 1.3 47.0 
95 − Detected by UPLC-MS[a] − 
Table 2. Products isolated after supplementation of A. mediterranei with 3-azido-5-hydroxybenzoic 
acid (94) and 3-hydroxy-5-nitrobenzoic acid (95). [a] UPLC-MS detection: m/z: [M+H]+ calcd for 
[C37H46NO12]
+: 696.3020, found: 696.3022. 
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Additionally, rifamycin B and rifamycin S were obtained in the yields of 2 mg/L and 1.3 
mg/L, respectively. Both rifamycins could be formed only after prior reduction of the aryl 
azide to the aryl amine which was processed further by the rif-PKS. The formation of the 
tetraketide 96 indicates that this reduction takes place before the PKS processing which is in 
agreement with results obtained for S. hygroscopicus.
[57]
 Alternatively, the reduction of the 
compound 96 may take place in competition with its release, while the reduced product is 
transformed into rifamycins. 
Supplementation of the mutant strain with 3-hydroxy-5-nitrobenzoic acid (95) resulted in the 
formation of rifamycin S (9) in trace amounts as detected by UPLC-MS. It has been the first 
example of a nitroarene reduced to an aryl amine by the ansamycin producer. Additionally, no 
pyranone has been detected in the fermentation extract. The chromatograms of the crude 
fermentation extracts after supplementation with 3-azido-5-hydroxybenzoic acid (94) and 3-
amino-5-hydroxybenzoic acid (7) as a positive control are presented in Figure 8. A similar 
result was obtained after feeding of 3-hydroxy-5-nitrobenzoic acid (95, Figure 9) to the 
growing culture. The peaks visible in each case at the same retention time (ca. 3.2 min) have 
been assigned to the mass of rifamycin B ([M-H]
– 
= 754). The chromatogram was recorded 
also for a zero control (fermentation medium without any mutasynthon) in which there were 
no peaks at the retention time tR = 3.2 min or for the mass of rifamycin B 756 in the positive 
mode and 754 in the negative mode. 
The characterization of rifamycins via mass spectrometry has been well described in the 
literature.
[79–81]
 However, HPLC with a tandem mass spectrometry LC-MS/MS system for the 
identification of rifamycins has been reported for the first time by Hewavitharana in 2007.
[82]
 
The fragmentation of a 755 m/z ion → 273 m/z ion was monitored during the characterization 
of rifamycin B (1) and rifamycin SV (10) in various strains of the marine sponge-derived 
bacterium Salinispora.  
The presence of a 273 m/z ion (a so-called chromophoric ion) corresponds to a naphthofuran 
system (Figure 10) which is the most useful ion indicative of rifamycins and provides clear 
evidence for the presence of these compounds.
[82]
 It is formed by the loss of an acetate group 
and the subsequent removal or fragmentation of the ansa group. The 273 m/z ion was also 
observed in the MS/MS spectrum of rifamycin B recorded at the collision energy of 30-45 eV 
(Figure 11) after feeding with mutasynthons 94 and 95. In both cases the fragmentation 
pattern was the same. 
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Figure 8. Chromatograms of the crude fermentation extracts after feeding with 3-azido-5-
hydroxybenzoic acid (94, IB F-33) and AHBA (7) as a positive control (IB pclm): [M-H]– = 754; tR = 
3.2 min. 
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Figure 9. Chromatograms of the crude fermentation extracts after feeding with 3-hydroxy-5-
nitrobenzoic acid (95, IB F-32) and AHBA (7) as a positive control (IB pclm): [M-H]– = 754; tR = 3.2 
min. 
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Figure 10. The naphthofuran system observed at 273 m/z. 
Another abundant ion in the low mass region of the MS/MS spectrum was observed at 151 
m/z. As suggested by Zerilli, it may originate from the ansa chain of rifamycins.
[79]
 In the high 
mass region of the spectrum no significant peaks were observed – noteworthy are a low-
intensity signal at 756 m/z corresponding to the [M+H]
+
 of rifamycin B and a 724 m/z 
corresponding to the loss of methanol. 
 
Figure 11. Fragmentation pattern of rifamycin B in MS/MS spectrum recorded at the collision energy 
of 30-45 eV. 
An MS/MS spectrum of rifamycin B recorded at the collision energy of 15-30 eV showed a 
lower degree of fragmentation (Figure 12). In the high mass region of the spectrum a low-
intensity signal of 756 m/z was observed while the most abundant ions 724 m/z and 664 m/z 
correspond to the loss of methanol and the following loss of acetic acid, respectively. 
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Figure 12. Fragmentation pattern of rifamycin B in MS/MS spectrum recorded at the collision energy 
of 15-30 eV. 
 
Figure 13. Chromatograms of the crude fermentation extracts after feeding with 3,5-dinitrobenzoic 
acid (97, IB F41) and 3-amino-5-nitrobenzoic acid (98, IB F44): [M+H]+ = 321; tR = 2.44 min. 
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It was observed during the HPLC purification steps that the amount of rifamycin S (9) in the 
fractions containing rifamycin B was gradually increasing which was most likely caused by 
exposure to light and air. These observations were also reported by Hewavitharana.
[82] 
Rifamycin B can be synthetically converted to its other forms, e.g. to rifamycin SV which can 
be further oxidized to rifamycin S. 
 
Scheme 19. Reductive properties of A. mediterranei after supplementation with nitrobenzoic acids 97 
and 98. 
A. mediterranei displayed more impressive reductive properties towards nitro groups when it 
was fed with 3,5-dinitrobenzoic acid (97) resulting in the formation of the tetraketide 102 with 
one amino and one nitro group (Scheme 19). Interestingly, the pyranone 102 was isolated in a 
similar yield (ca. 70 mg/L) after supplementation of 3-amino-5-nitrobenzoic acid (98) to the 
mutant strain (Figure 13). Additionally, in both fermentation extracts two detoxification 
products 99 and 100 could be detected by UPLC-MS. The reduction of only one nitro group 
results in the formation of an aminonitroarene which is different from dinitro- or 
diaminoarenes and therefore possesses different binding properties for the cryptic enzyme and 
is no longer a suitable substrate for further processing by rif-PKS. Surprisingly, these results 
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do not go in parallel with the kinetic data which found 3,5-dinitrobenzoic acid (97) to be 
rejected by the loading domain due to steric reasons.
[77]
 In the kinetic measurements for 
arylation of the loading domain carried out by Khosla and co-workers, also 3-nitrobenzoate 
and 3-sulfobenzoate were rejected as substrates for the A-T didomain. 
The formation of the tetraketides 96 and 102 confirms that the presence of electron-
withdrawing groups (a nitro group in this case or trifluoromethyl and nitrile groups in the 
mutasynthons 79-80, respectively), is not sufficient to promote a vicarious nucleophilic 
substitution reaction and therefore to lead to the formation of a dihydronaphthalene unit 
(Scheme 20). When compared to the proposed mechanism of the oxidative cyclization from a 
benzenoid to a naphthalenic structure depicted in Scheme 4, one can notice that in case of 
mutasynthons bearing electron-withdrawing groups only first oxidation may take place. The 
further processing towards the desired pentaketide is blocked either at the oxidation step or at 
the cyclization step via an intramolecular vicarious nucleophilic substitution reaction. 
However, while none of the expected products were detected during LC-MS analyses, the 
hypothesis of a direct release of the tetraketide from the module 3 in a lactone form is 
supported. 
 
Scheme 20. Proposed mechanism of the formation of a hypothetical pentaketide after feeding of the 
mutasynthons bearing electron-withdrawing groups (R = NO2, CF3, CN, CO2Me, F) to the AHBA(−) 
mutant strain of A. mediterranei. 
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Scheme 21. Results of the feeding experiment with 3-azido-2-hydroxybenzoic acid (63) as a 
mutasynthon. 
The bioreduction of aryl azides by S. hygroscopicus has been reported for the mutasynthons 
with the same 1,3,5-substitution pattern as in AHBA (7). After feeding with 3-azido-2-
hydroxybenzoic acid (63) to the AHBA(−) mutant of A. mediterranei, no tetraketide was 
formed probably due to the fact that 2,3-disubstituted benzoic acids are not accepted by the 
loading domain (Scheme 21). Simultaneously, hydroxylation at C-5 followed by oxidation 
and a Michael addition to form a dihydronaphthohydroquinone did not take place after 
feeding with the mutasynthon 63. However, the reduction product 103, which was also 
detected after supplementation of 3-amino-2-hydroxybenzoic acid (61), was isolated in the 
amount of 11.1 mg/L (Figure 14). 
Fermentations in the presence of the azido and nitro analogues of the natural starter unit 
AHBA provided rifamycins as well as pyranones and detoxification products with reduced 
nitro functionality. The reduction of the azido group may imply the presence of a specifically 
active azido reductase in A. mediterranei as it was also suggested for another strain explored 
in the Kirschning group – namely Actinosynnema pretiosum.[57] As a continuation of this 
research a series of chemical reactions was carried out using 3-azido-5-hydroxybenzoic acid 
(94) as a substrate to rule out a possible reduction of the azido group by free reducing agents 
(Table 3). The reactions were tested in different solvents (DMSO/H2O, CH3CN, CH2Cl2), 
buffers or their mixtures, in the presence of NADH as a reducing agent at 28 °C for 24 h, 
either in the presence or absence of magnesium perchlorate. 
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In case no product was observed, the reaction was continued for another 24 h stirring at  
40 °C. None of these reactions provided 3-amino-5-hydroxybenzoic acid (7) and the substrate 
could still be detected in the reaction mixture. 
 
Figure 14. Chromatograms of the crude fermentation extracts after feeding with 3-azido-2-
hydroxybenzoic acid (63, IB F-45) and 3-amino-2-hydroxybenzoic acid (61, IB F-46): [M-H]– = 193; 
tR = 1.92 min. IB F45 ZC = zero control. 
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Entry Substrate NADH Mg(ClO4)2 Solvent/Buffer Conditions 
1 1.0 eq. 1.5 eq. x phosphate buffer[a]  
28 °C, 24 h 
40 °C, 24h 
2 1.0 eq. 1.5 eq. x succinate buffer[b]  
28 °C, 24 h 
40 °C, 24h 
3 1.0 eq. 1.5 eq. x DMSO/H2O (1:1) 
28 °C, 24 h 
40 °C, 24h 
4 1.0 eq. 1.5 eq. x 
DMSO/H2O  
+ phosphate buffer[a] 
28 °C, 24 
40 °C, 24h 
5 1.0 eq. 1.5 eq. x CH3CN 
28 °C, 24 h 
40 °C, 24h 
6 1.0 eq. 1.5 eq. x CH2Cl2 
28 °C, 24 h 
40 °C, 24 h 
7 1.0 eq. 1.5 eq. 1.0 eq. phosphate buffer[a]  28 °C, 24 h 
8 1.0 eq. 1.5 eq. 1.0 eq. succinate buffer[b]  28 °C, 24 h 
9 1.0 eq. 1.5 eq. 1.0 eq. DMSO/H2O (1:1) 28 °C, 24 h 
10 1.0 eq. 1.5 eq. 1.0 eq. 
DMSO/H2O  
+ phosphate buffer[a] 
28 °C, 24 h 
11 1.0 eq. 1.5 eq. 1.0 eq. CH3CN 28 °C, 24 h 
12 1.0 eq. 1.5 eq. 1.0 eq. CH2Cl2 28 °C, 24 h 
Table 3. Studies on the bioreduction of the azido group ([a] pH = 7, [b] pH = 4). 
 
 
39 
 
1.3.7 Biological Activity of Tetraketides 
Biological tests were carried out in the Helmholtz Centre for Infection Research in 
Braunschweig, Germany. Tetraketides 41, 80, 94 and 98 have been analyzed in terms of their 
potential biological activity and cytotoxicity but all tests gave negative results (Table 4). The 
compounds submitted for the tests for the microbial activity with the use of three strains: 
Escherichia coli, Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus 
(MRSA) were found to be inactive and did not inhibit the growth of bacteria. 
 Sample E. coli P. aeruginosa MRSA  
  % growth % growth % growth 
  50µM 5µM 0.5µ
M 
50µM 5µM 0.5µ
M 
50µM 5µM 0.5µM 
 98 105.0 112.4 105.0 115.7 108.1 109.9 76.1 92.9 286.2 
 80 105.0 111.3 105.8 117.4 105.3 103.5 94.4 98.1 88.6 
 41 104.2 111.8 104.3 108.0 104.6 100.9 98.6 81.9 96.0 
 94 105.4 111.0 103.6 103.7 102.4 97.9 113.4 101.0 111.8 
Ctrl 1  0.7 48.9 103.3 3.8 41.2 100.3 1.0 16.9 125.0 
Ctrl 2  0.7 102.8 105.5 8.1 60.3 99.3 0.2 28.7 108.8 
Ctrl 3  0.8 103.3 103.5 46.3 100.2 101.6 -0.3 66.5 142.2 
DMSO  105.3 103.6 104.4 101.2 102.4 100.8 106.7 101.4 140.9 
E. coli Ciprofloxacin 20.0 2.0 0.10       
  10.0 1.0 0.10       
  5.0 0.5 0.05       
PA7 Amikacin    50.0 5.00 0.50    
     25.0 2.50 0.25    
     12.5 1.25 0.13    
MRSA Linezolid       20.0 2.0 0.2 
        10.0 1.0 0.1 
        5.0 0.5 0.05 
Table 4. The results of the tests for potential microbial activity with the use of mutasynthons 41, 80, 
94 and 98. 
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1.4 Summary and Outlook 
1.4.1 Summary and Conclusions 
In conclusion, the synthetic potential of the blocked mutant of A. mediterranei HGF003, the 
producer of rifamycin B, was evaluated using the concept of mutasynthesis. The rifamycin 
loading domain, similarly to the loading domain of geldanamycin and ansamycin PKSs, was 
found to be highly tolerant to unnatural benzoic acids, especially to 3-aminobenzoic acids 
with an additional substituent located at position C-5. Simultaneously, high substrate 
specificity of the enzymes involved in the naphthalene formation has been revealed as any 
oxidation products formed from the employed mutasynthons could be detected.  
Overall, thirty variously substituted and functionalized benzoic acids were fed to the 
AHBA(−) mutant strain of A. mediterranei HGF003 resulting in the isolation of thirteen 
tetraketides. A few of them were analyzed in terms of their potential biological activity and 
cytotoxicity but all tests gave negative results. Additionally, studies with azido- and nitro 
analogues of AHBA established remarkable reductive properties of A. mediterranei towards 
aryl azides and nitroarenes. It has been the second example of a microbial source possessing 
reductive properties towards aryl azide reported so far in the literature. As observed in S. 
hygroscopicus, the reduction likely takes place prior to loading onto the PKS and is not 
associated with the PKS enzymes. Unfortunately, the identification of the cryptic enzyme 
responsible for the reduction has not yet been achieved.
[83,84]
  
Feeding with 3-amino-4-bromobenzoic acid (41) revealed the formation of the undecaketide 
105 which was detected in the crude fermentation extract by UPLC-HRMS (Scheme 22). 
Although the methyl ester 106 has been prepared from a crude fermentation product, attempts 
to isolate the undecaketide by HPLC have not been successful, most likely due to the 
chemical lability of the enedione structure in both compounds. The formation of the 
compound 105 is remarkable because it reveals that the rif-PKS is able to process the 
tetraketide which cannot be cyclized to the dihydronaphthoquinone moiety. In case of all the 
other mutasynthons fed to the mutant strain, failure of the ring closure resulted in release of 
the pyranone. Furthermore, the hypothetical “paleo” undecaketide 107 may be considered as 
an evolutionary predecessor of an unknown rif-PKS product as some evolutionary changes 
are evident in the rif-PKS organization – these are inactive DH from the module 1 and KR 
from the module 3 (Scheme 23). Inactivation of these two domains might have been crucial 
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for the formation of a dihydronaphthoquinone moiety especially that the hypothetical “paleo” 
tetraketide 108 does not possess any structural features to initiate cyclization. 
 
Scheme 22. Detection of the undecaketide 105 in the crude fermentation material by UPLC-HRMS  
(tR = 3.59 min; m/z: [M+H]
+ calcd for [C36H55BrNO9]
+: 724.3060, found: 724.3058) and preparation of 
the methyl ester 106 for analytical purposes. Reaction conditions: a) (CH3)3SiCHN2, MeOH/toluene, 
RT, 30 min. 
As a result of evolution, new enzymes responsible for the dihydronaphthoquinone formation 
could become a part of the rifamycin biosynthesis. In fact, the meaning of evolutionary 
analyses has been discussed by Kalesse and co-workers in a report on the synthesis and 
biological evaluation of “paleo” soraphens which displayed a different biological activity than 
natural soraphen and affected other biological targets.
[85,86]
 
 
Scheme 23. Structures of hypothetical „paleo” undecaketide 107 and „paleo” tetraketide 108. 
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1.4.2 Outlook of the Project 
Although a few tetraketides submitted for biological tests did not display any microbial 
activity, the remaining ones should be screened in terms of their potential biological activity 
and cytotoxicity. Additionally, some of the isolated 2H-pyran-2-one derivatives can be used 
as chiral building blocks and serve as synthetic tools to create libraries of more advanced 
intermediates. Biologically active and therapeutically important 2-pyranones, including  
4-hydroxy-2-pyranone (or α,β-unsaturated lactones) have been found in a wide variety of 
organisms.
[87–93]
 Furthermore, numerous 2-pyranones have been already used as precursors in 
the synthesis of pharmacologically important compounds such as anticancer agents, HIV 
protease inhibitors, antimicrobials, antifungals, cardiotonics and plant growth regulators.
[94]
 
The high substrate tolerance of the loading domain of the rif-PKS for unnatural benzoic acids 
may be employed in the production of natural products derivatives through protein 
engineering techniques. While the benzoic acids were used as putative substrates in the 
project, the tolerance of the loading domain towards other types of aromatic compounds, e.g. 
variously substituted heterocyclic substrates, could be tested. Simultaneously, the 
identification of the cryptic enzyme responsible for the reduction of the nitro- and azido 
groups should be further deeply investigated. 
Furthermore, fermentation with the use of 3-amino-4-bromobenzoic acid (41) should be 
repeated on a larger, few-liter scale, followed by methylation and acylation of the hydroxyl 
groups to enable isolation of the undecaketide in amounts sufficient for full characterization. 
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2 Geldanamycin 
2.1 Introduction 
Heat shock proteins belong to a family of molecular chaperones which display the highest 
level of expression among all cellular proteins across all species.
[95–104]
 The heat shock protein 
90 (Hsp90) is one of the most abundant eukaryotic heat-related proteins but it has also been 
reported in procariotic organisms.
[105]
 There are two major forms of this protein in cytoplasm: 
the Hsp90α which is responsible for a fast cellular response and the Hsp90β which plays role 
in long-term adaptation of the cell.
[99,106]
 The Hsp90 stabilizes many proteins (called client 
proteins) required for the tumor growth by assistance in their proper folding and maturation, 
as well as the regulation of the cell cycle. In 2000 Hanahan and Weinberg published six 
properties of Hsp90 client proteins which are necessary for the formation of a cancer cell from 
a normal cell that require many alterations in cell functioning (Figure 15).
[107]
 These 
hallmarks are a) evasion of apoptosis, b) self-sufficiency in growth process, c) unlimited 
replication ability, d) insensitivity to anti-growth signals, e) ability to tissue invasion and 
metastasis, and f) sustained neoangiogenesis. Increased Hsp90 activity can often indicate the 
presence of cancer cells in a body. 
 
Figure 15. Hsp90 client proteins and six properties necessary for the formation of a cancer cell (RTK 
= receptor tyrosine kinase; IGF-1R = insuline-like growth factor; AKT = protein kinase B; HER2 = 
human epidermal growth factor receptor 2 (receptor tyrosine-protein kinase); KIT = cell growth factor 
receptor; MET = hepatocyte growth factor receptor; CDK = cyclin-dependent kinase; MMP2 = 
matrixmetalloproteinase-2; HIF = hypoxia-inducible factor; Src = proto-oncogene tyrosine-
protein kinase; VEGF = vascular endothelial growth factor). 
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A significant number of natural products have been identified as inhibitors of the chaperone 
function of Hsp90 so far.
[108]
 Among the most famous are geldanamycin (4), herbimycin 
(109)
[109,110]
 and macbecin (110)
[111]
 which belong to the group of ansamycin antibiotics 
(Figure 16). 
 
Figure 16. Chemical structures of ansamycin-class Hsp90 inhibitors. 
2.1.1 Biological Activity of Geldanamycin and Its Derivatives 
Geldanamycin (4) is a benzoquinone ansamycin antibiotic first isolated in 1970 from a culture 
extract of Streptomyces hygroscopicus var. geldanus var. nova.
[112]
 It displays antitumor 
properties by binding to the N-terminal ATP-binding pocket of Hsp90 and inhibition of its 
ATP-dependent chaperone activity which initiates the release of client proteins and their 
degradation by the ubiquitin-proteasome pathway.
[113]
  
 
Figure 17. Crystal structures of a) ADP and b) geldanamycin co-crystallized with yeast Hsp90.[114] 
As it has been proven by the crystal structure of geldanamycin co-crystallized with the yeast 
Hsp90 (Figure 17), the macrocyclic ring and the carbamate group at C-7 of the compound 4 
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are directed towards the bottom part of the binding pocket, while the benzoquinone ring is 
oriented towards the top of the pocket.
[115]
 Thus, the benzoquinone moiety interacts similarly 
to the phosphate backbone of ATP/ADP, while the carbamate group imitates H-bonding 
interactions of the purine system of ATP/ADP. 
Despite its anticancer in vitro potential in a wide range of cancers, geldanamycin has not been 
considered for clinical use due to a number of limitations: metabolic instability, severe 
hepatotoxic activity and low solubility in aqueous solutions.
[116,117]
 Instead, a few analogues 
of geldanamycin have been developed in semisynthetic approaches, mainly by alterations in 
the quinone structure at the C-17 postion and became drug candidates at different stages of 
clinical trials. Among them, tanespimycin (17-AAG, 111a) and alvespimycin (17-DMAG, 
112) have been the most promising (Figure 18).
[118–121]
  
 
Figure 18. Structures of geldanamycin derivatives - potential drug candidates. 
17-AAG (111a) has displayed anticancer properties at low nanomolar concentrations and 
entered clinical trials to evaluate its activity in patients with melanoma, prostate or breast 
cancer.
[117]
 The proposed mechanism of action of 17-AAG involves downregulation of some 
oncoproteins and reduction of the cell growth. Unfortunately, the compound 111a exhibited 
poor solubility and limited oral bioavailability. However, the latter case can be modulated by 
administration with other drugs, e.g. cyclosporine. 17-DMAG was found to be more active on 
tumor explants than 17-AAG but is less metabolized.
[119]
 
Additionally, some new fluorogeldanamycin derivatives 113-117 were obtained in a 
mutasynthetic approach by Kirschning and co-workers after feeding with monofluoro  
3-aminobenzoic acids to an AHBA-blocked mutant of S. hygroscopicus (Figure 19).
[54]
 
Although the compounds 113-117 are devoid of either quinone or hydroquinone moiety, they 
display very strong antiproliferative properties towards cancer cell lines. The geldanamycin 
derivative 113 is expected to be perfectly suited for further clinical evaluations. Furthermore, 
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two novel geldanamycin analogues 118 and 119 with higher solubility in water and decreased 
cytotoxicity were discovered in 2013 in S. hygroscopicus 17997.
[122]
 However, in this case 
more studies have to be conducted for the evaluation of these compounds as anticancer drug 
candidates. The strain S. hygroscopicus 17997 has also been found to produce sulfur-
containing geldanamycin derivatives 120-121 as reported by Wang in 2011.
[123,124]
 
 
Figure 19. Some geldanamycin derivatives as promising anticancer drug candidates. 
The toxicity of geldanamycin is caused by the metabolism of the benzoquinone moiety. This 
benzoquinone toxicophore 122 undergoes a two-electron reduction involving 
NAD(P)H/quinone oxidoreductase 1 (NQO1) to the dihydroquinones 123 which display 
higher Hsp90 inhibitor activity and better solubility in water. The benzoquinones 122 can also 
be metabolized with one-electron reductases: CYP reductase and B5 reductase generating the 
unstable semiquinones 124 which can be further oxidized to superoxide radicals by molecular 
oxygen (Scheme 24).
[125]
 Furthermore, as suggested by Strong, sulfur-containing 
nucleophiles, e.g. glutathione (GSH, 125), are able to modulate the toxicity of the quinone 
compounds. Benzoquinones 122 can interact with GSH via a classic 1,4-reductive Michael 
addition providing the hydroquinone conjugate intermediates 126 which are oxidized to the 
quinone conjugates 127 and thus inducing toxicity.
[126]
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As benzoquinone is an unfavorable structural feature of Hsp90 inhibitors, many approaches 
have been developed to modify the quinone moiety. In 2008 Martin and co-workers reported 
the use of biosynthetic engineering to deactivate the monooxygenase responsible for the 
quinone formation leading to the optimization of Hsp90 inhibitor macbecin (110).
[127]
 
Additionally, small synthetic molecules, e.g. SNX-2112, active as Hsp90 inhibitors and 
devoid of the quinone moiety have been obtained.
[128]
 
 
Scheme 24. A proposed metabolic pathway of benzoquinones by one- and two-electron reductases and 
conjugation with glutathione. 
2.1.2 Structure-Activity Relationship in Geldanamycin 
Ansamycin antibiotics are unique natural products not only because of their biological activity 
but also from a synthetic point of view. In the structure-activity studies summarized in a 
review
[95]
 by Kirschning and co-workers three tactics have been employed: synthetic, 
semisynthetic and mutasynthetic. Among all the ansamycins tested, over 500 geldanamycin 
derivatives have been analyzed and as a conclusion of these studies the ”SAR map” has been 
proposed (Figure 20). 
It was shown that introduction of a wide range of modifications was possible in the structure 
of geldanamycin. Modifications in the part spreading from C8 to C15 as well as the 
substitution pattern on the aromatic ring did not have a significant impact on the biological 
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activity of the compound 4 and its derivatives. However, the presence of a carbamate at C-7 
has been proved to be essential for the biological properties as it interacts with the carboxyl 
group of Asp79 in the Hsp90 binding pocket.
[114,129,130]
 Additionally, alkylation of the lactam 
nitrogen atom and removal of the methyl- or the methoxy substituents at C-6 results in loss of 
toxicity. 
 
Figure 20. Conclusions of structure-activity studies in geldanamycin and its derivatives.
[95]
 
2.1.3 Geldanamycin Biosynthesis 
The biosynthesis of geldanamycin (4) has been proposed by the Hutchinson group and it is 
presented in Scheme 25.
[131,132]
 The compound 4 is biosynthesized by the seven-module type I 
PKS, encoded by the gdmA1-A3 genes, from AHBA (7) and chain extender units: malonyl-
CoA, methylmalonyl-CoA and 2-methoxymalonyl-CoA. As in the case of rifamycins, the 
linear product released from the gdm-PKS is cyclized by the amide synthase encoded by 
gdmF gene to give progeldanamycin (128). The macrolactam product 128 is then subjected to 
the post-PKS transformations by tailoring enzymes: oxidation at C-17 (GdmL), oxidation at 
C-21 (GdmM), 4,5-dehydrogenation (GdmP), carbamoylation at C-7 (GdmN) and  
O-methylation at C-17 (enzyme not known). The post-PKS modifications have been 
investigated in 2004 by Hong and co-workers
[133]
 and a few years later by the Kirschning 
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group who proposed a sequence of post-PKS steps on the basis of mutasynthetic feeding 
experiments with AHBA(−) blocked mutant of S. hygroscopicus K390-61-1 (Scheme 26).[134]  
 
Scheme 25. The geldanamycin biosynthesis in Streptomyces hygroscopicus (LD = loading domain,  
ACP = acyl carrier protein; KS = ketosynthase; AT = acyltransferase; DH = dehydratase; ER = 
enoylreductase; KR = ketoreductase). 
Kirschning and co-workers employed 3-amino-(5-hydroxymethyl)benzoic acid (82) as a 
mutasynthon processed to a variety of geldanamycin derivatives by a mutant strain of S. 
hygroscopicus which were isolated and fully characterized. Carbamoylation at C-7 which 
yielded the compound 129 was proposed as the initiating step of the post-PKS modifications. 
The mutaproduct 129 was then oxidized at C-17 to provide the phenol 130, followed by a  
4,5-dehydrogenation step and the formation of the compound 131. The last two 
transformations were O-methylation at C-17 providing the mutaproduct 132 and oxidation at 
C-21 after which the fully transformed product 133 was obtained. The proposed sequence of 
modifications differs from the one proposed by Hong
[133]
 who placed carbamoylation at a later 
stage of the geldanamycin biosynthesis. 
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Scheme 26. Mutasynthetic feeding experiments with the benzoic acid 82. 
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2.2 Purpose of the Project: Synthesis of Progeldanamycin Derivatives 
The purpose of this project is the investigation of the tolerance and biosynthetic 
transformation of the complex substrates 134-137 by the heterologously expressed amide 
synthase (GdmF), the enzyme responsible for the macrolactamization in the biosynthesis of 
geldanamycin. To this end, the seco-progeldanamycin acid derivatives 134-137 are planned to 
be synthesized by total synthesis and used in enzyme expression studies of the amide synthase 
in which new progeldanamycin derivatives 138-140 are expected to be formed. Additionally, 
the SNAc esters could be fed to a knockout strain of S. hygroscopicus var. geldanus (K-390-
61-1), which is incapable of performing the AHBA biosynthesis, to obtain new geldanamycin 
derivatives 141-144 (Scheme 27). 
  
Scheme 27. Planned studies towards substrate flexibility of the amide synthase GdmF in enzyme 
assays and feeding experiments with the mutant of S. hygroscopicus var. geldanus K-390-61-1. 
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2.3 Discussion and Results 
2.3.1 Previous Work on the Substrate Flexibility of the Amide Synthase 
To investigate the substrate flexibility of the amide synthase both in enzyme assays and in the 
mutasynthetic approach with the mutant strain of S. hygroscopicus var. geldanus, Jekaterina 
Hermane prepared three SNAc esters 144-146. Unfortunately, feeding experiments with the 
seco-progeldanamycin acid derivatives 144-146 did not provide satisfying information on the 
flexibility of the amide synthase, probably due to poor membrane permeability or instability 
of the synthesized substrates. However, the compound 144 was successfully used in the 
enzymatic reaction with the heterologously expressed amide synthase which resulted in the 
formation of a geldanamycin derivative 147 (Scheme 28).
[135]
 This proved that GdmF is able 
to accept complex and modified biosynthetic intermediates and transform them to the 
corresponding macrolactams.  
 
Scheme 28. Structures of seco-progeldanamycin derivatives 144-146 prepared by Jekaterina Hermane 
and enzymatic reaction with the SNAc ester 144 and the amide synthase.[135] 
The preparation of the amide synthase GdmF and the optimization of the enzyme assays was 
developed in cooperation with Anja Heutling and Dr. Carsten Zeilinger. The synthesis of the 
seco-progeldanamycin acid derivatives is based on the previous work of Monika Vogt and 
Sascha Ceylan.
[136,137]
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2.3.2 Retrosynthesis 
In the selection of the target SNAc esters synthesized by Jekaterina Hermane
[135]
 as well as 
the compounds prepared in this thesis, the structure-activity relationship described in the 
section 2.1.2 has been taken into account. As the presence of the carbamate group at C-7 was 
proved to be essential for binding to the Hsp90, the hydroxyl function at C-7 should not be 
changed. Moreover, the substituents at C-6 play an important role as the removal of the 
methoxy group results in loss of toxicity. In contrast to this, modifications at C-8 should not 
have a significant impact on the anticancer activity of the compound. 
As a result of these considerations, the seco-progeldanamycin acid derivatives 133-136 were 
chosen to be synthesized (Scheme 29). The compounds 133-136 will be prepared in their  
N-acetylcysteamine thioester forms (SNAc esters). The enzyme assays and feeding 
experiments with the substrates 133-136 should provide information about the influence of 
the methyl groups at C-2 and C-8 on the acceptance by the amide synthase and about the 
impact of a substituent at C-6 on the biological activity. 
The planned strategy to synthesize the SNAc esters of the seco-progeldanamycin acid 
derivatives 133-136 has been presented in Scheme 29. As in the previous work carried out in 
the Kirschning group, each SNAc ester was retrosynthetically divided into two main parts: the 
western and eastern fragments, connected by means of olefin cross-metathesis.  
The introduction of the SNAc ester will be performed using the Wittig olefination. The 
western fragment 148 should be prepared from the aldehyde 153 through the selective boron-
mediated Roush crotylation. The synthesis of the compound 153 has been developed by 
Monika Vogt,
[136]
 while the Roush crotylation has been optimized by Jekaterina Hermane.
[135]
 
The key steps in the synthesis of the aldehyde 153 are the Sharpless epoxidation followed by 
an epoxide ring opening to introduce a stereocenter at C-12, the Wittig reaction and the Evans 
alkylation to form a stereocenter at C-14.  
The formation of the double bond in the eastern fragments 149-152 will be carried out 
through either syn- or anti-selective Grignard addition from the aldehyde 157. The synthesis 
of the corresponding aldehydes will be accomplished from the commercially available D- or 
L-glutamic acids (158-D and 158-L), depending on the desired stereochemistry of the final 
product. 
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Scheme 29. Retrosynthetic analysis of SNAc esters 134-137. 
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2.3.3 Synthesis of the Western Fragment 
The synthesis of the western fragment 148 started from 3,5-dihydroxybenzoic acid (65). The 
preparation of the methyl ester 159 from the compound 65 was reported in the literature in 
1983 by Rickards and involved a reaction with ammonia, followed by esterification with 
acetyl chloride in methanol (Scheme 30).
[138]
 
 
Scheme 30. Synthesis of the epoxide 165. Reaction conditions: a) conc. aq. NH3, NH4Cl, 180 °C,  
40 h; b) acetyl chloride, MeOH, 65 °C, 36 h; c) Boc2O, NaHCO3/THF, RT, 44 h; d) TBDPSCl, 
imidazole, 4-DMAP, CH2Cl2, 30 °C, 16 h, 84%; e) DIBAL-H, THF, −78 °C → RT, 16 h, 94%;  
f) PPh3, CBr4, CH2Cl2, RT, 30 min, 99%; g) NaI, acetone, RT, 2 h, 95%; h) oxazolidinone (S)-166, 
LDA, THF, −35 °C, 13 h, 60%, d.r. > 10 : 1; i) LiBH4, Et2O, 0 °C, 1.5 h, 78%; j) DMP, NaHCO3, 
CH2Cl2, RT, 1 h, 99%; k) 167, CHCl3, 50 °C, 15 h, 72%; l) DIBAL-H, CH2Cl2, −78 °C, 5 h, 75%;  
m) Ti(Oi-Pr)4, t-BuOOH, D-(−)-DET, MS 4Å, CH2Cl2, −20 °C, 20 h, 80%, d.r. > 10 : 1. 
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The further steps providing the benzyl alcohol 161 were established in the Kirschning group 
by Marco Brünjes and Florian Taft.[139–141] The Boc- and TBDPS-protection reactions of the 
ester 159 provided the compound 160 in 84% yield over the first four steps. Reduction of the 
ester 160 with diisobutylaluminium hydride to the benzyl alcohol 161 proceeded in 95% 
yield. Further synthesis towards the western fragment 148 was developed by Monika Vogt 
and Jekaterina Hermane.
[135,136]
 The Appel reaction with triphenylphosphine and 
tetrabromomethane in CH2Cl2 provided the benzyl bromide 156 in 99% yield. The compound 
156 was then subjected to the Filkenstein reaction affording the benzyl iodide 162 in 95% 
yield. The subsequent Evans alkylation with (S)-oxazolidinone 166 gave the desired 
diastereomer 163 in good yield. After removal of the auxiliary through reduction with lithium 
borohydride, the obtained alcohol was oxidized with the Dess-Martin periodinane to the 
aldehyde 155 which was then subjected to the Wittig reaction with triphenyl phosphonium 
ylide (167) providing the α,β-unsaturated ester 164 in 72% yield. The obtained ester 164 was 
reduced with DIBAL-H to the allyl alcohol 154 which reacted in the Sharpless epoxidation to 
give the desired epoxide 165 in 80% yield and a diastereomeric ratio higher than 10 : 1. 
 
Scheme 31. Synthesis of the western fragment 148. Reaction conditions: a) DIBAL-H, Et2O, RT, 5 h, 
85%; b) TBSOTf, 2,6-lutidine, CH2Cl2, 0 °C, 20 min, 74%; c) Proton Sponge, Me3OBF4, CH2Cl2, RT, 
1 h, 85%; d) LiBF4, MeCN, CH2Cl2, RT, 2 d, 75%; e) DMP, NaHCO3, CH2Cl2, RT, 1 h, 99%; f) 172, 
MS 4Å, toluene, −78 °C, 20 h, 80%, d.r. > 10 : 1. 
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In the second part of the synthesis, the epoxide 165 was reduced with DIBAL-H to give the 
diol 168 in 85% yield (Scheme 31). After the TBS-protection of the primary alcohol, 
methylation with trimethyloxonium tetrafluoroborate in the presence of Proton Sponge 
provided the compound 170 in 85% yield. The following deprotection and oxidation with 
DMP afforded the aldehyde 153 which was submitted to the last step of the western fragment 
synthesis – a stereoselective Roush crotylation. For the purpose of this reaction the (S,S)-
crotylboronate 172 was prepared according to the procedure described in a total synthesis of 
reblastatin.
[142]
 The synthesis of 172 involved two steps: preparation of the (Z)-
crotylaminoboronate complex from cis-butene, triisopropyl borate and diethanolamine, 
followed by the reaction with (S,S)-diisopropyl tartrate. Finally, the crotylation reaction 
between the aldehyde 153 and the (S,S)-crotylboronate 172 provided the desired western 
fragment 148 in 80% yield and a diastereomeric ratio higher than 10 : 1. The traces of the 
undesired diastereomer could easily be separated by flash chromatography. 
2.3.4 Synthesis of the Eastern Fragments 
2.3.4.1 Synthesis of the Eastern Fragment 149 
The synthesis of the eastern fragment 149 started with the diazotization of commercially 
available L-glutamic acid (158-L) providing the lactone 173a in 53% yield (Scheme 32). The 
compound 173a was then reduced with borane-dimethyl sulfide complex according to the 
procedure described by Herdeis, which afforded the corresponding hydroxymethyl derivative 
in 97% yield.
[143]
 Subsequently, the hydroxyl group was protected using p-methoxybenzyl 
trichloroacetimidate (179) which was prepared from 4-methoxybenzyl alcohol and 
trichloroacetonitrile as described by Jacobsen.
[144]
 In the next step the PMB-protected lactone 
174a was reduced to the diol 175a in 78% yield using lithium aluminium hydride. The 
following TBS-protection of the primary alcohol and the methylation of the second hydroxyl 
group provided the compound 177a in 94% yield. Removal of the p-methoxybenzyl group 
with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone afforded the alcohol 178a in 89% yield, 
which was subsequently oxidized to the aldehyde 157a with the DMP reagent.
[135]
 
The key step in the synthesis of the eastern fragment 149 was the Grignard addition in which 
stereoselectivity had to be controlled. For the transformation of the aldehyde 157a into the 
desired compound 149 two sets of conditions have been tested (Table 5). First, the carbonyl 
compound 157a was treated with isopropenylmagnesium bromide at −78 °C in CH2Cl2 in the 
presence of magnesium bromide ethyl etherate as a Lewis acid.
[145]
 This reaction provided the 
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desired syn-product 149 in 53% yield and with diastereomeric ratio syn : anti > 95 : 5. The 
second reaction was carried out in THF at −78 °C but without the Lewis acid leading to the 
product 149 in similar yield and with the same diastereoselectivity. Finally, the eastern 
fragment 149 has been prepared in 10% yield over nine steps. 
 
Scheme 32. Synthesis of the eastern fragment 149. Reaction conditions: a) NaNO2, HCl, H2O, 0 °C for 
2 h, then RT for 12 h, 53%; b) BH3·SMe2, THF, RT, 3 h, 97%; c) PMB-trichloroacetimidate (179), 
CSA, CH2Cl2, RT, 24 h, 60%; d) LiAlH4, THF, 0 °C, 30 min, 78%; e) TBSCl, imidazole, CH2Cl2, RT, 
1 h, 90%; f) NaH, MeI, THF, RT, 24 h, 94%; g) DDQ, CH2Cl2/H2O, RT, 1.5 h, 89%; h) DMP, 
NaHCO3, CH2Cl2, RT, 1 h, 99%; i) See Table 5. 
Entry Reaction conditions d.r. = syn : anti (yield) 
1 
Isopropenylmagnesium bromide,  
MgBr2·Et2O, CH2Cl2, −78 °C for 3 h, then RT 
> 95 : 5 (53%) 
2 
Isopropenylmagnesium bromide,  
THF, −78 °C for 3 h, then RT 
> 95 : 5 (56%) 
Table 5. Optimization of the Grignard reaction. 
To determine the absolute configuration of the stereogenic center at C-3, the secondary 
alcohol was transformed into the corresponding Mosher esters 180a and 180b using (S)-(+)- 
and (R)-(−)-α-methoxy-α-trifluoromethylphenylacetyl chlorides, respectively (Scheme 33). 
The obtained Mosher esters were analyzed using 
1
H NMR spectroscopy according to the 
Hoye’s protocol which bases on the fact that the MTPA esters display different chemical 
shifts of protons at the R
1
 and R
2 
substituents.
[146]
 The absolute configuration of the 
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stereogenic center at C-3 could be determined by analysis of the sign of the difference in 
chemical shifts for analogous pairs of protons (Table 6).  
 
Scheme 33. Synthesis of the Mosher esters 180a and 180b. Reaction conditions: a) (S)-(+)-MTPA-Cl, 
Et3N, DMAP, CH2Cl2, RT, 4 h, 84%; b) (R)-(−)-MTPA-Cl, Et3N, DMAP, CH2Cl2, RT, 4 h, 82%. 
Number 1H δ (S)-ester [ppm] δ (R)-ester[ ppm] ΔδSR = δS-δR 
2-Me 1.63 1.76 −0.13 
H-1a 5.08 5.13 −0.05 
H-1b 5.01 5.05 −0.04 
H-4 3.42 3.33 +0.09 
OMe 3.36 3.16 +0.20 
Table 6. Mosher ester analysis for the determination of the absolute configuration of the compound 
149 using 1H NMR.  
Based on empirical and computationally calculated models of conformations of the MTPA 
esters it has been known that the phenyl substituent imposes magnetic shielding effect on 
protons residing on or in close proximity to the axis perpendicular to the aryl ring (Scheme 
34).
[146]
  
 
Scheme 34. Conformations used for the analysis of the Mosher esters. 
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The protons of the R
2
 substituent are more shielded in the (S)-diastereomer which results in a 
more upfield chemical shift, while in the (R)-diastereomer the protons of the R
1
 group are 
more shielded. As a consequence, the sign of the ΔδSR value for protons of the R1 is positive 
and for those in R
2
 the sign is negative. In case of the eastern fragment 149 the sign of the 
ΔδSR value was positive for the proton H-4 and the methoxy group protons which indicates the 
S configuration of the stereogenic center at C-3. 
2.3.4.2 Synthesis of the Eastern Fragment 150a 
The synthesis of the aldehyde 157b is analogous to the preparation of the aldehyde 157a. It 
started from commercially available D-glutamic acid (158-D) which was subjected to 
diazotization to give the lactone 173b in 58% yield (Scheme 35).  
 
Scheme 35. Synthesis of the aldehyde 157b. Reaction conditions: a) NaNO2, HCl, H2O, 0 °C for 2 h, 
then RT for 12 h, 58%; b) BH3·SMe2, THF, RT, 3 h, 98%; c) PMB-trichloroacetimidate (179), CSA, 
CH2Cl2, RT, 24 h, 75%; d) LiAlH4, THF, 0 °C, 30 min, 73%; e) TBSCl, imidazole, CH2Cl2, RT, 1 h, 
92%; f) NaH, MeI, THF, RT, 24 h, 88%; g) DDQ, CH2Cl2/H2O, RT, 1.5 h, 89%; h) DMP, NaHCO3, 
CH2Cl2, RT, 1 h, 99%. 
The following reduction with borane-dimethyl sulfide complex and PMB-protection with  
p-methoxybenzyl trichloroacetimidate (179) provided the compound 174b in good yields. The 
lactone 174b was then reduced with lithium aluminium hydride in 73% yield to give the diol 
175b which was used in further syntheses of two other eastern fragments 151 and 152. The 
primary alcohol in the compound 175b was protected using tert-butyldimethylsilyl chloride in 
92% yield. The methylation of the hydroxyl group with methyl iodide proceeded in 88% yield 
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after which the following PMB-deprotection using 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone provided the compound 178b. Subsequently, the alcohol 178b was oxidized to 
the desired aldehyde 157b in 99% yield using the DMP reagent.
[135]
 
As it was shown for the eastern fragment 149, the Grignard addition to the aldehyde 157a 
underwent predominantly with syn-selectivity. In this case, the anti-diastereomer 150a was 
the desired one. Despite altering the reaction temperature and changing the solvent, the 
desired diastereoselectivity could not be achieved when isopropenylmagnesium bromide was 
employed (Table 7). When the aldehyde 157b was treated with isopropenylmagnesium 
bromide at −20 °C, the diastereomeric ratio amounted to 1 : 3 anti : syn (Entry 1). After 
lowering the temperature to −78 °C the ratio anti : syn remained unchanged (Entry 2). In 
another attempt the Grignard reagent was added to the aldehyde 157b in Et2O at −90 °C but 
this only improved undesired syn-selectivity (Entry 3).  
 
Entry Reaction conditions d.r. (anti : syn) 
1 
Isopropenylmagnesium bromide,  
Et2O, −20 °C for 2 h, then RT 
1 : 3 
2 
Isopropenylmagnesium bromide,  
Et2O, −78 °C for 3 h, then RT 
1 : 3 
3 
Isopropenylmagnesium bromide,  
Et2O, −90 °C for 3 h, then RT 
1 : 5 
Table 7. Optimization of the Grignard reaction. 
As the modification of the reaction conditions with the use of isopropropenymagnesium 
bromide did not provide a desired anti-selectivity, another approach has been taken into 
account (Scheme 36). 
Isopropenyllithium (183) has been prepared from lithium and 2-bromopropene (181) 
according to the procedure described by Leonard.
[147]
 The alcohol 178b was oxidized to the 
aldehyde 157b using the DMP reagent and treated with the prepared isopropenyllithium. 
Unfortunately, neither the anti-diastereomer 150a nor the syn-product 150b could be detected 
in the post-reaction mixture. 
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Scheme 36. Unsuccessful approach towards the eastern fragment 150a. Reaction conditions:  
a) 2-bromopropene (181), lithium, Et2O, RT, 3 h; b) DMP, NaHCO3, CH2Cl2, RT, 1 h, 98%;  
c) isopropenyllithium (182), Et2O, −78 °C, 3 h. 
Subsequently, a reduction reaction with chiral oxazoborolidinone catalyst 184 was tested 
(Scheme 37).
[148,149]
 Isopropenylmagnesium bromide was added to the aldehyde 157b 
providing the compound 150b with diastereomeric ratio syn : anti = 5 : 1 which was 
negligible at this point. The alcohol 150b was then oxidized to the ketone 183 in 86% yield 
with the use of the DMP reagent. The following reduction of the carbonyl group of 183 using 
the (S)-Corey-Bakshi-Shibata reagent (184) provided a 1 : 1 mixture of syn- and anti-products 
150. The desired anti-diastereomer 150a was purified by flash chromatography and obtained 
in 22% yield. Finally, the eastern fragment 150a has been prepared in 2.1% yield over eleven 
steps. 
 
Scheme 37. Synthesis of the eastern fragment 150a. Reaction conditions: a) isopropenylmagnesium 
bromide, Et2O, −90 °C, RT, 3 h, 50%, d.r. syn : anti = 5 : 1; b) DMP, NaHCO3, CH2Cl2, RT, 1 h, 86%; 
c) (S)-CBS (184), BH3·SMe2, THF, −78 °C, 24 h, d.r. syn : anti = 1 : 1; yields after separation: 25% 
for syn product, 22% for anti product. 
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2.3.4.3 Synthesis of the Eastern Fragment 151 
The eastern fragment 151 was synthesized from a commercially available D-glutamic acid 
(158-D) (Scheme 38). The synthetic pathway of the diol 175b was described in the previous 
section. Both hydroxyl groups in the compound 175b were protected with the use of  
tert-butyldimethylsilyl trifluoromethanesulfonate affording the compound 185 in 82% yield. 
The following deprotection of the PMB-group provided the alcohol 186 in 80% yield. The 
compound 186 was oxidized using the DMP reagent to give the aldehyde 157c in 99% 
yield.
[135] 
The subsequent Grignard addition with the use of isopropenylmagnesium bromide 
provided the desired eastern fragment 151 in 50% yield and with a diastereomeric ratio anti : 
syn = 8 : 1. Finally, the compound 151 has been prepared in 13.9% yield over eight steps. 
 
Scheme 38. Synthesis of the eastern fragment 151. Reaction conditions: a) NaNO2, HCl, H2O, 0 °C for  
2 h, then RT for 12 h, 58%; b) BH3·SMe2, THF, RT, 3 h, 98%; c) PMB-trichloroacetimidate (179), 
CSA, CH2Cl2, RT, 24 h, 75%; d) LiAlH4, THF, 0 °C, 30 min, 73%; e) TBSOTf, 2,6-lutidine, CH2Cl2, 
RT, 2.5 h, 82%; f) DDQ, CH2Cl2/H2O, RT, 1.5 h, 80%; g) DMP, NaHCO3, CH2Cl2, RT, 1 h, 99%; h) 
isopropenylmagnesium bromide, Et2O, −90 °C, 35 min, 50%, d.r. anti : syn = 8 : 1. 
The eastern fragment 151 has been predominantly formed as an anti-diastereomer (Figure 21), 
contrary to the synthesis of the eastern fragment 150 in which this selectivity was difficult to 
achieve. The bulky tert-butyldimethylsilyloxy group blocks the Cram-chelate pathway and 
favors the formation of the Felkin product. Similar observations have been reported by Shen 
and co-workers in their studies on the chelation-controlled isopropenylation of α-oxygenated 
64 
 
aldehydes.
[150]
 Switching the α-oxygenated substituent from methoxy to a more bulky  
α-OTBS group resulted in reversed selectivity and formation of the Felkin product. 
 
 
Figure 21. Diastereoselectivity in the Grignard reaction. 
To confirm the absolute configuration of the stereogenic center at C-3, the secondary alcohol 
was transformed into the Mosher esters 187a and 187b using (S)-(+)- and (R)-(−)-α-methoxy-
α-trifluoromethylphenylacetyl chlorides, respectively (Scheme 39). 
 
Scheme 39. Synthesis of the Mosher esters 187a and 187b. Reaction conditions: a) (S)-(+)-MTPA-Cl, 
Et3N, DMAP, CH2Cl2, RT, 3 h, 79%; b) (R)-(−)-MTPA-Cl, Et3N, DMAP, CH2Cl2, RT, 3 h, 70%. 
Similarly to the Mosher esters 180a and 180b, the absolute configuration at C-3 has been 
determined by analysis of the sign of the difference in chemical shifts for analogous pairs of 
protons in the 
1
H NMR spectra according to the Hoye’s protocol (Table 8).[146] In the eastern 
fragment 151 the sign of ΔδSR value was positive for the protons H-3 and H-4 and negative for 
H-1a, H-1b and the methyl group 2-Me which indicates the S configuration of the stereogenic 
center at C-3.  
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Number 1H δ (S)-ester [ppm] δ (R)-ester[ ppm] ΔδSR = δS-δR 
2-Me 1.69 1.78 −0.09 
H-1a 4.86 5.02 −0.16 
H-1b 4.74 5.00 −0.26 
H-4 3.90 3.85 +0.05 
H-3 5.45 5.38 +0.07 
 
Table 8. Mosher ester analysis for the determination of the absolute configuration of the compound 
151 using 1H NMR. 
2.3.4.4 Synthesis of the Eastern Fragment 152 
The eastern fragment 152 was prepared from the aldehyde 157c described in the previous 
section (Scheme 38). The Grignard reaction with the use of vinylmagnesium bromide 
provided the desired compound 152 in 60% yield and with diastereomeric ratio anti : syn =  
7 : 1 (Scheme 40). The eastern fragment 152 was previously described in the literature by 
Ōmura and co-workers and the Grignard reaction was optimized by Jekaterina Hermane 
towards better anti-selectivity.
[135,151]
 Finally, the compound 152 has been prepared in 12% 
yield over eight steps. 
 
Scheme 40. Synthesis of the eastern fragment 152 from the aldehyde 157c. Reaction conditions: 
vinylmagnesium bromide, Et2O, −90 °C, 35 min, 60%, d.r. anti : syn = 7 : 1. 
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2.3.5 Endgame of the Synthesis 
2.3.5.1 Olefin Metathesis Reaction 
One of the last steps in the synthesis of the desired seco-progeldanamycin acid derivatives 
was olefin cross-metathesis reaction between the western fragment 148 and the corresponding 
eastern fragments 149-152. To suppress a possible homodimerization of either of the olefins, 
one of the fragments ought to be used in excess. As the synthesis of the western fragment 148 
has been more time consuming, challenging and expensive, the corresponding eastern 
fragments were used in excess. 
 
Entry Catalyst 149 [eq.] Solvent T [° C] Time [h] 
1 Grubbs 2nd (189) 1.7 CH2Cl2 40 48 
2 Grubbs 2nd (189) 3.0 CH2Cl2 40 48 
3 Grubbs 2nd (189) 3.0 CH2Cl2 (degassed) 40 24 
4 Grubbs 2nd (189) 3.0 Toluene (degassed) 80 24 
5 
Hoveyda-Grubbs 2nd 
(190) 
1.7 CH2Cl2 40 48 
6 
Hoveyda-Grubbs 2nd 
(190) 
3.0 CH2Cl2 40 48 
7 Stewart-Grubbs (191) 3.0 CH2Cl2 40 48 
8 Catalyst 192 3.0 CH2Cl2 40 48 
9 Nitro-Grela (193) 3.0 CH2Cl2 40 48 
10 Nitro-Grela (193) 3.0 Toluene 80 48 
11 CAZ-1 (194) 3.0 CH2Cl2 40 48 
12 CAZ-1 (194) 3.0 Toluene 80 48 
Table 9. Screening of different catalysts for the olefin metathesis reaction. In each case the second 
portion of the catalyst was added after 10-12 h. 
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The approach towards the construction of the trisubstituted olefin in the geldanamycin (4) 
synthesis has been already reported by Andrus and co-workers.
[152]
 However, a challenging 
ring-closing metathesis involving a combination of a large ring and a trisubstituted olefin 
target was unsuccessful. The first metathesis reaction towards the compound 188 was tested 
between the western fragment 148 and the eastern fragment 149 (Table 9). A variety of 
conditions, including different catalysts (Figure 22), solvents, temperature and a number of 
eastern fragment equivalents was screened. 
 
Figure 22. Structures of catalysts tested in the metathesis reactions. 
The Grubbs
2nd 
catalyst (189) was explored as the first catalyst in four reactions carried out in 
CH2Cl2 or toluene with addition of 1.7 or 3 equivalents of the eastern fragment 149 (Entries 
1-4). Unfortunately, none of these reactions was successful and did not lead to the desired 
compound 188. The next catalyst used in the catalyst screening was the Grubbs-Hoveyda
2nd
 
catalyst (190) which was proven to be successful in the synthesis of the compounds 144-146 
prepared by Jekaterina Hermane.
[135]
 Unfortunately, also in this case no desired product 188 
was formed, probably due to the presence of an additional methyl group at C-6 when 
compared to the structures 144-146 (Entries 5-6). In the next two attempts, the Stewart-
Grubbs catalyst (191) and the catalyst 192 were used and the reactions were carried out in 
CH2Cl2 (Entries 7-8). Both catalysts have exhibited high efficiency in the preparation of 
tetrasubstituted olefins by cross-metathesis of sterically hindered olefins,
[153]
 however, the 
synthesis of the trisubstituted olefin 188 was unsuccessful. The nitro-analogue of Hoveyda-
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Grubbs
2nd
 catalyst (193)
[154]
, improved by changing the electronic properties of the Ru-
chelating fragment was used in the next two reactions (Entries 9-10). As with the catalyst 
CAZ-1 (194; Entries 11-12) and most of the above-described reactions, the substrates could 
be recovered from the post-reaction mixture while the formation of the trisubstituted olefin 
188 possessing a TBS substituent was not observed. 
Since the eastern fragments 150-151 also possess the methyl group at C-2, the metathesis 
reaction between the western fragment 148 and the corresponding olefins 150-151 has not 
been further explored. To synthesize the SNAc ester of 8-des-methyl-seco-progeldanamycin 
137, a cross-metathesis reaction between the western fragment 148 and the eastern fragment 
152 was carried out (Scheme 41). This reaction was optimized by Jekaterina Hermane and 
employed in the synthesis of the SNAc ester 146.
[135]
 The olefin 148 reacted with the alkene 
152 in the presence of the Grubbs-Hoveyda 2
nd
 catalyst (190). The reaction was performed in 
CH2Cl2 at 40 °C for 48 h and provided the desired product 195 in 40% yield. The coupling 
constant between H-6 and H-7 protons which was determined to be J = 15.2 Hz indicated an 
E-double bond in the prepared product. 
 
Scheme 41. Synthesis of 195. Conditions: Grubbs-Hoveyda 2nd (190), CH2Cl2, 40 °C, 48 h, 40%. 
2.3.5.2 Synthesis of the SNAc ester of 8-des-methyl-seco-progeldanamycin 137 
It has been known from the previous work of Jekaterina Hermane that open chain seco-acid 
derivatives and thioesters are unstable, while removal of the protecting groups may cause 
undesired reactions or degradation. Therefore, for the last steps of the total synthesis the 
mildest possible conditions had to be employed. All the reactions were controlled by mass 
spectrometry and TLC to monitor the progress of the reaction and when it had to be 
terminated. 
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First, the hydroxyl groups in the metathesis product 195 were planned to be protected with 
tert-butyldimethylsilyl trifluoromethanesulfonate (Table 10). Unfortunately, the results of 
these reactions at different conditions were not fruitful and did not provide the desired product 
196. After the first attempt with the use of 5 equivalents of 2,6-lutidine and 3 equivalents of 
TBSOTf, a single TBS-protection was observed (Entry 1). When the number of equivalents 
was increased to 6.5 and 4 for 2,6-lutidine and TBSOTf, respectively, both hydroxyl groups 
were protected but a simultaneous deprotection of the Boc group took place (Entry 2). A 
longer reaction with lower amounts of the reagents gave the same result (Entry 3). 
Unfortunately, increasing the number of equivalents along with a longer reaction time only 
resulted in decomposition of the substrate (Entry 4). 
  
Entry Reaction conditions Result 
1 RT, 3 h, CH2Cl2, TBSOTf (3.0 eq.), 2.6-lutidine (5.0 eq.) Single TBS-protection (71%) 
2 RT, 3 h, CH2Cl2, TBSOTf (4.0 eq.), 2.6-lutidine (6.5 eq.) Boc-deprotection (26%) 
3 RT, 12 h, CH2Cl2, TBSOTf (3.0 eq.), 2.6-lutidine (5.0 eq.) Boc-deprotection (26%) 
4 RT, 12 h, CH2Cl2, TBSOTf (3.5 eq.), 2.6-lutidine (6.0 eq.) decomposition 
Table 10. Unsuccessful TBS-protection reactions. 
Due to the problems with the TBS-protection reactions, another approach towards 8-des-
methyl-seco-progeldanamycin 137 was implemented (Scheme 42). The TBS groups were 
removed using pyridinium p-toluenesulfonate to give the polyol 197 in 90% yield. The 
following TBDPS-deprotection was carried out using tetra-n-butylammonium fluoride and 
optimized as presented in Table 11. The first two attempts with the use of 3 equivalents of 
TBAF·3H2O at 0 °C and RT did not provide the desired product 198 whereas the substrate 
197 could be recovered from the post-reaction mixture (Entries 1-2).  
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Scheme 42. Synthesis of seco-progeldanamycin derivative 137. Reaction conditions: a) PPTS, MeOH, 
40 °C, 48 h, 90%; b) See Table 11; c) TESOTf, 2,6-lutidine, CH2Cl2, −78 °C → RT, 1 h, 82%;  
d) (COCl)2, DMSO, DIPEA, CH2Cl2, −78 °C, 1.5 h, 80%; e) 202, CHCl3, 40 °C, 48 h, 86%, E/Z >  
10 : 1; f) TFA, 0 °C, 3 h, 73%. 
Also no product was observed for the next two reactions: with the use of a 1 M solution of 
TBAF in THF at −78 °C and at RT. However, in these cases the polyol 197 decomposed. The 
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use of 1.5 or 3 equivalents of TBAF·3H2O provided only traces of the product 198  
(Entries 5-6). Finally, the TBDPS-deprotected product 198 was obtained in 80% yield in the 
reaction carried out using 5 equivalents of TBAF·3H2O at −78 °C for 20 h (Entry 7). 
Entry Reaction conditions Result 
1 0 °C, 5 h, THF, TBAF·3H2O (3.0 eq.) No product, substrate recovered 
2 RT, 5 h, THF, TBAF·3H2O (3.0 eq.) No product, substrate recovered 
3 −78 °C, 20 h, THF, TBAF (1 M in THF, 5.0 eq.) No product, substrate decomposed 
4 RT, 20 h, THF, TBAF (1 M in THF, 5.0 eq.) No product, substrate decomposed 
5 −78 °C, 3 h, THF, TBAF·3H2O (1.5 eq.) Traces of the product 
6 −78 °C, 3 h, THF, TBAF·3H2O (3.0 eq.) Traces of the product 
7 −78 °C, 20 h, THF, TBAF·3H2O (5.0 eq.) 80% 
Table 11. Optimization of the TBDPS-deprotection reaction. 
All the hydroxyl groups in the polyol 198 were protected using triethylsilyl 
trifluoromethanesulfonate in 82% yield. The following Swern oxidation reaction provided the 
aldehyde 200 in 80% yield which was converted to the SNAc ester 201 using phosphonium 
ylide 202 in 86% yield. The ylide 202 was prepared according to the Hahn’s procedure in a 
two-step synthesis starting from 2-bromopropanoic acid.
[155]
 The final deprotection of the 
Boc- and TES-groups with the use of trifluoroacetic acid provided the desired 8-des-methyl-
seco-progeldanamycin acid derivative 137 in 73% yield. Overall, the compound 137 has been 
prepared in twenty-six steps (longest linear sequence) in the total yield of 5.6%. 
2.4 Summary and Outlook 
2.4.1 Summary 
The second part of the doctoral thesis was focused on another ansamycin antibiotic – 
geldanamycin. The total synthesis of new seco-progeldanamycin acid derivative was carried 
out to provide a substrate for the studies on the flexibility of the amide synthase (GdmF), a 
key enzyme in the geldanamycin biosynthesis responsible for the macrolactamization. 
The desired progeldanamycin derivative has been synthesized in twenty-six steps (longest 
linear sequence) in the overall yield of 5.6% (Scheme 42). On the basis of the previous work, 
the western fragment was prepared from 3,5-dihydroxybenzoic acid in nineteen steps in the 
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total yield of 4.7%. The key steps in the synthesis of this fragment were Sharpless 
epoxidation, Evans alkylation and Roush crotylation for the construction of the stereocenters 
at C-10 and C-11. 
 
Scheme 43. A) Synthesis of the eastern fragments 149-152. B) Synthesis of 8-des-methyl-seco-
progeldanamycin acid derivative 137. 
The eastern fragments were synthesized from D- of L-glutamic acid in 2-10% overall yields. 
The terminal double bond was installed by either syn- or anti-selective Grignard addition. To 
connect the western and eastern fragments olefin cross-metathesis reaction was carried out, 
while the introduction of the SNAc ester was achieved by the Wittig reaction.  
The seco-progeldanamycin acid derivative 137 has been obtained as one of the four 
compounds which had been planned to be synthesized. The most probable reason of the 
unsuccessful metathesis reaction was an additional methyl group at the terminal double bond 
of the eastern fragment which renders the sought trisubstituted olefin a much more difficult 
target to be achieved. 
The 8-des-methyl-seco-progeldanamycin acid derivative 137 is planned to be used in enzyme 
expression studies with the heterologously expressed amide synthase (GdmF) to investigate 
the tolerance and biosynthetic transformation by the enzyme. If the obtained amount of the 
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compound were larger, the prepared SNAc ester could be fed to a knockout strain of 
Streptomyces hygroscopicus var. geldanus (K-390-61-1) to obtain new geldanamycin 
derivative. 
2.4.2 Outlook of the Project 
For the future studies on the flexibility of the amide synthase (GdmF) more substrates should 
be prepared in order to investigate the tolerance and biosynthetic transformation by the 
enzyme (Scheme 44). 
 
Scheme 44. Possible pathways for the further investigation towards the substrate specificity of the 
amide synthase GdmF. 
The substrates could be modified at the positions C-2, C-6 and C-8. It has been known that 
the substituents at C-6 may affect toxicity, while modifications at C-8 should not have a 
significant impact on the anticancer activity of geldanamycin derivatives. The introduction of 
the methyl group at C-8 requires further optimization (e.g. relay metathesis) or new synthetic 
routes as all the attempts with the use of cross-metathesis reaction, unfortunately, failed. 
Additionally, an impact of alterations at C-10 and C-12 positions could be investigated. On 
the other hand, the synthesis could also be focused on the substrates which enable the 
production of 17- to 20-membered macrolactams. 
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The prepared progeldanamycin derivatives could be fed to the blocked mutant of S. 
hygroscopicus (K390-61-1) to obtain new geldanamycin derivatives. Additionally, the 
carbamoyl transferase (GdmN) could be expressed to investigate the carbamoylation of 
progeldanamycin derivatives. Following tests of biological activity of these compounds could 
provide essential information for the structure-activity relationship. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
3 Experimental Part 
3.1 Materials and Methods 
Reagents and Solvents 
Commercially available reagents (Acros Organics, Sigma Aldrich, ABCR, TCI) and solvents 
were used as received or purified by conventional methods prior to use as described in the 
literature.
[156]
 
Thin Layer and Column Chromatography 
Precoated silica gel 60 F254 plates (Merck, Darmstadt) were used for TLC and the spots were 
visualized with UV light at 254 nm or alternatively by staining with ninhydrine or potassium 
permanganate. Flash column chromatography was performed using silica gel MACHEREY-
NAGEL (grain size 40-63 μm). 
NMR Spectroscopy 
1
H NMR spectra were recorded with a Bruker 200 MHz spectrometer with DPX console, 
Bruker Avance-400 (400 MHz) with DPC console and Bruker DRX-500 (500 MHz) with 
DRX-console at room temperature. 
13
C NMR spectra were recorded at 100 MHz with a 
Bruker Avance-400 and at 125 MHz with a Bruker DRX-500. Chemical shifts are reported in 
δ (ppm) relative to TMS as the internal standard. Multiplicities are described using the 
following abbreviations: s – singlet, d – doublet, t – triplet, q – quartet, m – multiplet, b – 
broad. In 
13
C NMR following descriptors have been used for the order of the carbon atom: s –
quaternary, d – tertiary, t – secondary, q – primary. All coupling constants J are expressed in 
Hertz. 
HPLC 
High-performance liquid chromatography was performed using a VARIAN PROSTAR 
system (pump Prepstar Model 218, variable wavelength detector Prostar; preferred monitoring at 
λ = 248 nm) with the column TRENTEC Reprosil-Pur 120 C18 AQ (5 μm, 250 mm x 25 mm, 
with guard column 40 mm x 8 mm abbreviated C18-1) with parallel mass spectrometric 
detection (MICROMASS type ZMD ESI-Quad spectrometer). 
Semi-preparative high performance liquid chromatography was performed using a MERCK 
HITACHI Model 7000 system [pump L-7100, diode array detector L-7450 (λ = 220-400 nm, 
preferred monitoring at λ = 248 nm)] with the column NUCLEODUR C18 ISIS (5 μm, 250 mm 
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x 8 mm; abbreviated C18-2). Operating conditions and retention times (tR) are reported in the 
section 5.3. 
Mass Spectrometry 
Mass spectra were recorded with a type LCT (ESI) equipped with a lockspray dual ion source 
in combination with a WATERS Alliance 2695 LC system, or with a type QTOF premier 
(MICROMASS) spectrometer (ESI mode) in combination with a Waters Acquity S2 UPLC 
system equipped with a Waters Acquity UPLC BEH C18 1.7 μm (SN 01473711315545) 
column [solvent A: water + 0.1% (v/v) formic acid, solvent B: MeOH + 0.1% (v/v) formic 
acid; flow rate = 0.4 mL/min; gradient (t [min]/solvent B[%]: 0/5, 2.5/95, 6.5/95, 6.6/5, 8/5)]. 
Retention times (tR) are given in the section 3.3. Ion mass signals (m/z) are reported as values in 
atomic mass units. 
Melting Points 
Melting points (M.p.) were determined on a SRS OptiMelt apparatus and are reported 
uncorrected. 
Optical Rotation 
Specific optical rotation values [α]tD were measured on a polarimeter 341 (PERKIN ELMER) 
at a wavelength of 589 nm (D) and given temperature t. 
3.2 Mutasynthetic Experiments 
3.2.1 Bacterial Strain 
For a mutasynthetic approach a blocked mutant of Amycolatopsis mediterranei HGF003 was 
used. It is a knock-out of rifK – a gene encoding AHBA synthase which is indispensable in 
the biosynthesis of AHBA. Consequently, the bacterial strain is unable to produce rifamycin 
unless AHBA is added to the culture medium. 
3.2.2 Materials and Media 
All the work with bacteria was performed using sterile devices and media. The cultivation of 
A. mediterranei HGF003 strain was carried out on agar plates at 28 °C in a Heraeus or a 
Thermo Scientific Heratherm IGS100 incubator, while the cultivation in liquid medium was 
performed using a New Brunswick Scientific Innova
®
 4900 gyratory multi-shaker or a New 
Brunswick Scientific Innova® 44/44R stackable shaker at 200 rpm at 28 °C. The cultivation 
media were prepared using distilled water and sterilized by autoclaving: YMG-agar − 10 g/L 
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malt extract (Sigma Aldrich, Roth), 4 g/L yeast extract (Bacto, Duchefa Biochemie), 4 g/L D-
(+)-glucose·H2O (Roth), 22 g/L agar (Bacto, Roth); vegetative medium − 5 g/L beef extract 
powder (Sigma Aldrich), 5 g/L peptone (Roth), 5 g/L yeast extract (Bacto, Duchefa 
Biochemie), 2.5 g/L caseine hydrolysate (enzymatic, Roth), 1.5 g/L NaCl (Honeywell), 22 
g/L glucose·H2O; production medium: 25 g/L peanut meal, 9.6 g/L (NH4)2SO4, 9.5 g/L 
CaCO3, 126.5 g/L glucose·H2O, 1mL/L trace elements solution (1 g/L MgSO4·H2O, 1g/L 
CuSO4·5H2O, 1g/L FeSO4·7H2O, 1g/L MnSO4·H2O, 1g/L Co(NO3)2·6H2O). 
3.2.3 Cultivation Parameters 
Amycolatopsis mediterranei HGF003 was stored as spore suspensions in a 40% v/v 
glycerol/water solution at –80 °C and used for the inoculation of agar plates. For novel 
mutasynthons test fermentations were first carried out on 1-5 agar plates. When the 
acceptance of the substrate was confirmed by UPLC-MS, large-scale fermentation on 40 agar 
plates or in vegetative/production medium was conducted. Simultaneously, the microbial 
strain was fed with the natural starter building block 3-amino-5-hydroxybenzoic acid (AHBA, 
7) to monitor the productivity of the strain (positive control). The inoculated agar plates or 
flask charged with vegetative medium with no mutasynthon added constituted the zero 
control. 
Test fermentations were carried out on agar plates at 28 °C for 14 days. After 7 days 10 mg of 
a respective substrate dissolved in 1.5 mL of DMSO/water mixture per plate was added by 
sterile filtration. When cultivation was completed after additional seven days, homogenization 
by breaking agar plates and extraction with ethyl acetate was carried out. The combined 
extracts were dried over MgSO4 and the solvent was removed in vacuo.  
For cultivation in liquid medium, a few colonies were transferred directly from the agar plate 
after 7 days of growing to 500 mL baffled-bottom flasks or flasks with steel springs 
containing vegetative medium (50 mL per flask). Precultures were shaken for 3 days at 28 °C 
before inoculation of the main cultures (500 mL baffled-bottom flask or flask with steel 
springs charged with 50 mL of production medium, 0.0625 mmol of substrate dissolved in 4 
mL of a DMSO/water mixture, preferably 1 : 1). Shaking was continued at 28 °C for 4 days 
for total cultivation time of 13 days. Scale-up fermentations were carried out in vegetative (50 
mL per flask) and production media (1 L, 1.25 mmol/L of substrate in 4 mL of a 
DMSO/water mixture, 4 mL of inoculum from vegetative medium per flask) as described 
above. 
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3.2.4 HPLC and MS Analyses 
The purification and fractionation of the fermentation material in the amounts of >10 mg was 
carried out using preparative high-performance liquid chromatography equipped with a 
VARIAN PROSTAR system. For the amounts ≤10 mg semi-preparative high performance 
liquid chromatography with a MERCK HITACHI Model 7000 system was used (section 5.1). 
Before HPLC analysis, the crude material was filtered through a column chromatography 
(silica gel, elution with ethyl acetate) in order to remove the bacteria cells followed by a 
sequence of chromatographic purifications. Before each injection the sample was dissolved in 
a 1 : 1 mixture of methanol and water (HPLC grades) and filtered through a PTFE syringe 
filter Rotilabo (pore size: 0.45 µm, nominal diameter: 13 mm). 
For the detection of the products from the fermentation cultures samples from the culture 
broth (200 µL) were dissolved in methanol (200 µL), centrifuged (1 min, 4 °C) and screened 
by UPLC-MS (section 5.1). 
3.2.5 Preparation of the Spore Suspensions 
A. mediterranei strain HGF003 was stored as spore suspensions in a 40% (v/v) glycerol/water 
solution at –80 °C. Three weeks after inoculation of the YMG agar plates, 3-4 mL of water 
was added onto agar plate. The surface of the agar plate was rinsed and the liquid was filtered 
through a sterile cotton to a sterile falcon. After the subsequent addition of 1-2 mL of water 
and rinsing the plate, the solution was vortex mixed for ca 45 seconds, filtered through a 
sterile cotton to a new falcon and centrifuged (4 °C, 5 minutes, 5000 rpm). The supernatant 
was removed and the obtained precipitation was dissolved in a 40% (v/v) glycerol/water 
solution and transferred to a sterile Eppendorf vial. To monitor the productivity of the 
prepared spores, the microbial strain was fed with the natural starter building block AHBA (3-
amino-5-hydroxybenzoic acid) and test fermentations were carried out. For the detection of 
the expected product – rifamycin B, the crude material (200 µL) was dissolved in methanol  
(200 µL), centrifuged (1 min, 4 °C) and screened by UPLC-MS. When the productivity of the 
strain was confirmed by UPLC-MS, the spore suspensions were used for inoculation of YMG 
agar plates. 
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3.2.6 Optimization of Medium Components Under Liquid State Fermentation 
Conditions 
For the liquid state fermentation the medium components had to be optimized. For this 
purpose three sets of media were tested: 
1. Vegetative medium: 5 g/L beef extract powder, 5 g/L peptone, 5 g/L yeast extract, 2.5 
g/L caseine hydrolysate (enzymatic), 1.5 g/L NaCl, 22 g/L glucose·H2O.  
Production medium: 25 g/L peanut meal, 9.6 g/L (NH4)2SO4, 9.5 g/L CaCO3, 126.5 
g/L glucose·H2O, 1mL/L trace elements solution (1 g/L MgSO4·H2O, 1g/L 
CuSO4·5H2O, 1g/L FeSO4·7H2O, 1g/L MnSO4·H2O, 1g/L Co(NO3)2·6H2O). 
2. Vegetative medium: 20 g/L glucose·H2O, 3 g/L KH2PO4, 1.5 g/L K2HPO4, 0.016 g/L 
MgSO4·H2O, 0.001 g/L Zn(OAc)2, 5 g/L yeast extract. 
Production medium: 40 g/L glucose·H2O, 3g/L KH2PO4, 1.5 g/L K2HPO4, 0.016 g/L 
MgSO4·H2O, 0.001g/L Zn(OAc)2, 5g/L yeast extract. 
3. Vegetative medium: 20 g/L starch, 15 g/L glucose·H2O, 10 g/L soybean meal, 10 g/L 
peptone, 5 g/L KNO3, 0.3 g/L KH2PO4, 3 g/L CaCO3.  
Production medium: 120 g/L glucose·H2O, 20 g/L soybean meal, 10 g/L peptone, 5 
g/L fish meal, 8 g/L KNO3, 0.5 g/L KH2PO4, 1 mg/L CoCl2·6H2O, 5 g/L CaCO3. 
The concentration of rifamycins in the fermentation broth was determined 
spectrophotometrically according to the Pasqualucci’s method.[157] The measurement is 
possible because of the presence of the naphthoquinone-naphthohydroquinone system which 
has maximum absorption peak in the visible light region. The general procedure can be 
summarized as follows: the samples were prepared by taking two 1 mL portions from each 
fermentation flask. One aliquot was diluted 1 : 6 with buffer A (acetate buffer of pH 4.63 
prepared by mixing of 100 mL 1 M NaOH and 200 mL 1 M acetic acid, completing with 
distilled water to the final volume to 1 L) and the other similarly with buffer B (buffer A 
containing 0.1% w/v sodium nitrite) as blank. After shaking for 5 minutes, the absorbance of 
the solution diluted with buffer A was determined at 425 nm in a 1 cm cell against the 
solution diluted with solution B. The rifamycin B concentration was calculated from the 
measured absorbance using the formula: 
80 
 
rif B (
µg
mL
) =  
𝐴425  × 50 000
21.5
 
where A425 is the absorbance at 425 nm and 21.5 is the absorption of rifamycin B determined 
by this method. 
The rifamycin B concentration after the fermentation carried out under conditions described 
above in the point 1 was calculated as 307 mg/L (A425 = 0.132). Under the conditions reported 
in the point 2 bacteria did not grow. Under fermentation conditions 3 a growth was observed 
but no rifamycin B was produced. 
For additional detection of rifamycin B/novel products, 200 µL of samples from the 
fermentation broth were mixed with 200 µL of methanol and centrifuged at 14 000 rpm for 5 
minutes. The clear supernatant (200 µL) was subjected to UPLC-MS analyses (rifamycin B: 
HRMS-ESI (m/z): [M+H]
+
 calcd for [C39H50NO14]
+: 756.3231, found: 756.3228; [M−H]− 
calcd for [C39H48NO14]
−
: 754.3080, found: 754.3057; tR = 3.2 min; conditions: solvent A = 
water + 0.1% (v/v) formic acid, solvent B = MeOH + 0.1% (v/v) formic acid; flow rate = 0.4 
mL/min; gradient (t [min]/solvent B [%]): 0/5; 2.5/95; 6.5/95; 6.6/5; 8/5). 
For isolation of novel products from large-scale fermentations, the fermentation broth was 
extracted three times with ethyl acetate, dried over MgSO4, concentrated under reduced 
pressure and filtered through silica gel eluting with ethyl acetate followed by removal of the 
solvent in vacuo. The crude fermentation extract was subjected to chromatographic 
purification steps. 
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3.3 Characteristic of Rifamycins and the Mutasynthetically Produced Tetraketides 
Rifamycin B (1) 
 
Rifamycin B (1) was obtained as an orange solid after supplementing a culture of the blocked 
mutant of A. mediterranei (strain HGF003) with 3-hydroxy-5-nitrobenzoic acid (95) (fed 229 
mg – 1.25 mmol/L; HRMS, LC-MS/MS), 3-azido-5-hydroxybenzoic acid (94) (fed 168 mg – 
0.94 mmol/750 mL; isolated amount = 1.5 mg; 2 mg/L) and 3-amino-5-hydroxybenzoic acid 
(7) (fed 191 mg – 1.25 mmol/L; isolated amount = 20 mg/L). 
1. HPLC: preparative HPLC (C18-1): solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/20; 5/20; 50/55; 90/100; 100/100; tR = 82.0 min. 
2. HPLC: preparative HPLC (C18-1): solvent A: water, solvent B: MeOH; flow rate = 15.0 
mL/min; gradient (t [min]/solvent B [%]): 0/40; 5/40; 20/50; 50/50; 100/100; tR = 75.0 min. 
3. HPLC: preparative HPLC (C18-1): solvent A: water, solvent B: MeOH; flow rate = 15.0 
mL/min; gradient (t [min]/solvent B [%]): 0/10; 5/10; 85/100; 100/100; tR = 69.0 min. 
UPLC-MS (MeOH) tR = 3.2 min; HRMS-ESI (m/z): [M+H]
+
 calcd for [C39H50NO14]
+
: 
756.3231, found: 756.3228; [M−H]− calcd for [C39H48NO14]
−
: 754.3080, found: 754.3057. 
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Rifamycin S (9) 
 
Rifamycin S (9) was obtained as a yellow solid after supplementing a culture of the blocked 
mutant of A. mediterranei (strain HGF003) with 3-hydroxy-5-nitrobenzoic acid (95) (fed 229 
mg – 1.25 mmol/L; UPLC-HRMS), 3-azido-5-hydroxybenzoic acid (94) (fed 168 mg – 0.94 
mmol/750 mL; isolated amount = 1.0 mg; 1.3 mg/L) and 3-amino-5-hydroxybenzoic acid (7) 
(fed 191 mg – 1.25 mmol/L; isolated amount = 1.1 mg/L). Additionally, fermentation with 
AHBA (7) on agar plates (fed 50 mg – 0.33 mmol/125 mL; 10 mg/plate) yielded 0.3 mg of 
rifamycin S (9) (2.4 mg/L). 
1. HPLC: preparative HPLC (C18-1): solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/20; 5/20; 50/55; 90/100; 100/100; tR = 77.0 min. 
2. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/20; 5/20; 70/55; 90/100; 100/100; tR = 84.0 
min. 
3. HPLC: semi-preparative HPLC (C18-2) solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/20; 5/20; 50/60; 100/100; tR = 68.0 min. 
The analytical data are in accordance with the reported in the literature.
[158,159]
 
1
H NMR (500 MHz, C6D6, C6D5H = 7.16 ppm) δ (ppm): 12.73 (s, 1 H, 8-OH), 8.34 (s, 1 H, 
3-H), 8.29 (s, 1 H, 2-NH), 6.34 (d, J = 12.6 Hz, 1 H, 29-H), 6.28 (dd, J = 15.7, 8.3 Hz, 1 H, 
18-H), 5.86 (d, J = 8.3 Hz, 1 H, 17-H), 5.77 (dd, J = 15.7, 8.3 Hz, 1 H, 19-H), 5.27 (dd, J = 
12.6, 8.6 Hz, 1 H, 28-H), 4.63 (d, J = 1.5 Hz, 1 H, 25-H), 3.91 (d, J = 4.2 Hz, 1 H, 23-OH), 
3.71 (s, 1 H, 21-OH), 3.49 (d, J = 9.5 Hz, 1 H, 21-H), 3.01 (dd, J = 9.0, 3.4 Hz, 1 H, 27-H), 
2.96 (ddd, J = 10.1, 4.3, 1.7 Hz, 1 H, 23-H), 2.78 (s, 3 H, 37-H), 2.37 s, 3 H, 14-H), 2.28 – 
2.24 (m, 1 H, 20-H), 1.90 – 1.87 (m, 1 H, 26-H), 1.79 (s, 3 H, 30-H), 1.60 (s, 3 H, 13-H), 1.59 
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(s, 3 H, 36-H), 1.50 (m, 1 H, 22-H), 1.47 (m, 1 H, 24-H), 0.99 (d, J = 7.0 Hz, 3 H, 32-H), 0.64 
(d, J = 7.3 Hz, 3 H, 31-H), 0.45 (d, J = 7.1 Hz, 3 H, 33-H), 0.23 (d, J = 7.1 Hz, 3 H, 34-H); 
13
C NMR (125 MHz, C6D6, C6D6 = 128.06 ppm) δ (ppm): 190.7 (s, C-11), 185.4 (s, C-1), 
181.8 (s, C-4), 173.5 (s, C-35), 172.5 (s, C-6), 169.2 (s, C-15), 167.0 (s, C-8), 146.3 (d, C-29), 
142.5 (d, C-19), 139.8 (s, C-2), 133.1 (d, C-17), 131.5 (s, C-16), 131.5 (s , C-10), 124.7 (d, C-
18), 117.1 (d, C-3), 115.2 (d, C-28), 115.1 (s, C-7), 111.5 (s, C-5), 111.4 (s, C-9), 109.1 (s, C-
12), 82.8 (d, C-27), 78.0 (d, C-23), 73.9 (d, C-21), 73.9 (d, C-25), 56.3 (q, C-37), 40.4 (d, C-
20), 37.7 (d, C-26), 37.4 (d, C-24), 33.1 (d, C-22), 22.8 (q, C-13), 20.6 (q, C-36), 20.3 (q, C-
30), 16.6 (q, C-31), 12.4 (q, C-34), 11.8 (q, C-32), 8.9 (q, C-33), 7.5 (q, C-14); UPLC-MS 
(MeOH) tR = 3.0 min; HRMS-ESI (m/z): [M+H]
+
 calcd for [C37H46NO12]
+
: 696.3020, found: 
696.3022. 
Rifamycin W (24) 
 
Rifamycin W (24) was obtained as a yellow solid after supplementing a culture of the blocked 
mutant of A. mediterranei (strain HGF003) with 3-amino-5-hydroxybenzoic acid (7) (fed 50 
mg – 0.33 mmol/125 mL; 10 mg/plate) carried out on agar plates (isolated amount = 1.6 mg; 
12.8 mg/L). 
1. HPLC: preparative HPLC (C18-1): solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/20; 5/20; 50/55; 90/100; 100/100; tR = 67.0 min. 
2. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/20; 5/20; 70/55; 90/100; 100/100; tR = 74.0 
min. 
The analytical data are in accordance with the reported in the literature.
[30,31]
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1
H NMR (500 MHz, CD3OD, CHD2OD = 4.87 ppm) δ (ppm): 8.40 (bs, 1H, 2-NH), 7.57 (s, 
1H, 3-H), 6.50 (dd, J = 16.0, 11.0 Hz, 1H, 18-H), 6.41 (d, J = 10.0 Hz, 1H, 29-H), 6.25 (d, J = 
11.0 Hz, 1H, 17-H), 6.08 (dd, J = 16.0, 6.7 Hz, 1H, 19-H), 4.61 (bs, 1H, 6-OH), 4.39 (bs, 1H, 
8-OH), 4.04 (dd, J = 10.0, 1.0 Hz, 1H, 21-H), 4.01 (dd, J = 10.0, 1.0 Hz, 1H, 23-H), 3.58 (dd, 
J = 10.9, 7.9 Hz, 1H, 34aa-H), 3.48 (dd, J = 10.0, 2.0 Hz, 1H, 25-H), 3.44 (dd, J = 10.8, 6.5 
Hz, 1H, 34ab-H), 3.21 – 3.13 (m, 1H, 28-H), 2.63 (dd, J = 16.6, 7.3 Hz, 1H, 27-H), 2.38 – 
2.32 (m, 1H, 20-H), 2.16 (s, 3H, 14-H), 2.09 (bs, 3H, 13-H), 2.08 (bs, 3H, 30-H), 1.88 – 1.85 
(m, 1H, 22-H), 1.82 – 1.79 (m, 1H, 24-H), 1.44 – 1.38 (m, 1H, 26-H), 1.06 (d, J = 7.1 Hz, 3H, 
33-H or 34-H), 0.92 (d, J = 7.0 Hz, 3H, 31-H), 0.73 (d, J = 6.8 Hz, 3H, 33-H or 34-H), 0.43 
(d, J = 7.0 Hz, 3H, 32-H); 
13
C NMR (125 MHz, CD3OD, CD3OD = 49.0 ppm) δ (ppm): 201.2 
(s, C-11 ), 187.1 (s, C-4), 183.4 (s, C-1), 172.2 (s, C-15), 164.7 (s, C-8), 164.1 (s, C-6), 142.6 
(d, C-19), 141.5 (d, C-29), 140.9 (s, C-12), 140.8 (s, C-2), 135.2 (d, C-17), 132.1 (s, C-16), 
129.9 (s, C-10), 126.3 (d, C-18), 122.2 (s, C-5), 119.0 (s, C-7), 118.0 (d, C-3), 107.5 (s, C-9), 
79.0 (d, C-27), 74.8 (d, C-23), 71.0 (d, C-21), 69.1 (d, C-25), 64.5 (t, C-34a), 49.6 (d, C-28), 
44.1 (d, C-26), 39.1 (d, C-20), 37.9 (d, C-24), 34.3 (d, C-22), 20.2 (q, C-30), 18.0 (q, C-13), 
12.7 (q, C-34), 11.7 (q, C-32), 11.2 (q, C-31), 8.9 (q, C-33), 8.5 (q, C-14); UPLC-MS 
(MeOH) tR = 2.9 min; HRMS-ESI (m/z): [M+H]
+
 calcd for [C35H46NO11]
+
: 656.3071, found: 
656.3068. 
Tetraketide 42 
 
Tetraketide 42 was obtained after supplementing a culture of the blocked mutant of A. 
mediterranei (strain HGF003) with 3-amino-4-bromobenzoic acid (41) (fed 214 mg – 0.99 
mmol/800 mL). The fermentation was carried out in liquid medium providing compound 42 
as a colorless solid (isolated amount = 15.0 mg; 19.0 mg/L). The yield is better than the one 
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obtained after fermentation on agar plates (fed 300 mg – 0. 94 mmol/750 mL; 10 mg/plate; 
isolated amount = 7.0 mg/750 mL; 9.0 mg/L). 
1. HPLC: preparative HPLC (C18-1): solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/20; 5/20; 50/55; 90/100; 100/100; tR = 50.0 min. 
2. HPLC: preparative HPLC (C18-1): solvent A: water, solvent B: MeOH; flow rate = 15.0 
mL/min; gradient (t [min]/solvent B [%]): 0/10; 5/10; 50/55; 90/100; 100/100; tR = 56.0 min. 
3. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/10; 5/10; 80/45; 90/100; 100/100; tR = 64.0 
min. 
The analytical data are in accordance with the reported in the literature.
[68]
  
1
H NMR (400 MHz, CD3OD, CD2HOD = 3.31 ppm) δ (ppm): 7.33 (d, J = 8.2 Hz, 1H, H-12), 
6.82 (d, J = 2.0 Hz, 1H, H-9), 6.54 (dd, J = 8.2, 2.0 Hz, 1H, H-13), 6.04 (s, 1H, H-4), 4.63 (d, 
J = 8.6 Hz, 1H, H-7), 2.81 (dq, J = 14.1, 7.0 Hz, 1H, H-6), 1.87 (s, 3H, H-14), 0.99 (d, J = 7.1 
Hz, 3H, H-15); 
13
C NMR (100 MHz, CD3OD, CD3OD = 49.0 ppm) δ (ppm): 169.2 (s, C-1), 
168.2 (s, C-3), 165.8 (s, C-5), 146.5 (s, C-10), 144.3 (s, C-8), 133.3 (d, C-12), 118.1 (d, C-
13), 115.4 (d, C-9), 108.9 (s, C-11), 102.4 (d, C-4), 99.2 (s, C-2), 76.6 (d, C-7), 47.2 (d, C-6), 
15.5 (q, C-15), 8.3 (q, c-14); UPLC-MS (MeOH) tR = 2.6 min; HRMS-ESI (m/z): [M+H]
+
 
calcd for [C15H17BrNO4]
+
: 354.0341, found: 354.0341. 
Tetraketide 67 
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Tetraketide 67 was obtained after supplementing a culture of the blocked mutant of A. 
mediterranei (strain HGF003) with 3-hydroxybenzoic acid (64) (fed 173 mg – 1.25 mmol/L). 
The fermentation was carried out in liquid medium providing compound 67 as a colorless 
foam (isolated amount = 118.0 mg). 
HPLC: preparative HPLC (C18-1): solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/20; 5/20; 50/55; 90/100; 100/100; tR = 44.0 min. 
The analytical data are in accordance with the reported in the literature.
[75]
 
1
H NMR (400 MHz, CD3OD, CD2HOD = 3.31 ppm) δ (ppm): 7.15 (t, J = 8.1 Hz, 1H, H-12), 
6.82 – 6.76 (m, 2H, H-11 or H-13, H-9), 6.73 – 6.66 (m, 1H, H-11 or H-13), 6.06 (s, 1H, H-
4), 4.67 (d, J = 8.8 Hz, 1H, H-7), 2.83 (dq, J = 14.1, 7.1 Hz, 1H, H-6), 1.88 (s, 3H, H-14), 
0.98 (d, J = 7.0 Hz, 3H, H-15); 
1
H NMR (400 MHz, THF-d8, THF-d7 = 1.73 ppm) δ (ppm): 
7.06 (t, J = 7.8 Hz, 1H, H-12), 6.75 – 6.73 (m, 2H, H-11 or H-13, H-9), 6.62 (ddd, J = 8.0, 
2.3, 1.0 Hz, 1H, H-11 or H-13), 5.85 (s, 1H, H-4), 4.64 (d, J = 8.4 Hz, 1H, H-7), 2.71 (dq, J = 
15.0, 7.1 Hz, 1H, H-6), 1.83 (s, 3H, H-14), 0.93 (d, J = 7.1 Hz, 3H, H-15);  
13
C NMR (100 MHz, THF-d8, THF-d8 = 25.5 ppm) δ (ppm): 166.0 (s, C-3), 165.4 (s, C-5), 
165.2 (s, C-1), 158.6 (s, C-10), 146.0 (s, C-8), 129.6 (d, C-12), 118.6 (d, C-13), 115.2 (d, C-
11), 114.6 (d, C-9), 100.9 (s, C-2),98.7 (d, C-4), 76.2 (d, C-7), 47.4 (d, C-6), 15.3 (q, C-15), 
8.7 (q, C-14); UPLC-MS (MeOH) tR = 2.4 min; HRMS-ESI (m/z): [M+H]
+
 calcd for 
[C15H17O5]
+
: 277.1076, found: 277.1075; [α]20D = −14.3° (c = 1.0, MeOH). 
Tetraketide 68 
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Tetraketide 68 was obtained after supplementing a culture of the blocked mutant of A. 
mediterranei (strain HGF003) with 3,5-dihydroxybenzoic acid (65) (fed 193 mg – 1.25 
mmol/L). The fermentation was carried out in liquid medium providing compound 68 as a 
colorless solid (isolated amount = 4.2 mg). 
1. HPLC: preparative HPLC (C18-1): solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/20; 5/20; 50/55; 90/100; 100/100; tR = 41.0 min. 
2. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/10; 5/10; 80/45; 90/100; 100/100; tR = 32.0 
min. 
3. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/10; 5/10; 60/25; 90/90, 100/100; tR = 37.0 
min. 
The analytical data are in accordance with the reported in the literature.
[75]
 
1
H NMR (400 MHz, CD3OD, CD2HOD = 3.31 ppm) δ (ppm): 6.29 (d, J = 2.2 Hz, 2H, H-9, 
H-13), 6.19 (t, J = 2.2 Hz, 1H, H-11), 6.04 (s, 1H, H-4), 4.58 (d, J = 8.8 Hz, 1H, H-7), 2.78 
(dq, J = 14.2, 7.1 Hz, 1H, H-6), 1.87 (s, 3H, H-14), 0.99 (d, J = 7.1 Hz, 3H, H-15); 
13
C 
NMR (100 MHz, CD3OD, CD3OD = 49.0 ppm) δ (ppm): 169.4 (s, C-3), 169.0 (s, C-5), 165.9 
(s, C-1), 159.6 (s, C-10, C-12), 146.1 (s, C-8), 106.4 (d, C-9, C-13), 103.0 (d, C-11), 102.7 (s, 
C-4), 99.0 (d, C-2), 77.0 (d, C-7), 47.2 (d, C-6), 15.6 (q, C-15), 8.34 (q, C-14); UPLC-MS 
(MeOH) tR = 2.2 min; HRMS-ESI (m/z): [M+H]
+
 calcd for [C15H17O6]
+
: 293.1025, found: 
293.1028; [α]20D = −3.0° (c = 0.33, MeOH). 
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Tetraketide 69 
 
Tetraketide 69 was obtained after supplementing a culture of the blocked mutant of A. 
mediterranei (strain HGF003) with 3-hydroxy-5-(hydroxymethyl)benzoic acid (48) (fed 210 
mg – 1.25 mmol/L). The fermentation was carried out in liquid medium providing compound 
69 as a colorless solid which gradually decomposed during HPLC purification steps. 
1. HPLC: preparative HPLC (C18-1): solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/20; 5/20; 50/55; 90/100; 100/100; tR = 38.0 min. 
2. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/10; 5/10; 80/45; 90/100; 100/100; tR = 30.0 
min. 
3. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/10; 5/10; 60/25; 90/90, 100/100; tR = 47.0 
min. 
1
H NMR (400 MHz, CD3OD, CD2HOD = 3.31 ppm) δ (ppm): 6.81 (s, 1H, Ar), 6.74 (s, 1H, 
Ar), 6.68 (s, 1H, Ar), 6.04 (s, 1H, H-4), 4.67 (d, J = 8.8 Hz, 1H, H-7), 4.53 (s, 2H, ArCH2), 
2.82 (dq, J = 14.2, 7.1 Hz, 1H, H-6), 1.86 (s, 3H, H-14), 0.97 (d, J = 7.0 Hz, 3H, H-15); 
UPLC-MS (MeOH) tR = 2.0 min; HRMS-ESI (m/z): [M+H]
+
 calcd for 
[C16H19O6]
+
: 307.1182, found: 307.1187. 
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Tetraketide 87 
 
Tetraketide 87 was obtained after supplementing a culture of the blocked mutant of A. 
mediterranei (strain HGF003) with 3-amino-2-fluorobenzoic acid (55) (fed 194 mg – 1.25 
mmol/L). The fermentation was carried out in liquid medium providing compound 87 as a 
colorless solid (isolated amount = 25.0 mg). 
1. HPLC: preparative HPLC (C18-1): solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/20; 5/20; 50/55; 90/100; 100/100; tR = 39.0 min. 
2. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/5; 10/5; 20/10; 60/40; 90/100; 100/100; tR = 
46.0 min. 
3. HPLC: preparative HPLC (C18-1): solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/10; 10/10; 20/10; 60/40; 100/100; tR = 68.0 min. 
1
H NMR (400 MHz, CD3OD, CD2HOD = 3.31 ppm) δ (ppm): 6.90 (t, J = 7.8 Hz, 1H, H-12), 
6.78 – 6.71 (m, 2H, H-13, H-11), 6.06 (s, 1H, H-4), 5.09 (d, J = 8.9 Hz, 1H, H-7), 2.90 (dq, J 
= 14.4, 7.2 Hz, 1H, H-6), 1.86 (s, 3H, H-14), 1.01 (d, J = 7.0 Hz, 3H, H-15); 
13
C 
NMR (100 MHz, CD3OD, CD3OD = 49.0 ppm) δ (ppm): 169.2 (s, C-3), 168.2 (s, C-5), 165.7 
(s, C-1), 150.7 (s, C-9), 136.7 (s, C-10), 130.5 (s, C-8), 125.3 (d, C-12), 117.4 (d, C-13), 
117.2 (d, C-11), 102.5 (d, C-4), 99.2 (s, C-2), 70.3 (d, C-7), 46.8 (d, C-6), 15.3 (q, C-15), 8.3 
(q, C-14); UPLC-MS (MeOH) tR = 2.3 min; HRMS-ESI (m/z): [M+H]
+
 calcd for 
[C15H17FNO4]
+
: 294.1142, found: 294.1140; [α]20D = −11.2° (c = 1.15, MeOH). 
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Tetraketide 88 
 
Tetraketide 88 was obtained after supplementing a culture of the blocked mutant of A. 
mediterranei (strain HGF003) with 3-amino-4-fluorobenzoic acid (75) (fed 194 mg – 1.25 
mmol/L). The fermentation was carried out in liquid medium providing compound 88 as a 
colorless solid (isolated amount = 20 mg). 
1. HPLC: preparative HPLC (C18-1): solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/20; 5/20; 50/55; 90/100; 100/100; tR = 46.0 min. 
2. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/5; 10/5; 20/10; 60/40; 90/100; 100/100; tR = 
50.0 min. 
1
H NMR (400 MHz, CD3OD, CD2HOD = 3.31 ppm) δ (ppm): 6.90 (dd, J = 11.2, 8.3 Hz, 1H, 
H-12), 6.83 (dd, J = 8.7, 2.1 Hz, 1H, H-9), 6.60 (ddd, J = 8.3, 4.4, 2.1 Hz, 1H, H-13), 6.04 (s, 
1H, H-4), 4.62 (d, J = 8.8 Hz, 1H, H-7), 2.79 (dq, J = 14.1, 7.1 Hz, 1H, H-6), 1.86 (s, 3H, H-
14), 0.95 (d, J = 7.0 Hz, 3H, H-15); 
13
C NMR (100 MHz, CD3OD, CD3OD = 49.0 
ppm) δ (ppm): 169.2 (s, C-3), 168.1 (s, C-5), 166.0 (s, C-1), 152.7 (s, C-11), 140.1 (s, C-8), 
136.7 (s, C-10), 117.4 (d, C-13), 116.7 (d, C-9), 115.6 (d, C-12), 102.3 (d, C-4), 99.2 (s, C-2), 
76.6 (d, C-7), 47.3 (d, C-6), 15.6 (q, C-15), 8.3 (q, C-14); UPLC-MS (MeOH) tR = 2.4 min; 
HRMS-ESI (m/z): [M+H]
+
 calcd for [C15H17FNO4]
+
: 294.1142, found: 294.1144; [α]20D = 
−19.3° (c = 0.75, MeOH). 
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Tetraketide 89 
 
Tetraketide 89 was obtained after supplementing a culture of the blocked mutant of A. 
mediterranei (strain HGF003) with 3-amino-5-(azidomethyl)benzoic acid (77) (fed 240 mg – 
1.25 mmol/L). The fermentation was carried out in liquid medium providing compound 89 as 
a colorless solid (isolated amount = 2.5 mg). 
1. HPLC: preparative HPLC (C18-1): solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/20; 5/20; 50/55; 90/100; 100/100; tR = 36.0 min. 
2. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/10; 5/10; 50/35; 90/80; 100/100; tR = 49.0 
min. 
1
H NMR (500 MHz, CD3OD, CD2HOD = 3.31 ppm) δ (ppm): 6.69 (t, J = 1.6 Hz, 1H, H-13), 
6.65 – 6.60 (m, 2H, H-9, H-11), 6.04 (s, 1H, H-4), 4.64 (d, J = 8.8 Hz, H-7), 4.21 (s, 2H, 
ArCH2), 2.81 (dq, J = 14.1, 7.1 Hz, H-6), 1.86 (s, 3H, H-14), 0.97 (d, J = 7.1 Hz, H-15); 
13
C 
NMR (125 MHz, CD3OD, CD3OD = 49.0 ppm) δ (ppm): 169.4 (s, C-3), 168.9 (s, C-5), 165.9 
(s, C-1), 149.6 (s, C-10), 145.4 (s, C-8), 137.9 (s, C-12), 117.5 (d, C-13), 115.7 (d, C-11), 
114.8 (d, C-9), 102.7 (d, C-4), 99.1 (s, C-2), 77.0 (d, C-7), 55.7 (t, ArCH2), 47.3 (d, C-6), 15.6 
(q, C-15), 8.3 (q, C-14); UPLC-MS (MeOH) tR = 2.54 min; HRMS-ESI (m/z): [M+H]
+
 calcd 
for [C16H19N4O4]
+
: 331.1406, found: 331.1406; [α]20D = −4.3° (c = 0.2, MeOH). 
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Tetraketide 90 
 
Tetraketide 90 was obtained after supplementing a culture of the blocked mutant of A. 
mediterranei (strain HGF003) with 3-amino-5-fluorobenzoic acid hydrochloride (78·HCl) 
(fed 239 mg – 1.25 mmol/L). The fermentation was carried out in liquid medium providing 
compound 90 as a colorless solid (isolated amount = 2.5 mg). 
1. HPLC: preparative HPLC (C18-1): solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/20; 5/20; 50/55; 90/100; 100/100; tR = 39.0 min. 
2. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/10; 5/10; 80/45; 90/100; 100/100; tR = 62.0 
min. 
3. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/10; 10/10; 20/30; 60/40; 90/90, 100/100; tR = 
43.0 min. 
1
H NMR (500 MHz, CD3OD, CD2HOD = 3.31 ppm) δ (ppm): 6.45 (t, J = 2.0 Hz, 1H, H-9), 
6.35 – 6.32 (dt, J = 11.0, 2.0 Hz 1H, H-13), 6.31 – 6.29 (dt, J = 11.0, 2.0 Hz, 1H, H-11), 6.04 
(s, 1H, H-4), 4.59 (d, J = 8.7 Hz, H-7), 2.77 (dq, J = 14.0, 7.1 Hz, H-6), 1.85 (s, 3H, H-14), 
0.98 (d, J = 7.1 Hz, H-15); 
13
C NMR (125 MHz, CD3OD, CD3OD = 49.0 ppm) δ (ppm): 
169.3 (s, C-3), 168.8 (s, C-5), 165.7 (s, C-1), 165.3 (s, C-12), 146.9 (s, C-10), 146.8 (s, C-8), 
110.5 (d, C-9), 103.0 (d, C-13), 102.7 (s, C-2), 101.8 (d, C-11), 99.1 (d, C-4), 76.7 (d, C-7), 
47.1 (d, C-6), 15.6 (q, C-15), 8.3 (q, C-14); UPLC-MS (MeOH) tR = 2.3 min; HRMS-ESI 
(m/z): [M+H]
+
 calcd for [C15H17FNO4]
+
: 294.1142, found: 294.1140. 
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Tetraketide 91 
 
Tetraketide 91 was obtained after supplementing a culture of the blocked mutant of A. 
mediterranei (strain HGF003) with 3-amino-5-(trifluoromethyl)benzoic acid (79) (fed 256 mg 
– 1.25 mmol/L). The fermentation was carried out in liquid medium providing compound 91 
as a colorless solid (isolated amount = 1.0 mg). 
1. HPLC: preparative HPLC (C18-1): solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/20; 5/20; 50/55; 90/100; 100/100; tR = 57.0 min. 
2. HPLC: preparative HPLC (C18-1): solvent A: water, solvent B: MeOH; flow rate = 15.0 
mL/min; gradient (t [min]/solvent B [%]): 0/10; 5/10; 50/35; 90/100; 100/100; tR = 74.0 min. 
3. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/20; 5/20; 50/55; 90/100; 100/100; tR = 68.0 
min. 
4. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]):0/10; 5/10; 50/35; 90/100; 100/100; tR = 69.0 
min. 
1
H NMR (500 MHz, CD3OD, CD2HOD = 3.31 ppm) δ (ppm): 6.92 – 6.86 (m, 3H, H-13, H-
11, H-9), 6.01 (s, 1H, H-4), 4.72 (d, J = 8.5 Hz, 1H, H-7), 2.81 (dq, J = 14.0, 6.9 Hz, 1H, H-
6), 1.87 (s, 3H, H-14), 1.00 (d, J = 7.1 Hz, 3H, H-15); 
13
C NMR (125 MHz, CD3OD, 
CD3OD = 49.0 ppm) δ (ppm): 179.4 (s, C-3), 169.3 (s, C-5), 165.5 (s, C-1), 150.2 (s, C-10), 
146.0 (s, C-8), 132.4 (s, C-12), 125.8 (s, C-16), 117.6 (d, C-9), 112.8 (d, C-13), 111.3 (d, C-
11), 102.7 (d, C-4), 99.2 (s, C-2), 76.6 (d, C-7), 47.1 (d, C-6), 15.3 (q, C-15), 8.3 (q, C-14); 
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UPLC-MS (MeOH) tR = 2.6 min; HRMS-ESI (m/z): [M+H]
+
 calcd for [C16H17F3NO4]
+
: 
344.1110, found: 344.1114. 
Tetraketide 92 
 
Tetraketide 92 was obtained after supplementing a culture of the blocked mutant of A. 
mediterranei (strain HGF003) with 3-amino-5-cyanobenzoic acid (80) (fed 102 mg – 0.63 
mmol/500 mL). The fermentation was carried out in liquid medium providing compound 92 
as a colorless solid (isolated amount = 3.5 mg; 7.0 mg/L). 
1. HPLC: preparative HPLC (C18-1): solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/10; 5/10; 90/100; 100/100; tR = 41.0 min. 
2. HPLC: preparative HPLC (C18-1): solvent A: water, solvent B: MeOH; flow rate = 15.0 
mL/min; gradient (t [min]/solvent B [%]): 0/20; 5/20; 70/50; 90/100; 100/100; tR = 51.0 min. 
3. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/20; 5/20; 70/50; 90/100; 100/100; tR = 21.0 
min. 
3. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/5; 5/5; 50/5; 90/100; 100/100; tR = 65.0 min. 
1
H NMR (500 MHz, CD3OD, CD2HOD = 3.31 ppm) δ (ppm): 6.90 – 6.86 (m, 2H, H-11, H-
9), 6.84 (dd, J = 2.1. 1.5 Hz, 1H, H-3), 6.04 (s, 1H, H-4), 4.65 (d, J = 8.5 Hz, 1H, H-7), 2.81 
(dq, J = 14.2, 7.1 Hz, 1H, H-6), 1.86 (s, 3H, H-14), 0.99 (d, J = 7.1 Hz, 3H, H-15); 
13
C 
NMR (125 MHz, CD3OD, CD3OD = 49.0 ppm) δ (ppm): 169.3 (s, C-3), 168.3 (s, C-5), 165.6 
(s, C-1), 150.7 (s, C-10), 146.7 (s, C-8), 120.5 (s, C-16), 119.8 (d, C-11), 118.8 (d, C-9), 
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117.4 (d, C-13), 113.7 (s, C-12), 102.7 (d, C-4), 99.5 (s, C-2), 76.4 (d, C-7), 47.2 (d, C-6), 
15.6 (q, C-15), 8.5 (q, C-14); UPLC-MS (MeOH) tR = 2.1 min; HRMS-ESI (m/z): [M+H]
+
 
calcd for [C16H17N2O4]
+
: 301.1188, found: 301.1140. 
Tetraketide 93 
 
Tetraketide 93 was obtained after supplementing a culture of the blocked mutant of A. 
mediterranei (strain HGF003) with 5-amino-2-fluorobenzoic acid (83) (fed 194 mg – 1.25 
mmol/L). The fermentation was carried out in liquid medium providing compound 93 as a 
colorless solid (isolated amount = 1.1 mg). 
1. HPLC: preparative HPLC (C18-1): solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/20; 5/20; 50/55; 90/100; 100/100; tR = 26.0 min. 
2. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/10; 5/10; 80/45; 90/100; 100/100; tR = 50.0 
min. 
1
H NMR (500 MHz, CD3OD, CD2HOD = 3.31 ppm) δ (ppm): 8.25 (s, 1H, 7-OH), 7.64 (dd, J 
= 6.3, 2.6 Hz, H-12), 7.61 – 7.57 (m, 1H, H-9), 7.09 – 7.02 (m, 1H, H-11), 5.95 (s, 1H, H-4), 
5.15 (d, J = 8.4 Hz, 1H, H-7), 2.89 (dq, J = 14.5, 7.0 Hz, 1H, H-6), 1.85 (s, 3H, H-14) 1.06 (d, 
J = 7.0 Hz, H-15); 
13
C NMR (125 MHz, CD3OD, CD3OD = 49.0 ppm) δ (ppm): 164.2 (s, C-
3), 163.7 (C-5) 161.5 (s, C-1), 159.4 (s, C-13), 135.4 (s, C-10), 131.7 (s, C-8), 122.3 (d, C-
11), 121.0 (d, C-9), 117.0 (s, C-2), 116.4 (d, C-12), 98.0 (d, C-4), 69.8 (d, C-7), 46.8 (d, C-6), 
15.1 (q, C-15), 8.6 (q, C-14); UPLC-MS (MeOH) tR = 2.2 min; HRMS-ESI (m/z): [M+H]
+
 
calcd for [C15H17FNO4]
+
: 294.1142, found: 294.1130; [α]20D = −9.0° (c = 0.07, MeOH). 
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Tetraketide 96 
 
Tetraketide 96 was obtained after supplementing a culture of the blocked mutant of A. 
mediterranei (strain HGF003) with 3-azido-5-hydroxybenzoic acid (94) (fed 168 mg – 0.94 
mmol/750 mL). The fermentation was carried out in liquid medium providing compound 96 
as brown crystals (isolated amount = 35 mg; 47 mg/L). 
1. HPLC: preparative HPLC (C18-1): solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/20; 5/20; 50/55; 90/100; 100/100; tR = 53.0 min. 
2. HPLC: preparative HPLC (C18-1): solvent A: water, solvent B: MeOH; flow rate = 2.5 
mL/min; gradient (t [min]/solvent B [%]): 0/10; 5.0/10; 50/55; 90/100; 100/100; tR = 55.0 
min. 
1
H NMR (400 MHz, CD3OD, CHD2OD = 3.31 ppm) δ (ppm): 8.06 (s, 1H, 12-OH), 6.54 – 
6.51 (m, 1H, 9-H), 6.47 – 6.44 (m, 1H, 13-H), 6.33 (t, J = 2.1 Hz, 1H, 11-H), 6.01 (s, 1H, 4-
H), 4.62 (d, J = 8.4 Hz, 1H, 7-H), 3.89 (s, 1H, 7-OH), 2.76 (dq, J = 8.3, 7.1 Hz, 1H, 6-H), 
1.81 (s, 3H, 14-H), 0.95 (d, J = 7.1 Hz, 3H, 15-H); 
13
C NMR (100 MHz, CD3OD, CD3OD = 
49.0 ppm) δ (ppm): 169.1 (s, C-3), 167.8 (s, C-5), 165.6 (s, C-1), 159.9 (s, C-12), 147.1 (s, C-
10), 142.41 (s, C-8), 112.0 (d, C-9), 109.3 (d, C-11), 106.3 (d, C-13), 102.3 (s, C-2), 99.3 (d, 
C-4), 76.5 (d, C-7), 47.1 (d, C-6), 15.3 (q, C-15), 8.3 (q, C-14); UPLC-MS (MeOH) tR = 2.3 
min; HRMS-ESI (m/z): [M+H]
+
 calcd for [C15H16N3O5]
+
: 318.1090, found: 318.1080;  
[α]20D = +7.8° (c = 0.5, MeOH). 
 
 
97 
 
Tetraketide 102 
 
Tetraketide 102 was obtained after supplementing a culture of the blocked mutant of A. 
mediterranei (strain HGF003) with 3,5-dinitrobenzoic acid (97) (fed 27 mg – 0.12 mmol/100 
mL) and 3-amino-5-nitrobenzoic acid (98) (fed 57 mg – 0.31 mmol/250 mL). The 
fermentations were carried out in liquid medium providing compound 102 as a yellow solid 
(isolated amount = 7.0 mg; 70 mg/L and 18.0 mg; 72 mg/L, respectively). 
Fermentation with 3,5-dinitrobenzoic acid (97) (fed 50 mg – 0. 24 mmol/125 mL; 10 
mg/plate) carried out on agar plates provided 2.0 mg of the title compound 102 (16 mg/L). 
1. HPLC: semi-preparative HPLC (C18-2): solvent A: water + 0.1% (v/v) formic acid, 
solvent B: MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t 
[min]/solvent B [%]): 0/20; 5.0/20; 50/55; 90/100; 100/100; tR = 18.0 min. 
2. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/15; 5.0/15; 80/45; 90/100; 100/100; tR = 33.0 
min. 
3. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/5; 5.0/5; 15.0/5; 90/100; 100/100; tR = 68.0 
min. 
1
H NMR (400 MHz, CD3OD, CHD2OD = 3.31 ppm) δ (ppm): 7.51 − 7.43 (m, 1H, H-13), 
7.40 (t, J = 2.2 Hz, 1H, H-11), 7.00 − 6.94 (m, 1H, H-9), 6.05 (s, 1H, H-4), 4.76 (d, J = 8.3 
Hz, 1H, H-7), 4.59 (bs, 1H, OH), 2.86 (dq, J = 8.3, 7.1 Hz, 1H, H-6), 1.87 (s, 3H, H-14), 1.03 
(d, J = 7.1 Hz, 3H, H-15); 
13
C NMR (100 MHz, CD3OD, CD3OD = 49.0 ppm) δ (ppm): 171.4 
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(s, C-3), 169.8 (s, C-5), 164.7 (s, C-1), 150.9 (s, C-12), 150.7 (s, C-10), 146.6 (s, C-8), 119.8 
(d, C-11), 110.6 (d, C-13), 109.3 (d, C-4), 108.5 (d, C-9), 98.5 (s, C-2), 76.2 (d, C-7), 47.0 (d, 
C-6), 15.2 (q, C-15), 8.5 (q, C-14); UPLC-MS (MeOH) tR = 2.4 min; HRMS-ESI (m/z): 
[M+H]
+
 calcd for [C15H17N2O6]
+
: 321.1087, found: 354.1065. 
3-Acetamido-2-hydroxybenzamide (103) 
 
3-Acetamido-2-hydroxybenzamide (103) was obtained after feeding to the blocked mutant of 
A. mediterranei HGF003 3-azido-2-hydroxybenzoic acid (63) (fed 224 mg – 1.25 mmol/L). 
The fermentation was carried out in liquid medium providing compound 103 as a colorless 
solid (isolated amount = 11.1 mg). 
1. HPLC: preparative HPLC (C18-1): solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/20; 5/20; 50/55; 90/100; 100/100; tR = 23.0 min.  
2. HPLC: preparative HPLC (C18-1): solvent A: water, solvent B: MeOH; flow rate = 15.0 
mL/min; gradient (t [min]/solvent B [%]): 0/10, 20/15, 60/25, 90/45, 100/100; tR = 41.0 min. 
3. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/10, 20/15, 60/15, 90/45, 100/100; tR = 7.0 
min. 
4. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/5, 20/10, 60/10, 90/45, 100/100; tR = 7.0 min. 
1
H NMR (400 MHz, DMSO-d6, DMSO-d5 = 2.5 ppm) δ (ppm): 13.94 (s, 1H, OH), 9.21 (s, 
1H, NHAc), 8.67 (s, 1H, CONH2), 8.07 (dd, J = 7.8, 1.0 Hz, 1H, H-6), 7.93 (s, 1H, CONH2), 
7.56 (dd, J = 8.0, 1.2 Hz, 1H, H-4), 6.75 (t, J = 8.0 Hz, 1H, H-5); 
13
C 
NMR (100 MHz, CD3OD, CD3OD = 49.0 ppm) δ (ppm): 174.5 (s, CONH2), 171.9 (s, 
NHCOCH3), 154.2 (s, C-2), 128.6 (s, C-3), 127.0 (d, C-4), 124.1 (d, C-6), 118.7 (d, C-5), 
115.3 (s, C-1), 23.8 (q, NHCOCH3); UPLC-MS (MeOH) tR = 1.9 min; HRMS-ESI (m/z): 
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[M+H]
+
 calcd for [C9H11N2O3]
 +
: 195.0770, found: 195.0768; [M−H]− calcd for [C9H9N2O3]
−
: 
193.0619, found: 193.0612. 
3-Azido-2-hydroxybenzamide (104) 
 
3-Azido-2-hydroxybenzamide (104) was obtained after feeding to the blocked mutant of A. 
mediterranei HGF003 3-azido-2-hydroxybenzoic acid (63) (fed 224 mg – 1.25 mmol/L). The 
fermentation was carried out in liquid medium providing compound 104 as a brown solid 
(isolated amount = 7.7 mg). 
1. HPLC: preparative HPLC (C18-1): solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/20; 5/20; 50/55; 90/100; 100/100; tR = 44.0 min.  
2. HPLC: semi-preparative HPLC (C18-2): solvent A: water, solvent B: MeOH; flow rate = 
2.5 mL/min; gradient (t [min]/solvent B [%]): 0/10, 20/15, 60/25, 90/45, 100/100; tR = 27.0 
min. 
1
H NMR (400 MHz, DMSO-d6, DMSO-d5 = 2.5 ppm) δ (ppm): 14.11 (s, 1H, OH), 8.67 (s, 
1H, CONH2), 8.10 (s, 1H, CONH2), 7.67 (dd, J = 8.0, 1.3 Hz, 1H, H-6), 7.15 (dd, J = 7.6, 1.0 
Hz, 1H, H-4), 6.82 (t, J = 7.9 Hz, H-5); 
13
C NMR (100 MHz, CD3OD, CD3OD = 49.0 
ppm) δ (ppm): 174.2 (s, CONH2), 156.3 (s, C-2), 129.4 (s, C-3), 125.7 (d, C-4), 125.2 (d, C-
5), 119.6 (d, C-6), 116.4 (s, C-1); UPLC-MS (MeOH) tR = 1.92 min; HRMS-ESI (m/z): 
[M+H]
+
 calcd for [C7H7N4O2]
+
: 179.0569, found: 179.0560; [M−H]− calcd for 
[C7H5N4O2]
−
: 177.0418, found: 177.0416. 
3.4 Synthesis of Mutasynthons 
The preparation of the benzoic acid derivatives was carried out according to the literature 
procedures: 3-amino-4-fluorobenzoic acid (75),
[73,160]
 3-amino-5-(azidomethyl)benzoic acid 
(77),
[57]
 3-amino-5-cyanobenzoic acid (80),
[161]
 3-amino-5-(hydroxymethyl)benzoic acid 
(82),
[70]
 3-azido-5-hydroxybenzoic acid (94).
[57]
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Mutasynthons 41 (3-amino-4-bromobenzoic acid), 64 (3-hydroxybenzoic acid), 65 (3,5-
dihydroxybenzoic acid), 70 (anthranilic acid), 71 (2-amino-3-nitrobenzoic acid), 72 (2-amino-
4-nitrobenzoic acid), 73 (4-aminobenzoic acid), 74 (4-amino-3-nitrobenzoic acid), 79 (3-
amino-5-(trifluoromethyl)benzoic acid), 81 (3-amino-5-(methoxycarbonyl)benzoic acid), 84 
(5-amino-2-nitrobenzoic acid), 85 (3-amino-2,5,6-trifluorobenzoic acid), 86 (2,5-
dihydroxybenzoic acid), 95 (3-hydroxy-5-nitrobenzoic acid), 97 (3,5-dinitrobenzoic acid), 98 
(3-amino-5-nitrobenzoic acid) are commercially available. 
3-Amino-5-hydroxybenzoic acid hydrochloride (7·HCl) 
 
3,5-Dihydroxybenzoic acid (65) (22.5 g, 146 mmol, 1.0 eq.), ammonium chloride (19.1 g, 358 
mmol, 2.45 eq.) and conc. NH3 (30% in water, 67.5 mL) were placed in a steel bomb (model 
T304, PARR INSTRUMENT COMPANY) and heated at 180 °C for 40 h. After cooling 
down the reaction mixture was evaporated in vacuo to dryness and the residue was treated 
with 6 M HCl (50 mL) followed by heating under reflux for 3 h. After crystallization at 4 °C 
the brownish solid was recrystallized upon addition of activated charcoal from half-conc. 
HCl. The desired hydrochloride 7·HCl (15.5 g, 81.8 mmol, 56%) was obtained as a 
crystalline, beige solid. 
The analytical data are in accordance with the reported in the literature.
[138,139]
 
1
H NMR (400 MHz, CD3OD, CD2HOD = 3.31 ppm) δ (ppm): 7.51 (dd, J = 2.3, 1.3 Hz, 1H, 
H-6), 7.49 (dd, J = 2.0, 1.4 Hz, 1H, H-2), 7.07 (t, J = 2.2 Hz, 1H, H-4), 5.04 (s, NH3); 
13
C 
NMR (100 MHz, CD3OD, CD3OD = 49.0 ppm) δ (ppm): 168.0 (s, COOH), 160.4 (s, C-5), 
135.1 (s, C-3), 133.1 (s, C-1), 118.1 (d, C-4), 115.7 (d, C-6), 115.4 (d, C-2); HRMS-ESI 
(m/z): [M−H]− calcd for [C7H6NO3]
−
: 152.0348, found: 152.0351; [M+H]
+
 calcd for 
[C7H8NO3]
+
: 154.0504, found: 154.0507; M.p.: 200–203 °C (Lit. 199–200 °C).[139] 
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2-(3-Carboxy-5-hydroxyphenyl)-hydrazin-1-ium chloride (66·HCl) 
 
3-Amino-5-hydroxybenzoic acid hydrochloride (7·HCl) (0.1 g, 0.53 mmol, 1.0 eq.) was 
suspended in conc. HCl (5.0 mL) and cooled down to −10 °C. NaNO2 (0.06 g, 0.8 mmol, 1.5 
eq.) was dissolved in water (0.5 mL) and added to the substrate. After 30 minutes SnCl2·H2O 
(0.36 g, 1.58 mmol, 3.0 eq.) in conc. HCl (0.5 mL) was added and the reaction mixture was 
stirred at −10 °C for 3 h. The solid was filtered off and dried under vacuum. The product 66 
(0.102 g, 0.5 mmol, 95%) was obtained as a colorless solid. 
The analytical data are in accordance with the reported in the literature.
[135]
 
1
H NMR (400 MHz, DMSO-d6, DMSO-d5 = 2.50 ppm) δ (ppm): 10.71 (bs, 3H, NH3), 9.95 
(bs, 1H, NH), 8.37 (bs, 1H, OH), 7.00 (dd, J = 2.0, 1.4 Hz, 1H, H-4), 6.95 (dd, J = 2.1, 1.4 
Hz, 1H, H-2), 6.64 (t, J = 2.2 Hz, 1H, H-6); 
13
C NMR (100 MHz, DMSO-d6, DMSO-d6 = 
39.5 ppm) δ (ppm): 167.2 (s, COOH), 158.1 (s, C-Ar), 147.4 (s, C-Ar), 132.4 (s, C-Ar), 109.2 
(d, C-Ar), 105.9 (d, C-Ar), 105.6 (d, C-Ar); HRMS-ESI (m/z): [M+H]
+ 
calcd for 
[C7H9N2O3]
+
: 169.0613, found: 169.0612. 
3-Hydroxy-5-(hydroxymethyl)benzoic acid (48) 
 
5-Hydroxyisophthalic acid (45) (10 g, 55 mmol, 1.0 eq.) was dissolved in MeOH (50 mL) and 
treated with conc. H2SO4 (0.5 mL). The reaction mixture was stirred under refluxing 
conditions for 20 h. After that time MeOH was removed under reduced pressure and the 
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residue was dissolved in EtOAc. The organic phase was washed with water (30 mL) and NaCl 
solution (20 mL), dried over MgSO4 and concentrated in vacuo. The product 46 was obtained 
as a colorless solid (11.2 g, 53.4 mmol, 97%) and used in the next step without further 
purification. 
The analytical data are in accordance with the reported in the literature.
[160]
 
1
H NMR (400 MHz, DMSO-d6, DMSO-d5 = 2.50 ppm) δ (ppm): 10.30 (s, 1H, Ar-OH), 7.92 
(s, 1H, H-2), 7.55 (d, J = 1.5 Hz, 2H, H-4, H-6), 3.85 (s, 6H, COOMe); 
13
C 
NMR (100 MHz, DMSO-d6, DMSO-d6 = 39.5 ppm) δ (ppm): 165.4 (s, COOMe), 157.9 (s, C-
5), 131.4 (s, C-1, C-3), 120.3 (d, C-2), 120.1 (d, C-4, C-6), 52.4 (q, COOMe); HRMS-ESI 
(m/z): [M+Na]
+
 calcd for [C10H10O5Na]
+
: 233.0426, found: 233.0425; M.p.: 160–161 °C (Lit. 
158–159 °C).[162] 
Dimethyl 5-hydroxyisophthalate (46) (11.2 g, 53.4 mmol, 1.0 eq.) was dissolved in THF (150 
mL), cooled down to 0 °C and treated with a LiAlH4 solution (1 M in THF, 40 mmol, 40 mL, 
0.75 eq.) which was added dropwise for 2 h. At the end of the addition 60 mL of THF was 
added to enable stirring. The suspension was stirred at RT for another 1.5 h. After that time 
the reaction was terminated by addition of water and THF was removed under reduced 
pressure. HCl (2 M, 30 mL) was added to the residue to destroy the aluminate complexes and 
NaHCO3 was used to adjust pH of the solution to pH = 7. The obtained mixture was saturated 
with an aqueous NaCl solution and extracted three times with EtOAc. The combined organic 
phases were dried over MgSO4 and concentrated under reduced pressure. The crude product 
was purified by flash chromatography (PE : EA = 3 : 1 to 1 : 1) to give the ester 47 (4.3 g, 
23.6 mmol, 44%) as a colorless solid. 
The analytical data are in accordance with the reported in the literature.
[71]
 
1
H NMR (400 MHz, DMSO-d6, DMSO-d5 = 2.50 ppm) δ (ppm): 9.76 (s, 1H, Ar-OH), 7.38 
(s, 1H, H-6), 7.21 (s, 1H, H-2), 6.99 (s, 1H, H-4), 5.27 (s, 1H, CH2OH), 4.48 (s, 2H, CH2OH), 
3.82 (s, 3H, COOMe); 
13
C NMR (100 MHz, DMSO-d6, DMSO-d6 = 39.5 ppm) δ (ppm): 
166.4 (s, COOMe), 157.5 (s, C-3), 144.9 (s, C-5), 130.6 (s, C-1), 118.1 (d, C-Ar), 117.8 (d, C-
Ar), 114.0 (d, C-Ar), 62.4 (t, CH2OH), 52.1 (q, COOMe); HRMS-ESI (m/z): [M−H]
−
 calcd 
for [C9H9O4]
−
: 181.0501, found: 181.0502; M.p.: 140–141 °C. 
Methyl 3-hydroxy-5-(hydroxymethyl)benzoate (47) (2.5 g, 13.7 mmol, 1.0 eq.) was dissolved 
in MeOH (40 mL), treated with a 1 M solution of LiOH (68.6 mmol, 69 mL, 5.0 eq.) and the 
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mixture was stirred at RT for 2 h. After that time the solution was acidified to pH = 3 with 2 
M HCl and extracted three times with EtOAc. The combined organic phased were dried over 
MgSO4 and concentrated under reduced pressure to give the product 48 (2.2 g, 13.1 mmol, 
96%) as a colorless solid. 
The analytical data are in accordance with the reported in the literature.
[70]
 
1
H NMR (400 MHz, DMSO-d6, DMSO-d5 = 2.50 ppm) δ (ppm): 9.68 (s, 1H, Ar-OH), 7.35 
(s, 1H, H-6), 7.20 (s, 1H, H-2), 6.96 (s, 1H, H-4), 5.23 (s, 1H, CH2OH), 4.46 (s, 2H, CH2OH); 
13
C NMR (100 MHz, DMSO-d6, DMSO-d6 = 39.5 ppm) δ (ppm): 167.5 (s, COOH), 157.3 (s, 
C-3), 144.6 (s, C-5), 131.8 (s, C-1), 118.1 (d, C-6), 117.7 (d, C-4), 114.2 (d, C-2), 62.5 (t, 
CH2OH); HRMS-ESI (m/z): [M−H]
−
 calcd for [C8H7O4]
−
: 167.0344, found: 167.0344; M.p.: 
129–130 °C (Lit. 127 °C).[76]  
3-(Aminomethyl)-5-hydroxybenzoic acid (53) 
 
 
3-Hydroxy-5-(hydroxymethyl)benzoic acid (48) (561 mg, 3.34 mmol, 1.0 eq.) was dissolved 
in MeOH (90 mL) and treated with conc. H2SO4 (0.23 mL, 4.34 mmol, 1.3 eq.). The solution 
was heated under refluxing conditions for 24 h. After that time the solution of NaHCO3 was 
added to the reaction mixture and MeOH was removed in vacuo. The aqueous phase was 
extracted three times with EtOAc. The combined organic phases were washed with an 
aqueous NaCl solution, dried over MgSO4 and concentrated under reduced pressure. The 
product 47 (608 mg, 3.34 mmol, quant.) was obtained as colorless crystals and used directly 
in the next step without further purification. 
The analytical data are in accordance with the reported in the literature.
[71]
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1
H NMR (400 MHz, DMSO-d6, DMSO-d5 = 2.50 ppm) δ (ppm): 9.76 (s, 1H, Ar-OH), 7.38 
(s, 1H, H-6), 7.21 (s, 1H, H-2), 6.99 (s, 1H, H-4), 5.27 (s, 1H, CH2OH), 4.48 (s, 2H, CH2OH), 
3.82 (s, 3H, COOMe); 
13
C NMR (100 MHz, DMSO-d6, DMSO-d6 = 39.5 ppm) δ (ppm): 
166.4 (s, COOMe), 157.5 (s, C-3), 144.9 (s, C-5), 130.6 (s, C-1), 118.1 (d, C-Ar), 117.8 (d, C-
Ar), 114.0 (d, C-Ar), 62.4 (t, CH2OH), 52.1 (q, COOMe); HRMS-ESI (m/z): [M−H]
−
 calcd 
for [C9H9O4]
−
: 181.0501, found: 181.0502. 
Methyl 3-hydroxy-5-(hydroxymethyl)benzoate (47) (660 mg, 3.62 mmol, 1.0 eq.) was 
dissolved in CH2Cl2 (40 mL) and treated with PPh3 (1.9 g, 7.25 mmol, 2.0 eq.) and CBr4 (2.4 
g, 7.25 mmol, 2.0 eq.). After the reaction was completed (3 h), silica gel was added to the 
reaction mixture, the solvent was removed in vacuo and the residue was applied on the 
column. Flash chromatography (PE : EA = 3 : 1 to 1 : 1) afforded the desired product 49 (795 
mg, 3.25 mmol, 90%) as colorless crystals. 
1
H NMR (400 MHz, acetone-d6, acetone-d5 = 2.05 ppm) δ (ppm): 8.89 (s, 1H, Ar-OH), 7.58 
(t, J = 1.5 Hz, 1H, H-6), 7.42 (dd, J = 2.3, 1.4 Hz, H-2), 7.19 (t, J = 2.0 Hz, 1H, H-4), 4.64 (s, 
2H, CH2Br), 3.87 (s, 3H, COOMe); 
13
C NMR (100 MHz, acetone-d6, acetone-d6 = 206.26 
ppm) δ (ppm): 166.7 (s, COOMe), 158.5 (s, C-3), 141.2 (s, C-5), 132.9 (s, C-1), 122.1 (d, C-
Ar), 121.4 (d, C-Ar), 116.8 (d, C-Ar), 52.4 (q, COOMe), 33.5 (t, CH2Br). 
Methyl 3-(bromomethyl)-5-hydroxybenzoate (49) (2.2 g, 8.98 mmol, 1.0 eq.) was dissolved 
under nitrogen atmosphere in DMF (120 mL) and treated with phthalimide potassium salt 
(6.65 g, 35.9 mmol, 4.0 eq.) and anhydrous K2CO3 (7.44 g, 53.9 mmol, 6.0 eq.). The reaction 
mixture was stirred at RT for 3 h after which the reaction was terminated by addition of an 
aqueous NH4Cl solution. The mixture was extracted three times with Et2O, the combined 
organic layers were dried over MgSO4 and concentrated under reduced pressure. The residue 
was purified by flash chromatography (PE : EA = 4 : 1) providing the product 52 (1.7 g, 5.4 
mmol, 60%) as a colorless solid. 
1
H NMR (400 MHz, acetone-d6, acetone-d5 = 2.05 ppm) δ (ppm): 8.74 (s, 1H, ArOH), 7.90 – 
7.84 (m, 4H, Ar), 7.53 (t, J = 1.9 Hz, 1H, H-2), 7.37 (t, J = 1.9 Hz, 1H, H-6), 7.11 (t, J = 1.9 
Hz, 1H, H-4), 4.83 (s, 2H, ArCH2), 3.84 (s, 3H, COOMe); 
13
C NMR (100 MHz, acetone-d6, 
acetone-d6 = 206.26 ppm) δ (ppm): 168.5 (s, Ar(CO)2NH), 166.9 (s, COOMe), 158.6 (s, C-5), 
140.0 (s, C-3), 135.2 (d, Ar), 133.0 (s, C-1), 132.8 (s, Ar), 124.0 (d, Ar), 120.9 (d, C-2), 120.3 
(d, C-4), 116.1 (d, C-6), 52.4 (q, COOMe), 41.6 (t, ArCH2); HRMS-ESI (m/z): [M+Na]
+
 
calcd for [C17H13NO5Na]
+
: 334.0691, found: 334.0691. 
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Methyl 3-[(1,3-dioxoisoindolin-2-yl)methyl]-5-hydroxybenzoate (52) (1.2 g, 3.85 mmol, 1.0 
eq.) was dissolved under nitrogen atmosphere in CH2Cl2 (60 mL) and treated successively 
with imidazole (0.53 g, 7.7 mmol, 2.0 eq.), 4-DMAP (47 mg, 0.39 mmol, 0.1 eq.) and 
TBDPSCl (1.3 mL, 5.0 mmol, 1.3 eq.). After 5 h the reaction was terminated by addition of 
an aqueous NH4Cl solution and the phases were separated. The aqueous layer was extracted 
three times with CH2Cl2, the combined organic layers were dried over MgSO4 and the solvent 
was removed under reduced pressure. Purification by flash chromatography (PE : EA = 3 : 1 
to 1 : 1) provided the product 51 (2.12 g, 3.85 mmol, quant.) as a colorless oil. 
1
H NMR (400 MHz, acetone-d6, acetone-d5 = 2.05 ppm) δ (ppm): 7.90 – 7.83 (m, 4H, Ar), 
7.70 – 7.64 (m, 4H, SiPh), 7.60 (t, J = 1.5 Hz, 1H, H-6), 7.40 – 7.29 (m, 6H, SiPh), 7.40 – 
7.29 (m, 1H, H-2), 6.98 (dd, J = 2.4, 1.7 Hz, H-4), 4.72 (s, 2H, ArCH2), 3.80 (s, 3H, 
COOMe), 1.10 (s, 9H, Sit-Bu); 
13
C NMR (100 MHz, acetone-d6, acetone-d6 = 206.26 ppm) 
δ (ppm): 168.2 (s, Ar(CO)2NH), 166.5 (s, COOMe), 156.8 (s, C-3), 139.8 (s, C-5), 136.2 (d, 
Ar), 135.1 (s, Ar), 132.9 (d, Ar), 132.8 (s, Ar), 132.6 (s, C-1), 131.1 (d, Ar), 128.7 (d, Ar), 
124.2 (d, C-6), 124.0 (d, Ar), 122.6 (d, C-4), 120.5 (d, C-2), 52.4 (q, COOMe), 41.3 (t, 
ArCH2), 26.9 (q, Sit-Bu), 19.9 (s, Sit-Bu); HRMS-ESI (m/z): [M+Na]
+
 calcd for 
[C33H31NO5NaSi]
+: 572.1869, found: 572.1869. 
To a solution of phthalimide intermediate 51 (1.13 g, 2.05 mmol, 1.0 eq.) in EtOH (30 mL) 
hydrazine monohydrate (440 µL, 5.76 mmol, 2.8 eq.) was added. The reaction mixture was 
heated under refluxing conditions for 3 h, cooled down to RT and terminated by addition of 
water (20 mL). The reaction mixture was concentrated under reduced pressure to the final 
volume of ca 20 mL. Concentrated HCl (7 mL) was added and the reaction mixture was 
heated under refluxing conditions for another 2 h. After that time the mixture was cooled 
down to 0 °C and concentrated under reduced pressure to give the desired hydrochloride 
53·HCl (0.419 g, 2.05 mmol, quant.) as a colorless solid. 
1
H NMR (400 MHz, DMSO-d6, DMSO-d5 = 2.50 ppm) δ (ppm): 10.16 (s, 1H, ArOH), 8.53 
(bs, 2H, NH2), 7.49 (t, J = 1.3 Hz, 1H, H-2), 7.37 (dd, J = 2.3, 1.5 Hz, 1H, H-6), 7.14 (t, J = 
1.7 Hz, 1H, H-4), 3.97 (q, J = 5.6 Hz, 2H, ArCH2); 
13
C NMR (100 MHz, DMSO-d6, DMSO-
d6 = 39.5 ppm) δ (ppm): 167.1 (s, COOH), 157.8 (s, C-5), 135.8 (s, C-3), 132.3 (s, C-1), 120.6 
(d, C-2), 120.6 (d, C-4), 116.0 (d, C-6), 41.9 (t, ArCH2); HRMS-ESI (m/z): [M+H]
+
 calcd for 
[C8H10NO3]
+
: 168.0661, found: 168.0664; M.p.: 128–129 °C. 
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Methyl 3-(bromomethyl)-5-(tert-butyldiphenylsilyloxy)benzoate (50) 
 
Methyl 3-(bromomethyl)-5-hydroxybenzoate (49) (0.84 g, 3.44 mmol, 1.0 eq.) was dissolved 
under nitrogen atmosphere in CH2Cl2 (40 mL) and treated successively with imidazole (0.47 
g, 6.88 mmol, 2.0 eq.), 4-DMAP (42 mg, 0.34 mmol, 0.1 eq.) and TBDPSCl (1.2 mL, 4.47 
mmol, 1.3 eq.). After 5 h the reaction was terminated by addition of an aqueous NH4Cl 
solution and the phases were separated. The aqueous layer was extracted three times with 
CH2Cl2, the combined organic layers were dried over MgSO4 and the solvent was removed 
under reduced pressure. Purification by flash chromatography (PE : EA = 10 : 1 to 4 : 1) 
provided the product 50 (1.61 g, 3.33 mmol, 97%) as a colorless oil. 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.72 – 7.70 (m, 4H, SiPh), 7.57 (s, 
1H, H-2), 7.47 – 7.36 (m, 6H, SiPh), 7.47 – 7.36 (m, 1H, H-6), 6.91 – 6.89 (m, 1H, H-4), 4.37 
(s, 2H, ArCH2), 3.83 (s, 3H, COOMe), 1.14 (s, 9H, Sit-Bu); 
13
C NMR (100 MHz, CDCl3, 
CDCl3 = 77.2 ppm) δ (ppm): 166.4 (s, COOMe), 156.0 (s, C-5), 138.9 (s, C-3), 135.6 (d, C-
Ar), 132.3 (s, C-Ar), 131.8 (s, C-1), 130.2 (d, C-Ar), 128.0 (d, C-Ar), 124.4 (d, C-2), 122.5 (d, 
C-4), 121.0 (d, C-6), 52.3 (q, COOMe), 45.4 (t, CH2Br), 26.7 (q, Sit-Bu), 19.6 (s, Sit-Bu). 
3-amino-2-fluorobenzoic acid (55) 
 
2-Fluoro-3-nitrobenzoic acid (54) (930 mg, 5 mmol, 1.0 eq.) was dissolved in EtOH (5 mL). 
Triethylsilane (8 mL, 50 mmol, 10.0 eq.) and 10% Pd/C (93 mg) were added and the reaction 
mixture was stirred at RT for 1 h. After that time the catalyst was filtered through a pad of 
Celite
TM
 and washed with EtOH. After removal of the solvent under reduced pressure, 3-
amino-2-fluorobenzoic acid 55 was obtained as a pale yellow solid (756 mg, 4.9 mmol, 97%). 
The analytical data are in accordance with the reported in the literature.
[54,72]
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1
H NMR (400 MHz, CD3OD, CHD2OD = 3.31 ppm) δ (ppm): 7.15 (ddd, J = 7.8, 6.4, 1.8 Hz, 
1H, H-6), 7.01 (td, J = 7.9, 1.8 Hz, H-4), 6.98 – 6.89 (m, 1H, H-2); 1H NMR (400 MHz, 
DMSO-d6, DMSO-d5 = 2.50 ppm) δ (ppm): 7.03 – 6.85 (m, 3H), 5.30 (s, 2H, NH2); 
13
C NMR 
(100 MHz, CD3OD, CD3OD = 49.0 ppm) δ (ppm): 168.2 (s, COOH), 152.0 (s, C-2), 138.2 (s, 
C-3), 124.8 (d, C-5), 121.9 (d, C-4), 120.5 (d, C-6), 120.2 (s, C-1); HRMS-ESI (m/z): 
[M+H]
+
 calcd for [C7H7FNO2]
+
: 156.0461, found: 156.0457; M.p.: 180–181 °C. 
3-amino-2-hydroxybenzoic acid (61) 
 
Methyl 2-hydroxy-3-nitrobenzoate (59) was prepared according to the literature procedure.
[74]
 
Methyl 2-hydroxy-3-nitrobenzoate (59) (1 g, 5 mmol, 1.0 eq.) was dissolved in EtOH (5 mL) 
and 10% Pd/C (100 mg) was added. Afterwards triethylsilane (8.0 mL, 50 mmol, 10 eq.) was 
added dropwise to the reaction mixture under argon atmosphere. When the reaction was 
completed (monitored by TLC), the solution was filtered through a pad of Celite
TM
. After 
removal of the solvent in vacuo, the product was purified by a flash column chromatography 
(PE : EA = 5 : 1). The solvents were removed under reduced pressure providing compound 60 
(0.8 g, 4.8 mmol, 94%) as a yellow-brownish solid. 
The analytical data are in accordance with the reported in the literature.
[163]
 
1
H NMR (400 MHz, CD3OD, CHD2OD = 4.87 ppm) δ (ppm): 7.23 (dd, J = 8.0, 1.6 Hz, 1H, 
H-6), 6.96 (dd, J = 7.7, 1.6 Hz, 1H, H-4), 6.71 (t, J = 7.9 Hz, 1H, H-5), 3.95 (s, 3H, 
COOCH3); HRMS-ESI (m/z): [M+H]
+
 calcd for [C8H10NO3]
+
: 168.0661, found: 168.0666; 
M.p.: 86 °C (Lit. 88–89 °C).[163] 
Methyl 3-amino-2-hydroxybenzoate (60) (0.3 g, 1.8 mmol, 1.0 eq.) was dissolved in MeOH 
(15 mL) and a 1 M solution of LiOH (18.0 mL, 10 eq.) was added dropwise. The solution was 
heated to 40 °C and stirred until complete conversion was observed (monitored by TLC). 
After cooling down to RT, the mixture was hydrolyzed by addition of crushed ice. The 
reaction mixture was acidified with 1 M HCl to pH = 2–3 and extracted three times with 
EtOAc. The combined organic phases were dried over MgSO4 and after removal of the 
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solvent under reduced pressure the title compound 61 (0.24 g, 1.6 mmol, 88%) was obtained as 
dark brown crystals. No further purification was performed. 
The analytical data are in accordance with the reported in the literature.
[164,165]
 
1
H NMR (400 MHz, CD3OD, CD2HOD = 3.31 ppm) δ (ppm): 7.37 (dd, J = 8.0, 1.6 Hz, 1H, 
H-6), 7.03 (dd, J = 7.7, 1.5 Hz, 1H, H-4), 6.70 (t, J = 7.9 Hz, 1H, H-5); 
13
C 
NMR (100 MHz, CD3OD, CD3OD = 49.0 ppm) δ (ppm): 174.1 (s, COOH), 152.8 (s, C-2), 
143.7 (s, C-3), 123.4 (s, C-6), 123.0 (d, C-4), 119.6 (d, C-5), 114.8 (d, C-1); HRMS-ESI 
(m/z): [M+H]
+
 calcd for [C7H8NO3]
+
: 154.0504, found: 154.0502; M.p.: 232–233 °C (Lit. 
231–235 °C).[164] 
3-amino-4-nitrobenzoic acid (76) 
 
Methyl 3-amino-4-nitrobenzoate (203) was prepared according to the literature procedure.
[166]
 
A solution of methyl 3-amino-4-nitrobenzoate (203) (500 mg, 2.55 mmol, 1.0 eq.) in MeOH 
(50 mL) and 1 M NaOH (13 mL) was stirred at RT for 1 h. After that time the reaction 
mixture was washed with Et2O (20 mL). The pH of the aqueous phase was adjusted to 2 and 
the mixture was extracted three times with EtOAc. The combined organic extracts were 
collected and dried over MgSO4. The solvent was removed under reduced pressure providing 
a crude product which was crystallized from EtOH to give 3-amino-4-nitrobenzoic acid 76 as 
yellow crystals (360 mg, 1.97 mmol, 78%). 
1
H NMR (400 MHz, DMSO-d6, DMSO-d5 = 2.50 ppm) δ (ppm): 8.53 (d, J = 1.9 Hz, 1H, H-
2), 7.92 (s, 2H, NH2), 7.83 (dd, J = 8.9, 1.9 Hz, 1H, H-6), 7.04 (d, J = 8.9 Hz, 1H, H-5); 
13
C 
NMR (100 MHz, DMSO-d6, DMSO-d6 = 39.5 ppm) δ (ppm): 166.2 (s, COOH), 148.9 (s, C-
3), 135.4 (s, C-4), 129.8 (s, C-1), 128.3 (s, C-5), 119.4 (s, C-2), 117.7 (s, C-6); HRMS-ESI 
(m/z): [M−H]− calcd for [C7H5N2O4]
−
: 181.0249, found: 181.0255; M.p.: 295–297 °C. 
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3-Amino-5-fluorobenzoic acid hydrochloride (78·HCl) 
 
3-Amino-5-fluorobenzoic acid hydrochloride (78·HCl) was prepared according to the 
literature procedure.
[167]
 
4-Fluoro-2-nitroaniline (204) (5 g, 32 mmol, 1.0 eq.) was added to a solution of bromine (1.97 
mL, 38 mmol, 1.2 eq.) in 20 mL of glacial acetic acid at 15 °C. The mixture was stirred at RT 
for 1 h, poured into 125 mL of water, stored overnight in the freezer and filtered. The residue 
was dissolved in MeOH, treated with charcoal and recrystallized from a MeOH : H2O mixture 
providing 2-bromo-4-fluoro-6-nitroaniline (205) as an orange solid (5.4 g, 23 mmol, 72%).
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.90 (dd, J = 8.8, 3.0 Hz, 1H, H-5), 
7.56 (dd, J = 7.0, 3.0 Hz, 1H, H-3), 6.49 (s, 2H, NH2); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 
77.2 ppm) δ (ppm): 152.1 (s, C-4), 139.6 (s, C-1), 139.6 (s, C-6), 127.8 (d, C-3), 112.3 (s, C-
2), 111.8 (d, C-5); M.p.: 73–74 °C (Lit. 74–75 °C).[167] 
2-Bromo-4-fluoro-6-nitroaniline (205) (1.5 g, 6.4 mmol, 1.0 eq.) was cooled down to −5 °C 
and conc. H2SO4 (15 mL) was added with vigorous stirring. Sodium nitrite (0.48 g, 7 mmol, 
1.1 eq.) in 10 mL of water was added to the mixture at −2 to −3 °C over a period of 90 min 
(reaction progress monitored by TLC). After that time the mixture was stirred for further 15 
min, cooled down to −5 °C and 50% H3PO2 (4.73 mL, 7.0 eq.) and Cu2O (1 g, 7 mmol, 1.1 
eq.) were added in small portions with vigorous stirring for the next 90 min. After that time 
the reaction mixture was poured into 250 g of crushed ice and stored in the freezer for 1 h. 
The precipitate was filtered and washed with ice-cold water. The aqueous layer was extracted 
with CHCl3, the organic layers were combined, dried over MgSO4 and concentrated under 
reduced pressure to yield a dark oil. The crude product was purified by flash chromatography 
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(PE : EA = 5 : 1) to afford 3-bromo-5-fluoronitrobenzene (206) as a slightly yellow solid 
(0.84 g, 3.8 mmol, 60%). 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 8.20 (td, J = 1.8, 1.1 Hz, 1H, H-2), 
7.89 (dt, J = 8.1, 2.2 Hz, 1H, H-6), 7.60 (ddd, J = 7.4, 2.4, 1.7 Hz, 1H, H-4); 
13
C NMR (100 
MHz, CDCl3, CDCl3 = 77.0 ppm) δ (ppm): 163.7 (s, C-5), 149.0 (s, C-1), 123.1 (s, C-3), 
113.8 (d, C-2), 108.9 (d, C-4), 100.9 (d, C-6); M.p.: 27–28 °C (Lit. 27–28 °C).[167] 
Copper (I) cyanide (550 mg, 6.1 mmol, 1.1 eq.) was stored in vacuo overnight. The flask was 
then purged with nitrogen and the mixture of 3-bromo-5-fluoronitrobenzene (206) (1.27 g, 
5.75 mmol, 1.0 eq.) in DMF (10 mL) was added through a syringe. The reaction mixture was 
heated under reflux for 5 h. After that time it was diluted to 100 mL with 5 mL of 6 M HCl 
and 95 mL of water and extracted with EtOAc. The combined organic layers were washed 
with water and a solution of 5% NaHCO3 and dried over MgSO4. The solvent was removed 
under reduced pressure and the residue was purified by flash chromatography (PE : EA = 4 : 
1) providing 3-fluoro-5-nitrobenzonitrile 207 as a yellow solid (472 mg, 2,84 mmol, 49%). 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 8.36 (dt, J = 2.1, 1.2 Hz, 1H, H-6), 
8.21 (dt, J = 7.8, 2.3 Hz, 1H, H-2), 7.73 (ddd, J = 7.1, 2.4, 1.3 Hz, 1H, H-4); 
13
C NMR (100 
MHz, CDCl3, CDCl3 = 77.0 ppm) δ (ppm): 162.3 (s, C-3), 149.6 (s, C-5), 125.2 (d, C-6), 
123.3 (d, C-2), 116.2 (d, C-4), 115.58 (s, CN), 115.45 (s, C-1); HRMS-EI (m/z): [M+H]
+
 
calcd for [C7H3FN2O2]
+
: 166.0179, found: 166.0181; M.p.: 49–51 °C (Lit. 49–50 °C).[167] 
A mixture of 3-fluoro-5-nitrobenzonitrile (207) (470 mg, 2.83 mmol, 1.0 eq.) in 75% H2SO4 
(6 mL) was stirred at 150 °C for 2 h. The reaction mixture was poured into ice-cold water and 
NaHCO3 was added until gas evolution ceased. The solution was washed with Et2O, then 
acidified to pH = 1 with 6 M HCl and extracted twice with Et2O. The combined organic 
phases were dried over MgSO4 and concentrated under reduced pressure to give 3-fluro-5-
nitrobenzoic acid (208) as a yellow solid (447 mg, 2.42 mmol, 85%). 
1
H NMR (400 MHz, CD3OD, CHD2OD = 3.31 ppm, 4.87 ppm) δ (ppm): 8.51 (bs, 1H, H-6), 
8.14 (dt, J = 8.2 Hz, 2.2 Hz, 1H, H-2), 8.00 (d, J = 8.3 Hz, 1H, H-4); 
13
C NMR (100 MHz, 
CD3OD, CD3OD = 49.0 ppm) δ (ppm): 166.1 (s, COOH), 163.8 (s, C-3), 150.8 (s, C-5), 136.2 
(s, C-1), 123.4 (d, C-2), 121.4 (d, C-6), 115.95 (d, C-4); HRMS-EI (m/z): [M−H]− calcd for 
[C7H3FNO4]
−
: 184.0046, found: 184.0043, M.p.: 122–123 °C (Lit. 124–125 °C).[167] 
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3-Fluoro-5-nitrobenzoic acid (208) (300 mg, 1.62 mmol, 1.0 eq.) was dissolved in EtOH (20 
mL) and treated with 6 M HCl (3 mL) and 10% Pd/C (45 mg). The mixture was stirred under 
hydrogen atmosphere for 3 h and then filtered through acid-washed Celite
TM
 pad. The solvent 
was removed under reduced pressure providing 3-amino-5-fluorobenzoic acid 78 as pale 
yellow crystals (242 mg, 1.3 mmol, 78%). 
1
H NMR (400 MHz, CD3OD, CHD2OD = 3.31 ppm, 4.87 ppm) δ (ppm): 7.88 (dd, J = 2.3, 
1.0 Hz, 1H, H-2), 7.82 (ddd, J = 8.8, 2.5, 1.3 Hz, 1H, H-6), 7.44 (dt, J = 8.6, 2.3 Hz, 1H, H-
4); 
13
C NMR (100 MHz, CD3OD, CD3OD = 49.0 ppm) δ (ppm): 166.6 (s, COOH), 164.2 (s, 
C-5), 136.4 (s, C-3), 134.5 (s, C-1), 121.2 (d, C-2), 117.7 (d, C-6), 116.0 (d, C-4); HRMS-
ESI (m/z): [M+H]
+
 calcd for [C7H7FNO2]
+
: 156.0461, found: 156.0460; M.p.: 242–243 °C 
(Lit. 244 °C).[167] 
5-Amino-2-fluorobenzoic acid (83) 
 
5-Amino-2-fluorobenzoic acid (83) was prepared according to the literature procedure.
[168]
 
A mixture of fuming HNO3 (2.8 mL) and conc. H2SO4 (8.2 mL) was added to a solution of  
2-fluorobenzoic acid (209) (5 g, 36 mmol, 1.0 eq.) in conc. H2SO4 (19.6 mL). The reaction 
mixture was stirred at 90 °C for 45 min, then cooled down to RT, poured onto ice, filtered, 
washed with water and dried under vacuum providing 2-fluoro-5-nitrobenzoic acid (210) as 
colorless crystals (3.48 g, 18.8 mmol, 52%). 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 8.96 (dd, J = 6.1, 2.9 Hz, 1H, H-6), 
8.50 (ddd, J = 9.1, 3.9, 2.9 Hz, 1H, H-4), 7.39 (t, J = 9.3 Hz, 1H, H-3); 
13
C NMR (100 MHz, 
CDCl3, CDCl3 = 77.2 ppm) δ (ppm): 167.2 (s, COOH), 165.8 (s, C-2), 144.1 (s, C-5), 130.8 
(d, C-4), 129.0 (d, C-6), 118.8 (d, C-3), 118.9 (s, C-1); HRMS-ESI (m/z): [M−H]− calcd for 
[C7H3FNO4]
−
: 184.0046, found: 184.0048; M.p.: 140–141 °C (Lit. 141–142 °C).[168] 
A mixture of 2-fluoro-5-nitrobenzoic acid (210) (3.4 g, 18.4 mmol, 1.0 eq.), 10% Pd/C (2.9 
g), MeOH (40 mL) and cyclohexene (45 mL) was heated under refluxing conditions for 3 h. 
After that time the reaction mixture was filtered through a pad of Celite
TM
 to remove the 
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catalyst. The solvents were removed under reduced pressure to give a crude product which 
was crystallized from MeOH providing 5-amino-2-fluorobenzoic acid (83) as a colorless solid 
(2.13 g, 13.7 mmol, 75%). 
1
H NMR (400 MHz, DMSO-d6, DMSO-d5 = 2.50 ppm) δ: 7.02 (dd, J = 6.2, 3 Hz, 1H, H-2), 
6.93 (dd, J = 10.7, 8.8 Hz, 1H, H-5), 6.74 (ddd, J = 8.8, 4.1, 3.0 Hz, 1H, H-4), 3.17 (s, NH2); 
13
C NMR (100 MHz, CD3OD, CD3OD = 49.0 ppm) δ(ppm): 167.8 (s, COOH), 157.0 (s, C-
6), 143.5 (s, C-3), 122.7 (d, C-4), 120.3 (s, C-1), 119.2 (d, C-2), 118.2 (d, C-5); HRMS-ESI 
(m/z): [M+H]
+
 calcd for C7H6FNO2 156.0461, found: 156.0461; [M−H]
−
 calcd for 
[C7H5FNO2]
−
: 154.0304, found: 154.0307; M.p.: 190–191 °C (Lit. 190–192 °C).[168] 
3-Azido-2-hydroxybenzoic acid (63) 
 
Methyl 3-amino-2-hydroxybenzoate (60) (0.74 g, 4.4 mmol, 1.0 eq.) was dissolved in 2 M 
HCl (20 mL) and cooled with an ice-salt mixture. Subsequently, an ice cold solution of 
sodium nitrite (0.37 g, 5.3 mmol, 1.2 eq.) in water (1.3 mL) was added dropwise and after 10 
min of stirring urea (0.03 g, 0.52 mmol, 0.12 eq.) was added to destroy the excess of nitric 
acid. The formed diazonium salt solution was added dropwise to an ice cold solution of 
sodium azide (0.57 g, 8.8 mmol, 2.0 eq.) and sodium acetate (0.001 g, 0.01 mmol) in water 
(6.0 mL). After stirring for 2 h, the product was extracted three times with Et2O and the 
combined organic phases were dried over Na2SO4. The solvent was removed under reduced 
pressure providing compound 62 (0.85 g, 4.4 mmol, quant.) as dark red crystals. The product 
was used directly in the next step without further purification. 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 11.18 (s, 1H, OH), 7.62 (dd, J = 
8.0, 1.6 Hz, 1H, H-6), 7.16 (dd, J = 7.9, 1.4 Hz, 1H, H-4), 6.85 (t, J = 7.9 Hz, 1H, H-5); 
13
C 
NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 170.5 (s, COOCH3), 154.6 (s, C-2), 
128.3 (s, C-3), 126.1 (d, C-4), 126.0 (d, C-6), 119.3 (d, C-5), 113.5 (s, C-1), 52.8 (q, 
COOCH3); M.p.: 72–73 °C. 
Methyl 3-azido-2-hydroxybenzoate (62) (0.53 g, 2.73 mmol, 1.0 eq.) was dissolved in MeOH 
(25 mL) and 1 M solution of LiOH (27.3 mL, 10.0 eq.) was added dropwise. The solution was 
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heated to 40 °C and stirred until complete conversion was observed (monitored by TLC). 
After cooling down to RT, the mixture was hydrolyzed by the addition of crushed ice. The 
reaction mixture was acidified with 1 M HCl to pH = 2–3 and extracted three times with 
EtOAc The combined organic phases were dried over MgSO4 and after removal of the solvent 
under reduced pressure the title compound 63 (0.44 g, 2.5 mmol, 90%) was obtained as dark 
brown crystals. No further purification was conducted. 
1
H NMR (400 MHz, CD3OD, CD2HOD = 3.31 ppm) δ (ppm): 7.68 (dd, J = 8.0, 1.6 Hz, 1H, 
H-6), 7.17 (dd, J = 7.9, 1.6 Hz, 1H, H-4), 6.88 (t, J = 7.9 Hz, 1H, H-5); 
13
C NMR (100 MHz, 
CD3OD, CD3OD = 49.0 ppm) δ (ppm): 173.5 (s, COOH), 156.4 (s, C-2), 129.0 (s, C-3), 127.9 
(d, C-6), 127.1 (d, C-4), 120.1 (d, C-5), 115.1 (s, C-1); HRMS-ESI (m/z): [M−H]− calcd for 
[C7H4N3O3]
−
: 178.0253, found: 178.0252; M.p.: 157–160 °C. 
3.5 Synthesis of the Western Fragment 
Methyl 3-amino-5-hydroxybenzoate (159) 
 
3,5-Dihydroxybenzoic acid (65) (22.5 g, 146 mmol, 1.0 eq.), ammonium chloride (19.1 g, 358 
mmol, 2.45 eq.) and concentrated ammonia (30% in water, 67.5 mL) were placed in a steel 
bomb (model T304, PARR INSTRUMENT COMPANY) and heated at 180 °C for 40 h. After 
cooling down and evaporation of the reaction mixture to dryness, it was treated with MeOH 
(500 mL) and acetyl chloride (20.8 mL, 292 mmol, 2.0 eq.). The reaction mixture was heated 
under refluxing conditions for 36 h. After that time MeOH was removed under reduced 
pressure, the residue washed with ice-cold water and extracted three times with Et2O (ether 
phases were discarded). The aqueous layer was neutralized with NaHCO3 solution and 
extracted three times with EtOAc. The combined organic layers were dried over MgSO4 and 
the solvent was removed in vacuo. The crude product 159 was used in the following step 
without further purification. 
The analytical data are in accordance with the reported in the literature.
[141]
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1
H NMR (400 MHz, acetone-d6, acetone-d5 = 2.05 ppm) δ (ppm): 8.40 (bs, 1H, OH), 6.93 
(dd, J = 2.1, 1.5 Hz, 1H, H-4), 6.84 (dd, J = 2.3, 1.5 Hz, 1H, H-2), 6.48 – 6.50 (m, 1H, H-6), 
4.78 (s, 2H, NH2), 3.88 (s, 3H, OMe). 
Methyl 3-(tert-butoxycarbonylamino)-5-hydroxybenzoate (159a) 
 
Methyl ester 159 (17.7 g, 106 mmol, 1.0 eq.) was dissolved in a 1 : 4 (400 mL) mixture of  
THF : NaHCO3 (400 mL) and treated with di-tert-butyl dicarbonate (23.1 g, 106 mmol, 1.0 
eq.). After 1 h NaHCO3 (10.7 g, 127 mmol, 1.2 eq.) was added and the mixture was stirred at 
RT for 44 h. THF was removed under reduced pressure and the remaining aqueous layer was 
extracted three times with EtOAc. The combined organic layers were dried over Na2SO4 and 
the solvent was removed in vacuo providing the crude solid product 159a used in the 
following step without further purification. 
The analytical data are in accordance with the reported in the literature.
[141]
 
1
H NMR (400 MHz, acetone-d6, acetone-d5 = 2.05 ppm) δ (ppm): 8.59 (s, 1H, NH), 8.47 (bs, 
1H, OH), 7.68 (s, 1H, H-4), 7.35 (s, 1H, H-2), 7.08 (s, 1H, H-6), 3.80 (s, 3H, OMe), 1.44 (s, 
9H, t-Bu). 
Methyl 3-(tert-butoxycarbonylamino)-5-(tert-butyldiphenylsiloxy)benzoate (160) 
 
The ester 159a (27.45 g, 102.7 mmol, 1.0 eq.) was dissolved in dry CH2Cl2 (257 mL) under 
argon atmosphere. The mixture was treated successively with imidazole (8.39 g, 123 mmol, 
1.2 eq.), 4-DMAP (1.25 g, 10.3 mmol, 0.1 eq.) and TBDPSCl (28 mL, 108 mmol, 1.05 eq.) 
and stirred overnight at 30 °C. After the reaction was completed, an aqueous solution of 
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NH4Cl was added and the phases were separated. The aqueous layer was extracted three times 
with CH2Cl2, the combined organic layers were dried over MgSO4 and concentrated in vacuo. 
Purification by flash column chromatography (PE : EA = 20 : 1 to 10 : 1) afforded the desired 
product 160 as a colorless solid (43.4 g, 86 mmol, 84%). 
The analytical data are in accordance with the reported in the literature.
[141]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.72 – 7.69 (m, 4H, SiPh), 7.63 (s, 
1H, ArH), 7.45 – 7.35 (m, 6H, SiPh), 7.09 (m, 1H, ArH), 6.96 (s, 1H, ArH), 6.37 (s, 1H, NH), 
3.79 (s, 3H, OMe), 1.47 (s, 9H, t-Bu), 1.10 (s, 9H, Sit-Bu); 
13
C NMR (100 MHz, CDCl3, 
CDCl3 = 77.16 ppm) δ (ppm): 166.7 (s, COOMe), 156.2 (s, C-Ar), 152.4 (s, NCOt-Bu), 139.5 
(s, C-Ar), 135.6 (d, C-Ar), 132.5 (s, C-Ar), 131.8 (s, C-Ar), 130.2 (d, C-Ar), 128.0 (d, C-Ar), 
115.6 (d, C-Ar), 114.3 (d, C-Ar), 112.5 (d, C-Ar), 80.9 (s, t-Bu), 52.2 (q, OMe), 28.4 (q, t-
Bu), 26.6 (q, Sit-Bu), 19.6 (s, Sit-Bu); HRMS-ESI (m/z): [M+Na]
+
 calcd for 
[C29H35NO5NaSi]
+
: 528.2182, found: 528.2182. 
3-(tert-Butoxycarbonylamino)-5-(tert-butyldiphenylsiloxy)benzyl alcohol (161) 
 
The ester 160 (20 g, 39.5 mmol, 1.0 eq.) was dissolved in dry THF (106 mL) under argon 
atmosphere and cooled down to −78 °C. After addition of DIBAL-H (119 mL, 1 M solution in 
hexane, 3.0 eq.) the reaction mixture was warmed up to 0 °C and stirred overnight at RT. The 
reaction was terminated by careful addition of saturated K-Na-tartrate solution. After 
extraction with Et2O (4x) the combined organic layers were washed with NaCl solution (1x), 
dried over MgSO4 and the solvents were removed under reduced pressure. The crude product 
was purified by column chromatography (PE : EA = 5: 1 to 1 : 1) affording a colorless foamy 
solid 161 (17.7 g, 37.1 mmol, 94%). 
The analytical data are in accordance with the reported in the literature.
[141]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.73 – 7.68 (m, 4H, SiPh), 7.45 – 
7.34 (m, 6H, SiPh), 7.08 (s, 1H, ArH), 6.58 (s, 1H, AHr), 6.40 (s, 1H, ArH), 6.29 (bs, 1H, 
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NH), 4.42 (s, 2H, CH2OH), 1.61 (bs, 1H, OH), 1.47 (s, 9H, t-Bu), 1.08 (s, 9H, Sit-Bu);  
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 156.4 (s, C-Ar), 152.6 (s, NCOt-
Bu), 143.1 (s, C-Ar), 139.5 (s, C-Ar ), 135.6 (d, C-Ar), 132.9 (s, C-Ar), 130.1 (d, C-Ar), 127.9 
(d, C-Ar), 113.0 (d, C-Ar), 109.8 (d, C-Ar), 109.1 (d, C-Ar), 80.7 (s, t-Bu), 65.2 (t, CH2), 28.4 
(q, t-Bu), 26.6 (q, Sit-Bu), 19.6 (s, Sit-Bu); HRMS-ESI (m/z): [M+Na]+ calcd for 
[C28H35NO4NaSi]
+
: 500.2233, found: 500.2236. 
3-(tert-Butoxycarbonylamino)-5-(tert-butyldiphenylsiloxy)benzyl bromide (156) 
 
To a solution of the alcohol 161 (5.62 g, 11.8 mmol, 1.0 eq.) in dry CH2Cl2 (100 mL) PPh3  
(3.725 g, 14.2 mmol, 1.2 eq.) was added, followed by CBr4 (4.7 g, 14.2 mmol, 1.2 eq.). After 
the reaction was completed (ca. 30 min), the solvent was removed under reduced pressure and 
the residue was applied to silica gel. The flash column chromatography (PE : EA = 10 : 1 to  
5 : 1) afforded the desired product 156 as a colorless oil (6.31 g, 11.7 mmol, 99%). 
The analytical data are in accordance with the reported in the literature.
[141]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.73 – 7.67 (m, 4H, SiPh), 7.44 – 
7.37 (m, 6H, SiPh), 7.16 (s, 1H, ArH), 6.55 (s, 1H, ArH), 6.43 (s, 1H, ArH), 6.25 (s, 1H, NH), 
4.22 (s, 2H, CH2Br), 1.47 (s, 9H, t-Bu), 1.08 (s, 9H, Sit-Bu); 
13
C NMR (100 MHz, CDCl3, 
CDCl3 = 77.16 ppm) δ (ppm): 156.3 (s, C-Ar), 152.5 (s, NCOt-Bu), 139.5 (s, C-Ar), 135.6 (s, 
C-Ar), 132.7 (s, C-Ar), 130.1 (d, C-Ar), 128.0 (d, C-Ar), 115.3 (d, C-Ar), 111.9 (d, C-Ar), 
109.9 (d, C-Ar), 80.8 (s, t-Bu), 33.45 (t, CH2Br), 28.4 (q, t-Bu), 26.6 (q, Sit-Bu), 19.6 (s, Sit-
Bu); HRMS-ESI (m/z): [M+Na]
+ 
calcd for [C28H34NO3NaSiBr]
+
: 562.1389, found: 562.1391. 
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3-(tert-Butoxycarbonylamino)-5-(tert-butyldiphenylsiloxy)benzyl iodide (162) 
 
The bromide 156 (6.43 g, 11.9 mmol, 1.0 eq.) was dissolved in dry acetone (51 mL) and 
sodium iodide (2.68 g, 17.8 mmol, 1.5 eq.) was added. The reaction mixture was stirred at RT 
for 2 h. After the reaction was completed, distilled water was added and the aqueous layer 
was extracted with CH2Cl2. The combined organic layers were washed with NaCl solution 
and dried over MgSO4. The solvent was removed under reduced pressure and the product 162 
was obtained as a brownish foam (6.64 g, 11.3 mmol, 95%).
 
The analytical data are in accordance with the reported in the literature.
[62,141]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.73 – 7.68 (m, 4H, SiPh), 7.45 – 
7.36 (m, 6H, SiPh), 7.12 (s, 1H, ArH), 6.55 – 6.54 (m, 1H, ArH), 6.41 – 6.39 (m, 1H, ArH), 
6.27 (s, 1H, NH), 4.18 (s, 2H, CH2I), 1.48 (s, 9H, t-Bu), 1.09 (s, 9H, Sit-Bu);  
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 156.2 (s, NCOt-Bu), 140.9 (s, C-
Ar), 139.5 (s, C-Ar), 135.6 (d, C-Ar), 132.7 (s, C-Ar), 130.1 (d, C-Ar), 128.0 (d, C-Ar), 115.1 
(d, C-Ar), 111.6 (d, C-Ar), 109.6 (d, C-Ar), 80.8 (s, t-Bu), 28.4 (q, t-Bu), 26.6 (q, Sit-Bu), 
19.6 (s, Sit-Bu), 5.6 (t, CH2I); HRMS-ESI (m/z): [M+Na]
+ 
calcd for [C28H34NO3NaSiI]
+
: 
610.1250, found: 610.1251. 
(4S)-4-Benzyl-3-propionyl-2-oxazolidinone (166) 
 
To a cold (−78 °C) solution of (4S)-4-benzyl-2-oxazolidinone (166a) (2.19 g, 12.4 mmol) in 
THF (40 mL) n-BuLi (2.5 M solution in hexanes) (5.2 mL, 13.0 mmol) was added dropwise 
over a period of 10 min. The reaction mixture was stirred at −78 °C for 10 min and afterwards 
118 
 
propionyl chloride (1.18 mL, 1.26 g, 13.6 mmol) was added. The mixture was stirred at  
−78 °C for 1 h and then slowly warmed up to RT over 30 min. The reaction was terminated 
by the addition of saturated NH4Cl solution (8 mL). THF was removed under reduced 
pressure and the residue was extracted three times with CH2Cl2. The combined organic layers 
were washed with 1 M NaOH (20 mL) and NaCl solution (20 mL), dried over Na2SO4 and 
concentrated in vacuo. The crude product was purified by column chromatography (PE : EA 
= 4 : 1) to yield the desired compound 166 as a colorless crystalline solid (2.47 g, 10.6 mmol, 
88%). 
The analytical data are in accordance with the reported in the literature.
[169,170]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.31 – 7.11 (m, 5H, ArH), 4.62 − 
4.56 (m, 1H, NCH), 4.16 – 4.03 (m, 2H, CHCH2O), 3.22 (dd, J = 13.4, 3.2 Hz, 1H, 
CH2C6H5), 2.97 – 2.77 (m, 2H, CH2CH3), 2.69 (dd, J = 13.4, 9.6 Hz, 1H, CH2C6H5), 1.12 (t, J 
= 7.4 Hz, 3H, CH3); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 174.2 (s, 
COCH2CH3), 153.6 (s, NCOO), 135.4 (d, C-Ar), 129.5 (d, C-Ar), 129.1 (d, C-Ar), 127.4 (d, 
C-Ar), 66.3 (t, CHCH2O), 55.3 (q, NCH), 38.0 (s, NCOCH2), 29.3 (t, CH2CH3), 8.4 (d, 
CH2CH3); [α]
20
D = 99.0° (c = 1.0, EtOH; Lit. [α]
20
D = 99.5°, c = 1.01, EtOH)
[169]
;  
M.p.: 43–44 °C (Lit. 43–46 °C).[171] 
(2R,4S)-3-{3-[3-(tert-Butoxycarbonylamino)-5-(tert-butyldiphenylsiloxy)-phenyl]-2-
methylpropanoyl}-4-benzyloxazolidin-2-one (163) 
 
Diisopropylamine (4.30 mL, 30.8 mmol, 1.7 eq.) was dissolved in dry THF (150 mL) under 
argon atmosphere and cooled down to −78 °C. After the addition of n-BuLi (2.5 M solution in 
hexanes, 12.3 mL, 30.8 mmol, 1.7 eq.) the solution was stirred at 0 °C for 15 min and agaib 
cooled down to −78 °C. The oxazolidinone 166 (6.90 g, 29.6 mmol, 1.63 eq.) was dissolved 
in THF (100 mL) and cooled down to −78 °C. The prepared solution of LDA was added 
dropwise and the reaction mixture was warmed up to −40 °C. After cooling down to −78 °C 
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the iodide 163 (10.7 g, 18.1 mmol, 1.0 eq.) dissolved in THF (100 mL) was added to the 
reaction mixture. The mixture was slowly (ca 2 h) warmed up to −35 °C and stirred at this 
temperature for 13 h. The mixture was then hydrolyzed with a cold saturated solution of 
NH4Cl and warmed up to RT. THF was removed under reduced pressure and the remaining 
aqueous phase was extracted with EtOAc (3x). After drying over MgSO4 and concentrating of 
the solvent in vacuo, the residue was purified by column chromatography (PE : EA = 10 : 1 to 
5 : 1). The pure diastereomer 163 (7.52 g, 10.8 mmol, 60%) was obtained as a colorless foam.  
 The analytical data are in accordance with the reported in the literature.
[57,62]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.75 – 7.66 (m, 4H, SiPh), 7.39 – 
7.27 (m, 6H, SiPh), 7.12 – 7.09 (m, 2H, ArH), 6.86 (bs, 1H, ArH), 6.73 (bs, 1H, ArH), 6.29 – 
6.28 (m, 1H, ArH), 6.27 (bs, 1H, NH), 4.68 – 4.59 (m, 1H, CHBn), 4.19 – 4.09 (m, 2H, 
CH2CHBn), 3.86 – 3.81 (m, 1H, CHCH3), 3.16 (dd, J = 13.4, 3.2 Hz, 1H, CH2Ph), 2.93 (dd, J 
= 13.2, 6.2 Hz, 1H, CH2CHCH3), 2.61 (dd, J = 13.2, 8.4 Hz, 1H, CH2Ph), 2.33 (dd, J = 13.2, 
8.4 Hz, 1H, CH2CHCH3), 1.45 (s, 9H, t-Bu), 1.07 (s, 9H, Sit-Bu), 0.93 (d, J = 6.7 Hz, 3H, 
CH3); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 176.6 (s, NCOCH), 156.0 
(s, C-Ar), 153.1 (s, NCOOt-Bu), 152.5 (s, NCOO), 140.9 (s, C-Ar), 139.3 (s, C-Ar), 135.64 
(d, C-Ar), 135.62 (d, C-Ar), 132.97 (s, C-Ar), 132.93 (s, C-Ar), 130.0 (d, C-Ar), 129.5 (d, C-
Ar), 129.0 (d, C-Ar), 127.9 (d, C-Ar), 127.4 (d, C-Ar), 115.8 (d, C-Ar), 112.1 (d, C-Ar), 108.2 
(d, C-Ar), 80.4 (s, t-Bu), 66.1 (t, CH2O), 55.3 (d, CHN), 39.6 (t, CH2Ph), 39.5 (d, CHCH3) 
38.0 (d, CH2CH), 28.4 (q, t-Bu ), 26.6 (q, Sit-Bu), 19.6 (s, Sit-Bu), 16.2 (q, CH3); HRMS-ESI 
(m/z): [M+Na]
+
 calcd for [C41H48N2O6NaSi]
+
: 715.3179, found: 715.3177; [α]20D = −3.4° (c = 
1.5, CHCl3; Lit. [α]
20
D = −3.4°, c = 1.5, CHCl3).
[62]
 
(2R)-3-[3-(tert-Butoxycarbonylamino)-5-(tert-butyldiphenylsiloxy)-phenyl]-2-
methylpropan-1-ol (163a) 
 
The oxazolidinone 163 (10.2 g, 14.7 mmol, 1.0 eq.) was dissolved in Et2O (70 mL) under 
argon atmosphere, water (0.23 mL, 14.7 mmol, 1.0 eq.) was added and the mixture was 
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cooled down to 0 °C. Then LiBH4 (2 M solution in THF) (16.2 ml, 32.4 mmol, 2.2 eq.) was 
added dropwise and the reaction mixture was stirred at 0 °C for 1.5 h. The reaction was 
terminated by addition of an aqueous NH4Cl solution and the aqueous layer was extracted 
with EtOAc (3x). The combined organic layers were washed with NaCl solution, dried over 
MgSO4 and concentrated under reduced pressure. The residue was purified by column 
chromatography (PE : EA = 10 : 1 to 2 : 1) providing the alcohol 163a (5.95 g, 11.5 mmol, 
78%) as a colorless foam.  
The analytical data are in accordance with the reported in the literature.
[62]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.74 – 7.70 (m, 4H, SiPh), 7.44 – 
7.34 (m, 6H, SiPh), 6.81 (bs, 1H, ArH), 6.69 (t, J = 2.0 Hz, 1H, Ph), 6.33 (bs, 1H, NH), 6.11 
(t, J = 1.7 Hz, 1H, Ph), 3.24 (d, J = 3.8 Hz, 1H, CH2OH), 3.20 (d, J = 3.8 Hz, 1H, CH2OH), 
2.41 (dd, J = 13.3, 6.8 Hz, 1H, ArCH2), 2.16 (dd, J = 13.3, 6.8 Hz, 1H, ArCH2), 1.70 – 1.60 
(m, 1H, CHCH3), 1.49 (s, 9H, t-Bu), 1.24 (bs, 1H, OH), 1.08 (s, 9H, Sit-Bu), 0.70 (d, J = 6.8 
Hz, 3H, CHCH3); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 156.00 (s, C-
Ar), 152.7 (s, NCOO), 142.5 (s, C-Ar), 139.2 (s, C-Ar), 135.6 (d, C-Ar), 133.0 (s, C-Ar), 
130.0 (d, C-Ar), 127.9 (d, C-Ar), 115.5 (d, C-Ar), 112.1 (d, C-Ar), 107.7 (d, C-Ar), 80.5 (s, t-
Bu), 67.3 (t, CH2), 39.6 (t, CH2), 37.5 (d, CH), 28.5 (q, s, t-Bu), 26.6 (q, Sit-Bu), 19.5 (s, Sit-
Bu), 16.5 (q, CH3); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C31H41NO4NaSi]
+
: 542.2703, 
found: 542.2700; [α]20D = +4.0° (c = 1.2, CHCl3; Lit. [α]
20
D = +4.9°, c = 1.0, CHCl3).
[62]
 
(2R)-3-[3-(tert-Butoxycarbonylamino)-5-(tert-butyldiphenylsiloxy)phenyl]-2-
methylpropanal (155) 
 
The alcohol 163a (5.90 g, 11.4 mmol, 1.0 eq.) was dissolved in CH2Cl2 (170 mL), cooled 
down to 0 °C and treated successively with NaHCO3 (1.16 g, 13.6 mmol, 1.2 eq.) and DMP 
reagent (5.76 g, 13.6 mmol, 1.2 eq.). After 1 h the reaction was terminated by addition of an 
aqueous Na2SO3 solution and the aqueous phase was extracted three times with CH2Cl2. The 
combined organic phases were washed with the aqueous solution of NaCl, dried over MgSO4 
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and concentrated under reduced pressure. The aldehyde 155 (5.80 g, 11.2 mmol, 99%) was 
obtained as a colorless foam. The product was used directly in the next step without further 
characterization. 
Ethyl (4R)-5-[3-(tert-butoxycarbonylamino)-5-(tert-butyldiphenylsiloxy)phenyl]-4-
methylpent-2-enoate (164) 
 
The aldehyde 155 (5.80 g, 11.2 mmol, 1.0 eq.) was dissolved in CHCl3 (35 mL) and the 
phosphorus ylide 167 (5.85 g, 16.8 mmol, 1.5 eq.) was added. The reaction mixture was 
heated to 50 °C and stirred at 50 °C for additional 15 h. The solvent was removed under 
reduced pressure, the crude product was purified by flash chromatography (PE : EA = 15 : 1 
to 4 : 1) and the ester 164 (4.7 g, 8.0 mmol, 72%) was obtained as a colorless foam. 
 
 The analytical data are in accordance with the reported in the literature.
[136]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.72 – 7.67 (m, 4H, SiPh), 7.45 – 
7.33 (m, 6H, SiPh), 6.81 (dd, J = 15.2, 6.9 Hz, 1H, 3-H), 6.79 (s, 1H, Ph), 6.64 (s, 1H, Ph), 
6.24 (s, 1H, NH), 6.09 (s, 1H, Ph), 5.63 (dd, J = 15.9, 0.6 Hz, 1H, 2-H), 4.16 (q, J = 7.2 Hz, 
2H, OCH2), 2.54 – 2.47 (m, 1H, 5-Ha), 2.27 (dq, J = 6.8, 6.7 Hz, 1H, 4-H), 2.24 – 2.10 (m, 
1H, 5-Hb), 1.48 (s, 9H, t-Bu), 1.27 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.08 (s, 9H, Sit-Bu), 0.78 
(d, J = 6.1 Hz, 3H, 6-H); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 166.9 
(s, COOEt), 156.1 (s, C-Ar), 153.7 (s, C-3), 152.6 (s, NHCOO), 141.5 (s, C-Ar), 139.2 (s, C-
Ar), 133.0 (d, C-Ar), 133.0 (s, C-Ar), 130.0 (d, C-Ar), 130.0 (d, C-Ar), 127.9 (d, C-Ar), 119.8 
(d, C-2), 115.3 (d, C-Ar), 120.0 (d, C-Ar), 107.9 (d, C-Ar), 80.5 (s, t-Bu), 60.3 (t, OCH2), 
42.2 (t, C-5), 37.9 (d, C-4), 28.5 (q, t-Bu), 26.6 (q, Sit-Bu), 19.6 (s, Sit-Bu), 18.5 (q, C-6), 
14.4 (q, OCH2CH3); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C35H45NO5NaSi]
+
: 610.2965, 
found: 610.2969; [α]20D = −19.0° (c = 1.3, CH2Cl2; Lit. [α]
20
D = −18.9°, c = 1.3, CH2Cl2).
[136] 
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(4R)-5-[3-(tert-Butoxycarbonylamino)-5-(tert-butyldiphenylsiloxy)phenyl]-4-methylpent-
2-enol (154) 
 
The ester 164 (5.23 g, 8.9 mmol, 1.0 eq) was dissolved in CH2Cl2 (85 mL) under argon 
atmosphere, cooled down to −78 °C and DIBAL-H (1.0 M solution in toluene) (22.3 mL, 22.3 
mmol, 2.5 eq) was slowly added. The reaction mixture was stirred at −78 °C for 5 h and then 
warmed up to RT. The reaction was terminated by addition of an aqueous Na-K tartrate 
solution, and the reaction mixture was stirred at RT overnight. The aqueous phase was 
extracted three times with CH2Cl2. The combined organic phases were washed with an 
aqueous NaCl solution, dried over MgSO4 and the solvent was concentrated under reduced 
pressure. The crude product was purified by flash chromatography (PE : EA = 10 : 1 to 2 : 1) 
providing the alcohol 154 (3.65 g, 6.7 mmol, 75%) as a colorless foam. 
 The analytical data are in accordance with the reported in the literature.
[136]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.72– 7.70 (m, 4H, SiPh), 7.44 – 
7.34 (m, 6H, SiPh), 6.92 (s, 1H, Ph), 6.48 (m, 1H, Ph), 6.28 (bs, 1H, NH), 6.15 (m, 1H, Ph), 
5.50 (dd, J = 15.5, 7.0 Hz, 1H, 3-H), 5.39 (dt, J = 15.5, 5.5 Hz, 1H, 2-H), 3.99 (t, J = 5.5 Hz, 
2H, 1-H), 2.38 (dd, J = 13.1, 7.3 Hz, 1H, 5-Ha), 2.28 (dd, J = 13.1, 6.7 Hz, 1H, 5-Hb), 2.16 
(m, 1H, 4-H), 1.79 (bs, 1H, CH2OH), 1.48 (s, 9H, t-Bu), 1.08 (s, 9H, Sit-Bu), 0.80 (d, J = 6.8 
Hz, 3H, 6-H); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 155.8 (s, C-Ar), 
152.9 (s, NCOO), 142.4 (s, C-Ar), 138.7 (s, C-Ar), 138.0 (d, C-3), 135.6 (d, C-Ar), 133.0 (s, 
C-Ar), 130.0 (d, C-Ar), 127.9 (d, C-2), 115.7 (d, C-Ar), 112.9 (d, C-Ar), 107.7 (d, C-Ar), 80.6 
(s, t-Bu), 63.9 (t, C-1), 43.4 (t, C-5), 37.8 (d, C-4), 28.5 (q, t-Bu), 26.6 (q, Sit-Bu), 19.7 (q, 6-
Me), 19.6 (s, Sit-Bu); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C33H43NO4NaSi]
+
: 568.2859, 
found: 568.2858; [α]20D = −10.0° (c = 1.0, CHCl3; Lit. [α]
20
D = −1.1°, c = 1.0, CH2Cl2).
[136] 
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(2R,3R,4R)-5-[3-(tert-Butoxycarbonylamino)-5-(tert-butyldiphenylsiloxy)phenyl]-4-
methylpent-2,3-oxiranylpentan-2-ol (165) 
 
Molecular sieves 4Å (20.0 g) were suspended in CH2Cl2 under argon atmosphere (400 mL), 
cooled down to −20 °C and D-(−)-diethyl tartrate (1.75 mL, 10.0 mmol, 1.2 eq) and titanium 
isopropoxide (2.50 mL, 8.3 mmol, 1.0 eq) were added. The reaction mixture was stirred at 
−20 °C for 30 min and then treated with tert-butylhydroperoxide (2.00 mL, 10.8 mmol, 1.3 
eq.). After 30 min, the alcohol 154 (4.54 g, 8.3 mmol, 1.0 eq) in CH2Cl2 (50 mL) was added 
to the reaction mixture and the reaction mixture was stirred at −20 °C for 20 h. The reaction 
was terminated by addition of an aqueous NaOH solution (2.0 M). After stirring for 3 h the 
reaction mixture was filtered through Celite
TM
 and the aqueous phase was extracted three 
times with CH2Cl2. The combined organic phases were washed with an aqueous NaCl 
solution, dried over MgSO4 and concentrated under reduced pressure. The crude product was 
purified by flash chromatography (PE : EA = 10 : 1 to 2 : 1) yielding the epoxide 165 (3.7 g, 
6.6 mmol, 80%) as a colorless foam. 
The analytical data are in accordance with the reported in the literature.
[136]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.72 – 7.69 (m, 4H, SiPh), 7.43 – 
7.34 (m, 6H, SiPh), 6.84 (s, 1H, Ph), 6.64 (m, 1H, Ph), 6.34 (bs, 1H, NH), 6.12 (m, 1H, Ph), 
3.81 (ddd, J = 12.5, 5.9, 2.5 Hz, 1H, 1-Ha), 3.56 (ddd, J = 12.5, 6.9, 3.9 Hz, 1H, 1-Hb), 2.84 
(ddd, J = 4.3, 2.6, 2.4 Hz, 1H, 2-H), 2.70 (dd, J = 6.9, 2.3 Hz, 1H, 3-H), 2.61 (dd, J = 13.3, 
5.1 Hz, 1H, 5-Ha), 2.22 (dd, J = 13.2, 8.8 Hz, 1H, 5-Hb), 1.91 (bs, 1H, OH), 1.54 – 1.50 (m, 
1H, 4-H), 1.48 (s, 9H, t-Bu), 1.08 (s, 9H, Sit-Bu), 0.59 (d, J = 6.8 Hz, 3H, 5-Me); 
13
C 
NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 156.00 (s, C-Ar), 152.7 (s, NCOO), 
141.4 (s, C-Ar), 139.1 (s, C-Ar), 135.6 (d, C-Ar), 135.6 (d, C-Ar), 133.0 (s, C-Ar), 132.9 (s, 
C-Ar), 130.0 (d, C-Ar), 130.0 (d, C-Ar), 127.9 (d, C-Ar), ), 127.9 (d, C-Ar), 115.6 (d, C-Ar), 
112.4 (d, C-Ar), 107.9 (d, C-Ar), 80.6 (s, t-Bu), 61.8 (t, C-1 ), 59.9 (d, C-3), 57.2 (d, C-2), 
40.1 (t, C-5), 36.4 (d, C-4), 28.5 (q, t-Bu), 26.6 (q, Sit-Bu), 19.6 (s, Sit-Bu), 14.8 (q, 5-Me); 
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HRMS-ESI (m/z): [M+Na]
+
 calcd for [C33H43NO5NaSi]
+
: 584.2808, found: 584.2809; [α]20D 
= +9.2° (c = 1.0, CHCl3; Lit. [α]
20
D = +2.2°, c = 0.9, CH2Cl2).
[136]
 
(2S,4R)-5-[3-(tert-Butoxycarbonylamino)-5-(tert-butyldiphenylsiloxy)phenyl]-4-methyl-
1,2-pentandiol (168) 
 
The epoxide 165 (3.45 g, 6.1 mmol, 1.0 eq.) was dissolved in Et2O (220 mL) under argon 
atmosphere, cooled down to 0 °C and treated with DIBAL-H (1.0 M solution in hexanes) (31 
mL, 31.0 mmol, 5.0 eq.). The reaction mixture was warmed up to RT and stirred for 
additional 5 h. Then it was washed with Na-K tartrate solution and stirred overnight. The 
aqueous phase was extracted three times with EtOAc, the combined organic phases were 
dried over MgSO4 and concentrated under reduced pressure. The crude product was purified 
by flash chromatography (PE : EA = 1 : 1 to 1 : 4) and the diol 168 (3.0 g, 5.2 mmol, 85%) 
was obtained as a colorless foam. 
 The analytical data are in accordance with the reported in the literature.
[136]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.73 – 7.68 (m, 4H, SiPh), 7.41 – 
7.34 (m, 6H, SiPh), 6.80 (bs, 1H, Ph), 6.63 (m, 1H, Ph), 6.26 (bs, 1H, NH), 6.11 (m, 1H, Ph), 
3.72 – 3.65 (m, 1H, 2-H), 3.52 (ddd, J = 10.8, 5.8, 3.3 Hz, 1H, 1-Ha), 3.30 (ddd, J = 10.8, 7.3, 
4.0 Hz, 1H, 1-Hb), 2.31 (dd, J = 13.3, 6.6 Hz, 1H, 5-Ha), 2.19 (dd, J = 13.3, 7.8 Hz, 1H, 5-
Hb), 1.86 (dd, J = 5.8, 4.0 Hz, 1H, 1-OH), 1.77 (d, J = 4.4 Hz, 1H, 2-OH), 1.73 – 1.64 (m, 
1H, 4-H), 1.47 (s, 9H, t-Bu), 1.31 (ddd, J = 13.8, 9.3, 4.6 Hz, 1H, 3-Ha), 1.07 (s, 9H, Sit-Bu), 
0.97 (ddd, J = 13.8, 9.7 3.9 Hz, 1H, 3-Hb); 0.69 (d, J = 6.4 Hz, 3H, 6-H); 
13
C 
NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 155.9 (s, C-Ar), 152.7 (s, NCOO), 
142.6 (s, C-Ar), 139.0 (s, C-Ar), 135.6 (d, C-Ar), 133.0 (s, C-Ar), 129.9 (d, C-Ar), 127.8 (d, 
C-Ar), 115.5 (d, C-Ar), 112.3 (d, C-Ar), 107.9 (d, C-Ar), 80.5 (s, t-Bu), 70.1 (d, C-2), 67.5 (t, 
C-1), 44.0 (t, C-5), 39.7 (t, C-3), 30.8 (d, C-4), 28.4 (q, t-Bu), 26.6 (q, Sit-Bu), 19.5 (s, Sit-
Bu), 14.7 (q, 6-Me); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C33H45NO5NaSi]
+
: 586.2965, 
found: 586.2969; [α]20D = −10.1° (c = 1.0, CHCl3; Lit. [α]
20
D = −11.0°, c = 0.6, CH2Cl2).
[136]
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(2S,4R)-5-[3-(tert-Butoxycarbonylamino)-5-(tert-butyldiphenylsiloxy)-phenyl]-4-methyl-
1-(tert-butyldemethylsiloxy)-pentan-2-ol (169) 
 
The alcohol 168 (5.35 g, 9.27 mmol, 1.0 eq.) was dissolved under argon atmosphere in 
CH2Cl2 (380 mL), cooled down to 0 °C and treated with 2,6-lutidine (1.07 mL, 9.27 mmol, 
1.0 eq.) and then TBSOTf (2.13 mL, 9.27 mmol, 1.0 eq.). After 20 min the reaction was 
terminated by addition of an aqueous NH4Cl solution. The phases were separated and the 
aqueous phase was extracted three times with CH2Cl2. The combined organic phases were 
washed with an aqueous NaCl solution, dried over MgSO4 and concentrated under reduced 
pressure. The crude product was purified by flash chromatography (PE : EA = 15 : 1 to 4 : 1) 
and the protected alcohol 169 (4.65 g, 6.86 mmol, 74%) was obtained as a colorless foam. 
 The analytical data are in accordance with the reported in the literature.
[136]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.72 – 7.70 (m, 4H, SiPh), 7.41 – 
7.35 (m, 6H, SiPh), 6.78 (s, 1H, Ph), 6.66 (m, 1H, Ph), 6.27 (bs, 1H, NH), 6.15 (m, 1H, Ph), 
3.69 – 3.64 (m, 1H, 2-H), 3.52 (dd, J = 9.9, 3.4 Hz, 1H, 1-Ha), 3.31 (dd, J = 9.9, 7.6 Hz, 1H, 
1-Hb), 2.40 (dd, J = 13.3, 6.0 Hz, 1H, 5-Ha), 2.24 (s, 1H, 2-OH), 2.13 (dd, J = 13.3, 8.4 Hz, 
1H, 5-Hb), 1.85 – 1.72 (m, 1H, 4-H), 1.48 (s, 9H,t-Bu), 1.37 – 1.30 (m, 1H, 3-Ha), 1.08 (s, 
9H, Sit-Bu), 0.97 – 0.93 (m, 1H, 3-Hb), 0.90 (s, 9H, Sit-Bu), 0.67 (d, J = 6.6 Hz, 3H, 4-Me), 
0.07 (s, 6H, SiMe); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 155.9 (s, C-
Ar), 152.6 (s, NCOO), 142.9 (s, C-Ar), 139.0 (s, C-Ar), 135.6 (d, C-Ar), 133.1 (s, C-Ar), 
129.9 (d, C-Ar), 127.9 (d, C-Ar), 115.6 (d, C-Ar), 112.3 (d, C-Ar), 107.6 (d, C-Ar), 80.5 (s, t-
Bu), 69.7 (d, C-2), 68.0 (t, C-1), 44.3 (t, C-5), 39.7 (t, C-3), 31.0 (d, C-4), 28.5 (q, t-Bu), 26.7 
(q, Sit-Bu), 26.0 (q, Sit-Bu), 19.6 (s, Sit-Bu), 18.7 (q, 4-Me), 18.4 (s, Sit-Bu), -5.2 (q, SiMe); 
HRMS-ESI (m/z): [M+Na]
+
 calcd for [C39H59NO5NaSi2]
+
: 700.3830, found: 700.3827;  
[α]20D = −2.5° (c = 1.0, CHCl3; Lit. [α]
20
D = −4.7°, c = 1.8, CH2Cl2).
[136]
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(2S,4R)-5-[3-(tert-Butoxycarbonylamino)-5-(tert-butyldiphenylsiloxy)-phenyl]-4-methyl-
1-(tert-butyldemethylsiloxy)-2-methoxypentane (170) 
 
The alcohol 169 (4.0 g, 5.90 mmol, 1.0 eq.) was dissolved under argon atmosphere in CH2Cl2 
(120 mL) and 1,8-bis(dimethylamino)-naphthalene (4.42 g, 20.7 mmol, 3.5 eq.), and 
Me3OBF4 (2.18 g, 14.8 mmol, 2.5 eq.) were added. After 1 h the reaction was terminated by 
addition of water. The phases were separated and the aqueous phase was extracted three times 
with CH2Cl2. The combined organic phases were washed with aqueous NaCl solution, dried 
over MgSO4 and concentrated under reduced pressure. The crude product was purified by 
flash chromatography (PE : EA = 15 : 1 to 4 : 1) to give the methylated alcohol 170 (3.47 g, 
5.0 mmol, 85%) as a colorless foam. 
The analytical data are in accordance with the reported in the literature.
[136]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.72 – 7.69 (m, 4H, SiPh), 7.43 – 
7.33 (m, 6H, SiPh), 6.78 (s, 1H, Ph), 6.74 (m, 1H, Ph), 6.38 (bs, 1H, NH), 6.18 (m, 1H, Ph), 
3.62 (dd, J = 10.5, 5.8 Hz, 1H, 1-Ha), 3.50 (dd, J = 10.5, 4.7 Hz, 1H, 1-Hb), 3.39 (s, 3H, 
OMe), 3.25 – 3.19 (m, 1H, 2-H), 2.44 (dd, J = 13.2, 5.4 Hz, 1H, 5-Ha), 2.09 (dd, J = 13.1, 9.1 
Hz, 1H, 5-Hb), 1.74 – 1.66 (m, 1H, 4-H), 1.48 (s, 9H, t-Bu), 1.42 – 1.35 (m, 1H, 3-Ha), 1.08 
(s, 9H, Sit-Bu), 0.98 – 0.93 (m, 1H, 3-Hb), 0.93 (s, 9H, Sit-Bu), 0.66 (d, J = 6.5 Hz, 3H, 4-
Me), 0.05 (s, 6H, SiMe); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 155.9 
(s, C-Ar), 152.6 (s, NCOO), 143.0 (s, C-Ar), 139.0 (s, C-Ar), 135.6 (d, C-Ar), 133.1 (s, C-
Ar), 129.9 (d, C-Ar), 127.8 (d, C-Ar), 115.5 (d, C-Ar), 112.3 (d, C-Ar), 107.6 (d, C-Ar), 80.3 
(s, t-Bu), 80.0 (d, C-2), 66.0 (t, C-1), 58.1 (q, OMe), 44.3 (t, C-5), 39.1 (t, C-3), 31.2 (d, C-4), 
28.4 (q, t-Bu), 26.6 (q, Sit-Bu), 26.0 (q, Sit-Bu), 19.5 (s, Sit-Bu), 19.0 (q, 4-Me), 18.4 (s, Sit-
Bu), -5.2 (q, SiMe); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C39H59NO5NaSi2]
+
: 586.2965, 
found: 586.2969; [α]20D = −7.5° (c = 1.0, CHCl3; Lit. [α]
20
D = −7.4°, c = 1.0, CHCl3).
[136]
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(2S,4R)-5-[3-(tert-Butoxycarbonylamino)-5-(tert-butyldiphenylsiloxy)-phenyl]-4-methyl-
2-methoxypentane (171) 
 
The alcohol 170 (3.40 g, 4.91 mmol, 1.0 eq.) was dissolved under argon atmosphere in 
CH2Cl2 (35 mL) and treated with MeCN (35 mL) and LiBF4 (1.0 M solution in acetonitrile) 
(14.7 mL, 14.7 mmol, 3.0 eq.). After 48 h the reaction was terminated by addition of water. 
The phases were separated and the aqueous phase was extracted three times with CH2Cl2. The 
combined organic phases were washed with NaCl solution, dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by flash 
chromatography (PE : EA = 10 : 1 to 2 : 1) followed by preparative HPLC (C18 column, H2O 
: MeOH = 80 : 20 (5 min), gradient H2O : MeOH = 80 : 20 to 0 : 100 (85 min, 15 mL/min, tR 
= 85.0 min) to give the methylated alcohol 171 (2.13 g, 3.68 mmol, 75%) as a colorless foam. 
The analytical data are in accordance with the reported in the literature.
[136]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.73 – 7.68 (m, 4H, SiPh), 7.44 – 
7.33 (m, 6H, SiPh), 6.78 (s, 1H, Ph), 6.67 (m, 1H, Ph), 6.30 (bs, 1H, NH), 6.12 (m, 1H, Ph), 
3.64 – 3.56 (m, 1H, 1-Ha), 3.41 – 3.35 (m, 1H, 1-Hb), 3.31 (s, 3H, OMe), 3.28 – 3.21 (m, 1H, 
2-H), 2.39 (dd, J = 13.3, 5.7 Hz, 1H, 5-Ha), 2.08 (dd, J = 13.3, 8.6 Hz, 1H, 5-Hb), 1.91 (bs, 
1H, 1-OH), 1.64 – 1.58 (m, 1H, 4-H), 1.48 (s, 9H, t-Bu), 1.53 – 1.46 (m, 1H, 3-Ha), 1.08 (s, 
9H, Sit-Bu), 1.05 – 1.00 (m, 1H, 3-Hb), 0.65 (d, J = 6.6 Hz, 3H, 4-Me; 13C 
NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 156.0 (s, C-Ar), 152.7 (s, NCOO), 
142.8 (s, C-Ar), 139.1 (s, C-Ar), 135.6 (d, C-Ar), 133.1 (s, C-Ar), 129.9 (d, C-Ar), 127.9 (d, 
C-Ar), 115.5 (d, C-Ar), 112.3 (d, C-Ar), 107.7 (d, C-Ar), 80.5 (s, t-Bu), 79.6 (d, C-2), 64.3 (t, 
C-1), 57.1 (q, OMe), 44.0 (t, C-5), 38.0 (t, C-3), 31.4 (d, C-4), 28.5 (q, t-Bu), 26.6 (q, Sit-Bu), 
19.6 (s, Sit-Bu), 19.5 (q, 4-Me); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C34H47NO5NaSi]
+
: 
600.3121, found: 600.3120; [α]20D = +6.0° (c = 1.0, CH2Cl2; Lit. [α]
20
D = +5.0°, c = 1.1, 
CH2Cl2).
[136]
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(2S,4R)-5-[3-(tert-Butoxycarbonylamino)-5-(tert-butyldiphenylsiloxy)-phenyl]-4-methyl-
1-(tert-butyldemethylsiloxy)-2-methoxy-1-pentanal (153) 
 
The alcohol 171 (0.087 g, 0.15 mmol, 1.0 eq.) was dissolved in CH2Cl2 (12 mL), cooled down 
to 0 °C and treated with NaHCO3 (0.015 g, 0.18 mmol, 1.2 eq.) and DMP reagent (0.077 g, 
0.18 mmol, 1.2 eq.). After 1 h at RT the reaction was terminated by addition of an aqueous 
Na2SO3 solution. The phases were separated and the aqueous phase was extracted three times 
with CH2Cl2. The combined organic phases were washed with aqueous NaCl solution, dried 
over MgSO4 and concentrated under reduced pressure providing the aldehyde 153 (0.085 g, 
0.15 mmol, 99%) as a colorless foam. The product was used directly in the next step without 
further characterization. 
(Z)-Crotylboronate (172) 
(Z)-Crotylboronate 172 was prepared according to the procedure of White et al.
[172]
  
 
Potassium tert-butoxide (2.0 g, 18.0 mmol, 1.1 eq.) was suspended under argon atmosphere in 
THF (10 mL) and cooled down to −78 °C. cis-Butene (1.45 mL, 16.4 mmol, 1.0 eq.) was 
added dropwise via cannula to the reaction mixture, followed by n-BuLi (2.5 M in hexanes) 
(5.6 mL, 14.0 mmol, 0.8 eq.). The mixture was stirred at −78 °C for 1 h, then warmed up to 
−25 °C and stirred at this temperature for 45 min. The reaction mixture was again cooled 
down to −78 °C and triisopropyl borate (3.14 mL, 14.0 mmol, 0.8 eq.) was added dropwise. 
The mixture was stirred at −78 °C for 30 min and the reaction was terminated with 1 M 
hydrochloric acid (5.0 mL). While vigorous stirring additional 1 M hydrochloric acid (20 mL) 
was added and the solution was extracted three times with EtOAc. The combined organic 
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phases were added under argon atmosphere to powdered 4Å molecular sieves and 
diethanolamine (1.1 mL, 12.0 mmol, 0.7 eq.). The mixture was stirred for 3 h, filtered and 
washed with EtOAc. Removal of the solvent under reduced pressure provided (Z)-
crotylaminoboronate complex 172a as a white solid which was recrystallized from a 
dichloromethane-diethyl ether mixture to give colorless crystals. The obtained material was 
stored under argon atmosphere. 
 
(S,S)-Diisopropyl tartrate (0.1 mL, 0.47 mmol, 1.0 eq.) was added to a rapidly stirred 
suspension of the (Z)-crotylaminoboronate complex 172a (0.08 g, 0.47 mmol, 1.0 eq.) in Et2O 
(1.5 mL) under argon atmosphere at RT. The mixture was stirred for 5 min, brine (1.5 mL) 
was added and the rapid stirring was continued for 5 min. The mixture was extracted three 
times with Et2O and the combined organic extracts were dried over MgSO4. Removal of the 
solvent under reduced pressure afforded the product 172 as a colorless oil (0.14 g, 0.47 mmol) 
which was used immediately for the preparation of the western fragment 148. 
(3S,4R,5S,7R)-8-[3-(tert-Butoxycarbonylamino)-5-(tert-butyldiphenylsiloxy)-phenyl]-4-
hydroxy-5-methoxy-3,7-dimethyl-oct-2-en (148) 
 
(Z)-Crotylboronate 172 (0.112 g, 0.38 mmol, 2.5 eq.) was dissolved under argon atmosphere 
in toluene (1.5 mL). Then, 4Å molecular sieves (0.063 g) were added, the reaction mixture 
was stirred at RT for 20 min and then cooled down to −78 °C. The aldehyde 153 (0.085 g, 
0.15 mmol, 1.0 eq.) was dissolved in toluene (0.7 mL) and slowly added to the reaction 
mixture. The reaction was terminated after 20 h by addition of an aqueous NaCl solution (1.0 
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M). The reaction mixture was warmed up to RT and stirred for 1 h. The molecular sieves were 
removed by filtration through Celite
TM
 and the aqueous phase was extracted three times with 
Et2O. The combined organic phases were washed with aqueous NaCl solution, dried over 
MgSO4 and concentrated under reduced pressure. The crude product was purified by flash 
chromatography (PE : EA = 10 : 1 to 4 : 1) providing the alkene 148 (0.076 g, 0.12 mmol, 
80%) as a colorless foam. 
The analytical data are in accordance with the reported in the literature.
[135]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.73 – 7.68 (m, 4H, SiPh), 7.42 – 
7.34 (m, 6H, SiPh), 6.77 (s, 1H, Ph), 6.65 (m, 1H, Ph), 6.24 (bs, 1H, NH), 6.16 (m, 1H, Ph), 
5.60 (ddd, J = 17.2, 10.3, 8.6 Hz 1H, 2-H), 5.03 (d, J = 10.1 Hz, 1H, 1-Ha), 4.99 (d, J = 3.0 
Hz 1H, 1-Hb), 3.58 (d, J = 8.9 Hz 1H, 4-H), 3.29 (s, 3H, OMe), 3.23 – 3.15 (m, 1H, 5-H), 
2.42 (dd, J = 13.3, 5.5 Hz, 1H, 8-Ha), 2.27 – 2.15 (m, 1H, 3-H), 2.09 (bs, 1H, 4-OH), 2.09 – 
2.06 (m, 1H, 8-Hb), 1.71 – 1.63 (m, 1H, 7-H), 1.56 – 1.52 (m, 1H, 6-Ha), 1.48 (s, 9H, t-Bu), 
1.12 (d, J = 6.6 Hz, 3H, 3-Me), 1.08 (s, 9H, Sit-Bu), 1.07 – 1.02 (m, 1H, 6-Hb), 0.58 (d, J = 
6.5 Hz, 3H, 7-Me); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 155.9 (s, C-
Ar), 152.6 (s, NCOO), 143.1 (s, C-Ar), 140.1 (d, C-2), 139.0 (s, C-Ar), 135.7 (d, C-Ar), 133.1 
(s, C-Ar), 129.9 (d, C-Ar), 127.8 (d, C-Ar), 115.6 (t, C-1), ), 115.3 (d, C-Ar), 112.3 (d, C-Ar), 
107.7 (d, C-Ar), 80.4 (s, t-Bu), 80.2 (d, C-5), 73.5 (d, C-4), 57.1 (q, OMe), 44.7 (t, C-8), 40.5 
(d, C-3), 34.8 (t, C-6), 30.9 (d, C-7), 28.5 (q, t-Bu), 26.7 (q, Sit-Bu), 19.6 (s, Sit-Bu), 18.6 (q, 
7-Me), 17.5 (q, 3-Me); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C38H53NO5NaSi]
+
: 654.3591, 
found: 654.3590; [α]20D = −17.6° (c = 1.0, CHCl3; Lit. [α]
20
D = −17.8°, c = 1.0, CHCl3).
[135]
 
3.6 Synthesis of the Eastern Fragments 
 (S)-5-Oxotetrahydrofuran-2-carboxylic acid (173a) 
 
L-Glutamic acid (158-L) (19.0 g, 129 mmol, 1.0 eq.) was dissolved in water (140 mL), treated 
with HCl (2 M, 85 mL) and cooled down to −10 °C. NaNO2 (10.7 g, 155 mmol, 1.2 eq.) was 
dissolved in water (85 mL) and slowly added to the reaction mixture over a period of 3 h. The 
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reaction mixture was warmed up to RT and stirring was continued for 12 h. The aqueous 
phase was extracted three times with EtOAc. The combined organic phases were dried over 
MgSO4 and concentrated under reduced pressure. The acid 173a (8.95 g, 68.8 mmol, 53%) 
was obtained as a colorless solid. 
The analytical data are in accordance with the reported in the literature.
[173]
 
1
H NMR (400 MHz, CD3OD, CD2HOD = 3.31 ppm) δ (ppm): 5.00 (dd, J = 7.8, 5.0 Hz, 1H, 
H-5), 2.71 – 2.54 (m, 2H, H-3), 2.54 – 2.41 (m, 1H, H-4a), 2.38 – 2.25 (m, 1H, H-4b); 
HRMS-ESI (m/z): [M+Na]
+
 calcd for [C5H6O4Na]
+
: 153.0164, found: 153.0161;  
M.p.: 70 °C; [α]20D = +14.0° (c = 1.0, MeOH; Lit. [α]
20
D = +15.6°, c = 2.0, EtOH).
[173]
 
(S)-5-(Hydroxymethyl)-2-oxotetrahydrofuran (red-173a) 
 
The acid 173a (8.95 g, 68.8 mmol, 1.0 eq.) was dissolved under nitrogen atmosphere in THF 
(240 mL), cooled down to 0 °C and treated slowly with BH3·SMe2 (9.8 mL, 103.2 mmol, 1.5 
eq.). The reaction mixture was warmed to RT and stirred at RT for additional 3 h. The 
reaction was terminated by addition of MeOH. The solvent was removed under reduced 
pressure to give the lactone red-173a (7.75 g, 66.7 mmol, 97%) as a colorless oil. 
The analytical data are in accordance with the reported in the literature.
[173]
 
1
H NMR (400 MHz, CD3OD, CD2HOD = 3.31 ppm) δ (ppm): 4.67 – 4.56 (m, 1H, H-5), 3.78 
(dd, J = 11.9, 3.1 Hz, 1H, H-6a), 3.59 (dd, J = 11.9, 4.5 Hz, 1H, H-6b), 2.61 – 2.52 (m, 2H, 
H-3), 2.37 – 2.03 (m, 2H, H-4); [α]20D = +44.5° (c = 1.0, CHCl3; Lit. [α]
20
D = +31.3°,  
c = 2.92, EtOH).
[173]
 
4-Methoxybenzyl-2,2,2-trichloroacetimidate (179) 
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A dried 200 mL round bottom flask was charged with sodium hydride (60% dispersion in 
mineral oil, 0.64 g, 16.0 mmol). Et2O (50 mL) was added followed by 4-methoxy-benzyl 
alcohol (20.0 mL, 160 mmol) which was added slowly over a period of 15 min. The mixture 
was stirred at RT for 30 min and then cooled down to 0 °C. Trichloroacetonitrile (17.7 mL, 
176 mmol) was added dropwise over a period of 20 min. After 1 h the reaction was warmed 
up to RT and stirred for 45 min. The reaction was then concentrated in vacuo to give a dark 
orange oil. This crude residue was treated with a mixture of pentane and MeOH (170 mL,  
pentane : MeOH = 275 : 1) and stirring was continued for 30 min. The heterogeneous mixture 
was filtered through a plug of Celite
TM
 and the filtrate was concentrated in vacuo to afford the 
trichloroacetimidate 179 (43.0 g, 152 mmol, 95%) as an orange oil. 
The analytical data are in accordance with the reported in the literature.
[144]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 8.36 (s, 1H, NH), 7.37 (d, J = 8.8 
Hz, 2H, , Ar), 6.91 (d, J = 8.8 Hz, 2H, Ar), 5.27 (s, 2H, CH2), 3.82 (s, 3H, OMe). 
(S)-5-(4-Methoxybenzyloxymethyl)-2-oxotetrahydrofuran (174a) 
 
The alcohol red-173a (1.0 g, 8.61 mmol, 1.0 eq.) was dissolved in CH2Cl2 (50 mL) under 
nitrogen atmosphere and treated with PMB-trichloroacetimidate (179) (9.73 g, 34.5 mmol, 4.0 
eq.) and CSA (0.80 g, 3.45 mmol, 0.4 eq.). After 24 h the reaction was terminated by addition 
of an aqueous NaHCO3 solution. The phases were separated and the aqueous phase was 
extracted three times with CH2Cl2. The combined organic phases were washed with aqueous 
NaCl solution, dried over MgSO4 and concentrated under reduced pressure. The crude product 
was purified by flash chromatography (PE : EA = 10 : 1 to 2 : 1) and the PMB-protected 
alcohol 174a (1.2 g, 5.1 mmol, 60%) was obtained as a colorless oil. 
The analytical data are in accordance with the reported in the literature.
[174]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.26 (d, J = 8.7 Hz, 2H, PMB), 
6.90 (d, J = 8.7 Hz, 2H, PMB), 4.69 – 4.64 (m, 1H, H-5), 4.55 – 4.44 (m, 2H, PMB), 3.82 (s, 
3H, PMB), 3.66 (dd, J = 10.8, 3.4 Hz, 1H, H-6a), 3.57 (dd, J = 10.7, 4.2 Hz, 1H, H-6b), 2.67 
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– 2.58 (m, 1H, H-3a), 2.53 – 2.44 (m, 1H, H-3b), 2.34 – 2.24 (m, 1H, H-4a), 2.17 – 2.06 (m, 
1H, H-4b); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 177.5 (s, C-2), 159.5 
(s, PMB), 129.4 (d, PMB), 114.0 (d, PMB), 79.2 (d, C-5), 73.4 (t, PMB), 71.4 (t, C-6), 55.4 
(q, PMB), 28.5 (t, C-3), 24.3 (t, C-4); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C13H16O4Na]
+
: 
259.0946, found: 259.0947; [α]20D = +9.0° (c = 1.0, CHCl3; Lit. [α]
20
D = +10.6°, c = 1.0, 
CHCl3).
[174]
 
(S)-5-(4-Methoxybenzyloxy)pentan-1,4-diol (175a) 
 
The lactone 174a (1.2 g, 5.08 mmol, 1.0 eq.) was dissolved in THF (140 mL) under nitrogen 
atmosphere, cooled down to 0 °C and treated with LiAlH4 portionwise (0.21 g, 5.59 mmol, 
1.1 eq.). After 30 min the reaction was terminated by addition of water. After another 10 min 
the precipitate was filtered through Celite
TM
, the filtrate was diluted with water and extracted 
three times with EtOAc. The combined organic phases were dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by flash 
chromatography (PE : EA = 1 : 1 to 1 : 5) to give the diol 175a (0.95 g, 3.95 mmol, 78%) as a 
colorless oil. 
The analytical data are in accordance with the reported in the literature.
[135]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.29 (d, J = 8.5 Hz, 2H, PMB), 
6.91 (d, J = 8.7 Hz, 2H, PMB), 4.51 (s, 2H, PMB), 3.91 – 3.85 (m, 1H, H-4), 3.84 (s, 3H, 
PMB), 3.74 – 3.63 (m, 2H, H-1), 3.50 (dd, J = 9.4, 3.3 Hz, 1H, H-5a), 3.35 (dd, J = 9.4, 8.0 
Hz, 1H, H-5b), 2.84 (bs, 1H, 4-OH), 2.42 (bs, 1H, 1-OH), 1.76 – 1.67 (m, 2H, H-2), 1.66– 
1.58 (m, 1H, H-3a), 1.56– 1.47 (m, 1H, H-3b); 13C NMR (100 MHz, CDCl3, CDCl3 = 77.16 
ppm) δ (ppm): 159.5 (s, PMB), 129.6 (d, PMB), 114.0 (d, PMB), 74.3 (d, C-4), 73.2 (t, PMB), 
70.5 (t, C-5), 63.0 (t, C-1), 55.4 (q, PMB), 30.3 (t, C-2), 29.3 (t, C-3); HRMS-ESI (m/z): 
[M+Na]
+
 calcd for [C13H20O4Na]
+
: 263.1259, found: 263.1257; [α]20D = +1.8° (c = 1.0, 
CHCl3; Lit. [α]
20
D = +1.9°, c = 1.0, CHCl3).
[135] 
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(S)-5-(tert-Butyldimethylsilyloxy)-1-(4-methoxybenzyloxy)pentan-2-ol (176a) 
 
The diol 175a (1.0 g, 4.16 mmol, 1.0 eq.) was dissolved in CH2Cl2 (30 mL) under nitrogen 
atmosphere, cooled down to 0 °C and treated with imidazole (0.57 g, 8.32 mmol, 2.0 eq.) 
followed by TBSCl (0.69 g, 4.6 mmol, 1.1 eq.). The reaction mixture was warmed up to RT 
and stirred for 1 h. The reaction was terminated by addition of an aqueous NH4Cl solution. 
The phases were separated and the aqueous phase was extracted three times with CH2Cl2. The 
combined organic phases were washed with an aqueous NaCl solution, dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by flash 
chromatography (PE : EA = 5 : 1 to 2 : 1) to give the protected alcohol 176a (1.33 g, 3.7 
mmol, 90%) as a colorless foam. 
The analytical data are in accordance with the reported in the literature.
[135]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.30 (d, J = 8.7 Hz, 2H, PMB), 
6.92 (d, J = 8.7 Hz, 2H, PMB), 4.52 (s, 2H, PMB), 3.94 – 3.84 (m, 1H, H-2), 3.84 (s, 3H, 
PMB), 3.73 – 3.63 (m, 2H, H-5), 3.51 (dd, J = 9.4, 3.7 Hz, 1H, H-1a), 3.37 (dd, J = 9.4, 7.4 
Hz, 1H, H-1b), 2.92 (bs, 1H, 2-OH), 1.77 – 1.48 (m, 2H, H-4), 1.77 – 1.48 (m, 2H, H-4), 0.93 
(s, 9H, Sit-Bu), 0.09 (s, 6H, SiMe); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 
ppm) δ (ppm): 159.4 (s, PMB), 129.5 (s, PMB), 114.0 (d, PMB), 74.4 (d, C-2), 73.1 (t, PMB), 
70.4 (t, C-1), 63.4 (t, C-5), 55.4 (q, PMB), 30.4 (t, C-4), 29.1 (t, C-3), 26.1 (q, Sit-Bu), 18.5 
(s, Sit-Bu), -5.2 (q, SiMe); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C19H34O4NaSi]
+
: 377.2124, 
found: 377.2126; [α]20D = −2.0° (c = 1.0, CHCl3; Lit. [α]
20
D = −2.3°, c = 1.0, CHCl3).
[135]
 
(S)-5-(tert-Butyldimethylsilyloxy)-1-(4-methoxybenzyloxy)-2-methoxypentan (177a) 
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The alcohol 176a (1.2 g, 3.39 mmol, 1.0 eq.) was dissolved in THF (40 mL) under nitrogen 
atmosphere, cooled down to 0 °C and treated with NaH (0.12 g, 5.08 mmol, 1.5 eq.) followed 
by MeI (0.23 mL, 3.72 mmol, 1.1 eq.). The reaction mixture was warmed up to RT and stirred 
for 24 h. The reaction was terminated by addition of water. The phases were separated and the 
aqueous phase was extracted three times with EtOAc. The combined organic phases were 
washed with aqueous NaCl solution, dried over MgSO4 and concentrated under reduced 
pressure. The crude product was purified by flash chromatography (PE : EA = 5 : 1 to 2 : 1) to 
give the protected alcohol 177a (1.18 g, 3.19 mmol, 94%) as a colorless foam. 
The analytical data are in accordance with the reported in the literature.
[135]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.26 (d, J = 8.6 Hz, 2H, PMB), 
6.87 (d, J = 8.7 Hz, 2H, PMB), 4.48 (s, 2H, PMB), 3.80 (s, 3H, PMB), 3.63 – 3.57 (m, 2H, H-
5), 3.45 (d, J = 4.9 Hz, 2H, H-1), 3.40 (s, 3H, Me), 3.39 – 3.34 (m, 1H, H-2), 1.60 – 1.49 (m, 
2H, H-4), 0.89 (s, 9H, Sit-Bu), 0.04 (s, 6H, SiMe); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 
77.16 ppm) δ (ppm): 159.3 (s, PMB), 130.6 (s, PMB), 129.4 (d, PMB), 113.9 (d, PMB), 80.1 
(d, C-2), 73.1 (t, PMB), 71.9 (t, C-1), 63.4 (t, C-5), 57.6 (q, OMe), 55.4 (q, PMB), 28.8 (t, C-
4), 27.9 (t, C-3), 26.1 (q, Sit-Bu), 18.5 (s, Sit-Bu), -5.1 (q, SiMe); HRMS-ESI (m/z): 
[M+Na]
+
 calcd for [C20H36O4NaSi]
+
: 391.2281, found: 391.2281; [α]20D = −6.0° (c = 1.0, 
CHCl3; Lit. [α]
20
D = −6.0°, c = 1.0, CHCl3).
[135]
 
(S)-5-(tert-Butyldimethylsilyloxy)-2-methoxypentan-1-ol (178a) 
 
The alcohol 177a (1.18 g, 3.19 mmol, 1.0 eq.) was dissolved under nitrogen atmosphere in 
CH2Cl2 (90 mL), cooled down to 0 °C and treated with water (9 mL) and DDQ (0.87 g, 3.84 
mmol, 1.2 eq.). The reaction mixture was warmed up to RT and stirred for 3 h. The reaction 
was terminated by addition of an aqueous NaHCO3 solution. The phases were separated and 
the aqueous phase was extracted three times with CH2Cl2. The combined organic phases were 
washed with aqueous NaCl solution, dried over MgSO4 and removed under reduced pressure. 
The crude product was purified by flash chromatography (PE : EA = 15 : 1 to 5 : 1) and the 
deprotected alcohol 178a (0.7 g, 2.82 mmol, 89%) was obtained as a colorless oil. 
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The analytical data are in accordance with the reported in the literature.
[135]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 3.71 – 3.65 (m, 1H, H-1a), 3.63 – 
3.60 (m, 2H, H-5), 3.52 – 3.45 (m, 1H, H-1b), 3.40 (s, 3H, OMe), 3.32 – 3.26 (m, 1H, H-2), 
2.08 – 2.05 (m, 1H, OH), 1.66 – 1.47 (m, 2H, H-4), 0.88 (s, 9H, Sit-Bu), 0.04 (s, 6H, SiMe); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 81.5 (d, C-2), 64.1 (t, C-1), 63.2 
(t, C-5), 57.2 (q, OMe), 28.6 (t, C-4), 26.7 (t, C-3), 26.1 (q, Sit-Bu), 18.5 (s, Sit-Bu), -5.2 (q, 
SiMe); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C12H28O3NaSi]
+
: 271.1705, found: 271.1707; 
[α]20D = +20.0° (c = 1.0, CHCl3; Lit. [α]
20
D = +20.0°, c = 1.0, CHCl3).
[135]
 
(S)-5-(tert-Butyldimethylsilyloxy)-2-methoxypentan-1-al (157a) 
 
The alcohol 178a (15.0 mg, 60 µmol, 1.0 eq.) was dissolved under nitrogen atmosphere in 
CH2Cl2 (5 mL), cooled down to 0 °C and treated with NaHCO3 (6.0 mg, 72 µmol, 1.2 eq.) 
and DMP reagent (31.0 mg, 72 µmol, 1.2 eq.). After stirring at RT for 1 h the reaction was 
terminated by addition of an aqueous Na2SO3 solution. The phases were separated and the 
aqueous phase was extracted three times with CH2Cl2. The combined organic phases were 
washed with an aqueous NaCl solution, dried over MgSO4 and concentrated under reduced 
pressure providing the aldehyde 157a (14.7 mg, 59 µmol, 99%) as a colorless solid. The 
product was used for the next step without further characterization. 
(3S,4S)-7-(tert-Butyldimethylsilyloxy)-4-methoxy-2-methylhept-1-en-3-ol (149) 
 
1st Method: 
The aldehyde 157a (14.7 mg, 59 µmol, 1.0 eq.) was dissolved under nitrogen atmosphere in 
CH2Cl2 (1 mL), cooled down to 0 °C and treated with MgBr2·Et2O (37 mg, 145 µmol, 2.4 
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eq.). The reaction mixture was stirred at 0 °C for 30 min and then cooled down to −78 °C 
followed by a slow addition of isopropenylmagnesium bromide (0.5 M in THF) (0.3 mL, 150 
µmol, 2.5 eq.). After 3 h the reaction mixture was warmed up to RT, stirred for additional 30 
min and terminated by addition of an aqueous NH4Cl solution. The phases were separated and 
the aqueous phase was extracted three times with CH2Cl2. The combined organic phases were 
washed with NaCl solution, dried over MgSO4 and concentrated under reduced pressure. The 
crude product was purified by flash chromatography (PE : EA = 5 : 1 to 2 : 1) providing the 
product 149 (9.0 mg, 31 µmol, 53%, d.r. syn : anti > 95:5) as a colorless oil. 
2nd Method: 
Isopropenylmagnesium bromide (0.5 M in THF) (3.2 mL, 1.6 mmol, 2.0 eq.) was diluted in 
THF (8 mL), cooled down to −78 °C and transferred via cannula to a cooled solution of 
aldehyde 157a (196 mg, 0.8 mmol, 1.0 eq.) in THF (10 mL). After 30 min of stirring at −78 
°C the reaction was terminated by addition of NaHCO3 and the mixture was diluted with 
EtOAc. The phases were separated and the aqueous phase was extracted three times with 
EtOAc. The combined organic phases were washed with an aqueous NaCl solution, dried over 
MgSO4 and concentrated under reduced pressure. The crude product was purified by flash 
chromatography (PE : EA = 5 : 1 to 2 : 1) providing the product 149 (130 mg, 0.45 mmol, 
56%, d.r. syn : anti > 95:5) as a colorless oil. 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 5.03 – 5.00 (m, 1H, H-1a), 4.95 – 
4.91 (m, 1H, H-1b), 3.94 (d, J = 6.8 Hz, 1H, H-3), 3.62 – 3.58 (m, 2H, H-7), 3.42 (s, 3H, 
OMe), 3.27 – 3.23 (m, 1H, H-4), 2.63 (d, 1H, 3-OH), 1.75 (s, 3H, 2-Me), 1.63 – 1.55 (m, 2H, 
H-5), 1.63 – 1.55 (m, 2H, H-6), 0.89 (s, 9H, Sit-Bu), 0.04 (s, 6H, SiMe);  
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 144.4 (s, C-2), 114.1 (t, C-1), 
82.1 (d, C-4), 77.5 (d, C-3), 63.2 (t, C-7), 58.0 (q, OMe), 28.2 (t, C-6), 26.4 (t, C-5), 26.1 (q, 
Sit-Bu), 18.5 (s, Sit-Bu), 18.0 (q, 2-Me), -5.2 (q, SiMe); HRMS-ESI (m/z): [M+Na]
+
 calcd 
for [C15H32O3NaSi]
+
: 311.2018, found: 311.2011; [α]20D = +22.5° (c = 2.0, CH2Cl2). 
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(R)-Mosher ester (180a) 
 
The alcohol 149 (7.3 mg, 25.3 µmol, 1.0 eq.) was dissolved under nitrogen atmosphere in 
CH2Cl2 (1.0 mL), cooled down to 0 °C and treated with Et3N (14 µl, 101 µmol, 4.0 eq.) and 
DMAP (0.3 mg, 2.5 µmol, 0.1 eq.) followed by (S)-Mosher acid chloride (7.7 mg, 30.4 µmol, 
1.2 eq.). The reaction mixture was warmed up to RT and stirred for 4 h. The reaction was 
terminated by addition of an aqueous NH4Cl solution. The phases were separated and the 
aqueous phase was extracted three times with CH2Cl2. The combined organic phases were 
washed with NaCl solution, dried over MgSO4 and concentrated under reduced pressure. The 
crude product was purified by flash chromatography (PE : EA = 20 : 1) to give the ester (R)-
180a (10.7 mg, 21.2 µmol, 84%) as a colorless oil. 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.55 – 7.53 (m, 2H, Ph), 7.41 – 
7.37 (m, 3H, H-Ph), 5.41 (d, J = 8.0 Hz, 1H, H-3), 5.13 (s, 1H, H-1a), 5.06 – 5.02 (m, 1H, H-
1b), 3.60 – 3.54 (m, 2H, H-7), 3.56 (s, 3H, 2’-OMe), 3.36 – 3.30 (m, 1H, H-4), 3.03 (s, 3H, 4-
OMe), 1.76 (s, 3H, 2-Me), 1.63 – 1.50 (m, 2H, H-5), 1.63 – 1.50 (m, 2H, H-6), 0.87 (s, 9H, 
Sit-Bu), 0.02 (s, 6H, SiMe); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C25H39O5F3NaSi]
+
: 
527.2417, found: 527.2420. 
(S)-Mosher ester (180b) 
 
The alcohol 149 (8.8 mg, 30.5 µmol, 1.0 eq.) was dissolved under nitrogen atmosphere in 
CH2Cl2 (1.5 mL), cooled down to 0 °C and treated with Et3N (17 µl, 122 µmol, 4.0 eq.) and 
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DMAP (0.4 mg, 3.7 µmol, 0.1 eq.) followed by (R)-Mosher acid chloride (9.3 mg, 36.7 µmol, 
1.2 eq.). The reaction mixture was warmed up to RT and stirred for 4 h. The reaction was 
terminated by addition of an aqueous NH4Cl solution. The phases were separated and the 
aqueous phase was extracted three times with CH2Cl2. The combined organic phases were 
washed with an aqueous NaCl solution, dried over MgSO4 and concentrated under reduced 
pressure. The crude product was purified by flash chromatography (PE : EA = 20 : 1) to give 
the ester (S)-180b (12.7 mg, 25.2 µmol, 82%) as a colorless oil. 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.57 – 7.55 (m, 2H, Ph), 7.41 – 
7.37 (m, 3H, H-Ph), 5.35 (d, J = 8.4 Hz, 1H, H-3), 5.08 (s, 1H, H-1a), 5.03 – 4.98 (m, 1H, H-
1b), 3.63 – 3.53 (m, 2H, H-7), 3.57 (s, 3H, 2’-OMe), 3.45 – 3.39 (m, 1H, H-4), 3.36 (s, 3H, 4-
OMe), 1.80 – 1.40 (m, 2H, H-5), 1.80 – 1.40 (m, 2H, H-6), 1.63 (s, 3H, 2-Me), 0.88 (s, 9H, 
Sit-Bu), 0.03 (s, 6H, SiMe); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C25H39O5F3NaSi]
+
: 
527.2417, found: 527.2422. 
(R)-5-Oxotetrahydrofuran-2-carboxylic acid (173b) 
 
D-Glutamic acid (158-D) (21.0 g, 143 mmol, 1.0 eq.) was dissolved in water (143 mL), treated 
with HCl (2 M, 85 mL) and cooled down to −10 °C. NaNO2 (11.8 g, 171 mmol, 1.2 eq.) was 
dissolved in water (85 mL) and slowly added to the reaction mixture over a period of 3 h. The 
reaction mixture was warmed to RT and stirred for 12 h. The aqueous phase was extracted 
three times with EtOAc. The combined organic phases were dried over MgSO4 and 
concentrated under reduced pressure. The acid 173b (10.8 g, 83.0 mmol, 58%) was obtained 
as a colorless solid. 
The analytical data are in accordance with the reported in the literature.
[143]
 
1
H NMR (400 MHz, CD3OD, CD2HOD = 3.31 ppm) δ (ppm): 5.00 (dd, J = 7.8, 5.0 Hz, 1H, 
H-5), 2.71 – 2.54 (m, 2H, H-3), 2.54 – 2.41 (m, 1H, H-4a), 2.38 – 2.25 (m, 1H, H-4b); 
HRMS-ESI (m/z): [M-H]
−
 calcd for [C5H5O4]
−
: 129.0188, found: 129.0188; M.p. = 71 °C 
(Lit. 71 °C) [143]; [α]20D = −13.0° (c = 1.0, MeOH; Lit. [α]
20
D = −15.5°, c = 2.0, EtOH).
[143]
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(R)-5-(Hydroxymethyl)-2-oxotetrahydrofuran (red-173b) 
 
The acid 173b (9.7 g, 74.6 mmol, 1.0 eq.) was dissolved under nitrogen atmosphere in THF 
(160 mL), cooled down to 0 °C and treated slowly with BH3·SMe2 (10.6 mL, 111.5 mmol, 1.5 
eq.). The reaction mixture was warmed up to RT and stirred at RT for additional 3 h. The 
reaction was terminated by addition of MeOH. The solvent was removed under reduced 
pressure to give the lactone red-173b (8.45 g, 72.8 mmol, 98%) as a colorless oil. 
The analytical data are in accordance with the reported in the literature.
[135,143]
 
1
H NMR (400 MHz, CD3OD, CD2HOD = 3.31 ppm) δ (ppm): 4.67 – 4.56 (m, 1H, H-5), 3.78 
(dd, J = 11.9, 3.1 Hz, 1H, H-6a), 3.59 (dd, J = 11.9, 4.5 Hz, 1H, H-6b), 2.61 – 2.52 (m, 2H, 
H-3), 2.37 – 2.03 (m, 2H, H-4); [α]20D = −44.0° (c = 1.0, CHCl3; Lit. [α]
20
D = −33.0°, c = 3.0, 
EtOH).
[143]
 
(R)-5-(4-Methoxybenzyloxymethyl)-2-oxotetrahydrofuran (174b) 
 
The alcohol red-173b (1.0 g, 8.61 mmol, 1.0 eq.) was dissolved in CH2Cl2 (50 mL) under 
nitrogen atmosphere and treated with PMB-trichloroacetimidate (179) (9.73 g, 34.5 mmol, 4.0 
eq.) and CSA (0.80 g, 3.45 mmol, 0.4 eq.). After 24 h the reaction was terminated by addition 
of an aqueous NaHCO3 solution. The phases were separated and the aqueous phase was 
extracted three times with CH2Cl2. The combined organic phases were washed with an 
aqueous NaCl solution, dried over MgSO4 and concentrated under reduced pressure. The 
crude product was purified by flash chromatography (PE : EA = 10 : 1 to 2 : 1) and the PMB-
protected alcohol 174b (1.52 g, 6.5 mmol, 75%) was obtained as a colorless oil. 
The analytical data are in accordance with the reported in the literature.
[175]
 
141 
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.26 (d, J = 8.7 Hz, 2H, PMB), 
6.90 (d, J = 8.7 Hz, 2H, PMB), 4.69 – 4.64 (m, 1H, H-5), 4.55 – 4.44 (m, 2H, PMB), 3.82 (s, 
3H, PMB), 3.66 (dd, J = 10.8, 3.4 Hz, 1H, H-6a), 3.57 (dd, J = 10.7, 4.2 Hz, 1H, H-6b), 2.67 
– 2.58 (m, 1H, H-3a), 2.53 – 2.44 (m, 1H, H-3b), 2.34 – 2.24 (m, 1H, H-4a), 2.17 – 2.06 (m, 
1H, H-4b); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 177.5 (s, C-2), 159.5 
(s, PMB), 129.4 (d, PMB), 114.0 (d, PMB), 79.2 (d, C-5), 73.4 (t, PMB), 71.3 (t, C-6), 55.4 
(q, PMB), 28.6 (t, C-3), 24.3 (t, C-4); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C13H16O4Na]
+
: 
259.0946, found: 259.0945; [α]20D = −9.5° (c = 1.0, CHCl3; Lit. [α]
20
D = −9.8°, c = 0.43, 
CHCl3).
[175]
 
(R)-5-(4-Methoxybenzyloxy)pentan-1,4-diol (175b) 
 
The lactone 174b (1.05 g, 4.44 mmol, 1.0 eq.) was dissolved in THF (100 mL) under nitrogen 
atmosphere, cooled down to 0 °C and treated with LiAlH4 portionwise (0.19 g, 4.89 mmol, 
1.1 eq.). After 30 min the reaction was terminated by addition of water. After further 10 min 
the precipitate was filtered through Celite
TM
, the filtrate was diluted with water and extracted 
three times with EtOAc. The combined organic phases were dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by flash 
chromatography (PE : EA = 1 : 1 to 1 : 5) to give the diol 175b (0.78 g, 3.2 mmol, 73%) as a 
colorless oil. 
The analytical data are in accordance with the reported in the literature.
[135]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.29 (d, J = 8.5 Hz, 2H, PMB), 
6.91 (d, J = 8.7 Hz, 2H, PMB), 4.51 (s, 2H, PMB), 3.91 – 3.85 (m, 1H, H-4), 3.84 (s, 3H, 
PMB), 3.74 – 3.63 (m, 2H, H-1), 3.50 (dd, J = 9.4, 3.3 Hz, 1H, H-5a), 3.35 (dd, J = 9.4, 8.0 
Hz, 1H, H-5b), 2.84 (bs, 1H, 4-OH), 2.42 (bs, 1H, 1-OH), 1.76 – 1.67 (m, 2H, H-2), 1.66– 
1.58 (m, 1H, H-3a), 1.56– 1.47 (m, 1H, H-3b); 13C NMR (100 MHz, CDCl3, CDCl3 = 77.16 
ppm) δ (ppm): 159.5 (s, PMB), 129.6 (d, PMB), 114.0 (d, PMB), 74.3 (d, C-4), 73.2 (t, PMB), 
70.6 (t, C-5), 63.0 (t, C-1), 55.4 (q, PMB), 30.3 (t, C-2), 29.3 (t, C-3); HRMS-ESI (m/z): 
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[M+Na]
+
 calcd for [C13H20O4Na]
+
: 263.1259, found: 263.1258; [α]20D = −2.0° (c = 1.0, 
CHCl3; Lit. [α]
20
D = −2.0°, c = 1.0, CHCl3).
[135]
 
(R)-5-(tert-Butyldimethylsilyloxy)-1-(4-methoxybenzyloxy)pentan-2-ol (176b) 
 
The diol 175b (0.50 g, 2.08 mmol, 1.0 eq.) was dissolved in CH2Cl2 (20 mL) under nitrogen 
atmosphere, cooled down to 0 °C and treated with imidazole (0.28 g, 4.16 mmol, 2.0 eq.) 
followed by TBSCl (0.35 g, 2.29 mmol, 1.1 eq.). The reaction mixture was warmed up to RT 
and stirred for 1 h. The reaction was terminated by addition of an aqueous NH4Cl solution. 
The phases were separated and the aqueous phase was extracted three times with CH2Cl2. The 
combined organic phases were washed with an aqueous NaCl solution, dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by flash 
chromatography (PE : EA = 5: 1 to 2: 1) to give the protected alcohol 176b (0.68 g, 1.9 mmol, 
92%) as a colorless foam. 
The analytical data are in accordance with the reported in the literature.
[135]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.30 (d, J = 8.7 Hz, 2H, PMB), 
6.92 (d, J = 8.7 Hz, 2H, PMB), 4.52 (s, 2H, PMB), 3.94 – 3.84 (m, 1H, H-2), 3.84 (s, 3H, 
PMB), 3.73 – 3.63 (m, 2H, H-5), 3.51 (dd, J = 9.4, 3.7 Hz, 1H, H-1a), 3.37 (dd, J = 9.4, 7.4 
Hz, 1H, H-1b), 2.92 (bs, 1H, 2-OH), 1.77 – 1.48 (m, 2H, H-4), 1.77 – 1.48 (m, 2H, H-4), 0.93 
(s, 9H, Sit-Bu), 0.09 (s, 6H, SiMe); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 
ppm) δ (ppm): 159.4 (s, PMB), 130.3 (s, PMB), 113.9 (d, PMB), 74.4 (d, C-2), 73.1 (t, PMB), 
70.3 (t, C-1), 63.4 (t, C-5), 55.4 (q, PMB), 30.4 (t, C-4), 29.1 (t, C-3), 26.1 (q, Sit-Bu), 18.4 
(s, Sit-Bu), -5.2 (q, SiMe); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C19H34O4NaSi]
+
: 377.2124, 
found: 377.2124; [α]20D = +2.5° (c = 1.0, CHCl3; Lit. [α]
20
D = +2.4°, c = 1.0, CHCl3).
[135] 
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(R)-5-(tert-Butyldimethylsilyloxy)-2-methoxy-1-(4-methoxybenzyloxy)pentane (177b) 
 
The alcohol 176b (0.56 g, 1.58 mmol, 1.0 eq.) was dissolved in THF (20 mL) under nitrogen 
atmosphere, cooled down to 0 °C and treated with NaH (0.06 g, 2.37 mmol, 1.5 eq.) followed 
by MeI (0.1 mL, 1.74 mmol, 1.1 eq.). The reaction mixture was warmed up to RT and stirred 
for 24 h. The reaction was terminated by addition of water. The phases were separated and the 
aqueous phase was extracted three times with EtOAc. The combined organic phases were 
washed with an aqueous NaCl solution, dried over MgSO4 and concentrated under reduced 
pressure. The crude product was purified by flash chromatography (PE : EA = 5 : 1 to 2 : 1) to 
give the protected alcohol 177b (0.51 g, 1.38 mmol, 88%) as a colorless foam. 
The analytical data are in accordance with the reported in the literature.
[135]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.26 (d, J = 8.6 Hz, 2H, PMB), 
6.87 (d, J = 8.7 Hz, 2H, PMB), 4.48 (s, 2H, PMB), 3.80 (s, 3H, PMB), 3.63 – 3.57 (m, 2H, H-
5), 3.45 (d, J = 4.9 Hz, 2H, H-1), 3.40 (s, 3H, Me), 3.39 – 3.34 (m, 1H, H-2), 1.60 – 1.49 (m, 
2H, H-4), 0.89 (s, 9H, Sit-Bu), 0.04 (s, 6H, SiMe); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 
77.16 ppm) δ (ppm): 159.3 (s, PMB), 130.6 (s, PMB), 129.4 (d, PMB), 113.9 (d, PMB), 80.1 
(d, C-2), 73.1 (t, PMB), 71.9 (t, C-1), 63.4 (t, C-5), 57.6 (q, OMe), 55.4 (q, PMB), 28.8 (t, C-
4), 27.9 (t, C-3), 26.1 (q, Sit-Bu), 18.5 (s, Sit-Bu), -5.1 (q, SiMe); HRMS-ESI (m/z): 
[M+Na]
+
 calcd for [C20H36O4NaSi]
+
: 391.2281, found: 391.2283; [α]20D = +6.1° (c = 1.0, 
CHCl3; Lit. [α]
20
D = +6.3°, c = 1.0, CHCl3).
[135]
 
(R)-5-(tert-Butyldimethylsilyloxy)-2-methoxypentan-1-ol (178b) 
 
The alcohol 177b (0.4 g, 1.09 mmol, 1.0 eq.) was dissolved under nitrogen atmosphere in 
CH2Cl2 (30 mL), cooled down to 0 °C and treated with water (3 mL) and DDQ (0.30 g, 1.30 
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mmol, 1.2 eq.). The reaction mixture was warmed up to RT and stirred for 1.5 h. The reaction 
was terminated by addition of an aqueous NaHCO3 solution. The phases were separated and 
the aqueous phase was extracted three times with CH2Cl2. The combined organic phases were 
washed with an aqueous NaCl solution, dried over MgSO4 and removed under reduced 
pressure. The crude product was purified by flash chromatography (PE : EA = 15: 1 to 5: 1) 
and the deprotected alcohol 178b (0.24 g, 0.97 mmol, 89%) was obtained as a colorless oil. 
The analytical data are in accordance with the reported in the literature.
[135]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 3.71 – 3.65 (m, 1H, H-1a), 3.63 – 
3.60 (m, 2H, H-5), 3.52 – 3.45 (m, 1H, H-1b), 3.40 (s, 3H, OMe), 3.32 – 3.26 (m, 1H, H-2), 
2.08 – 2.05 (m, 1H, OH), 1.66 – 1.47 (m, 2H, H-4), 0.88 (s, 9H, Sit-Bu), 0.04 (s, 6H, SiMe); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 81.5 (d, C-2), 64.1 (t, C-1), 63.2 
(t, C-5), 57.2 (q, OMe), 28.6 (t, C-4), 26.7 (t, C-3), 26.1 (q, Sit-Bu), 18.5 (s, Sit-Bu), -5.2 (q, 
SiMe); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C12H28O3NaSi]
+
: 271.1705, found: 271.1706; 
[α]20D = −20.6° (c = 1.0, CHCl3; Lit. [α]
20
D = −20.8°, c = 1.0, CHCl3).
[135]
 
(R)-5-(tert-Butyldimethylsilyloxy)-2-methoxypentan-1-al (157b) 
 
The alcohol 178b (500 mg, 2.0 mmol, 1.0 eq.) was dissolved under nitrogen atmosphere in 
CH2Cl2 (100 mL), cooled down to 0 °C and treated with NaHCO3 (203 mg, 2.42 mmol, 1.2 
eq.) and DMP reagent (1.0 g, 2.42 mmol, 1.2 eq.). After stirring at RT for 1 h the reaction was 
terminated by addition of an aqueous Na2SO3 solution. The phases were separated and the 
aqueous phase was extracted three times with CH2Cl2. The combined organic phases were 
washed with an aqueous NaCl solution, dried over MgSO4 and concentrated under reduced 
pressure providing the aldehyde 157b (491 mg, 1.99 mmol, 99%) as a colorless solid. The 
product was used for the next step without further characterization. 
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(3R,4R)-7-(tert-Butyldimethylsilyloxy)-4-methoxy-2-methylhept-1-en-3-ol (150b) 
 
The aldehyde 157b (450 mg, 1.83 mmol, 1.0 eq.) was dissolved under nitrogen atmosphere in 
THF (70 mL), cooled down to −78 °C and treated with isopropenylmagnesium bromide (0.5 
M in THF, 7.3 mL, 3.65 mmol, 2.0 eq.). After 1 h the reaction was terminated by addition of 
an aqueous NH4Cl solution. The phases were separated and the aqueous phase was extracted 
three times with EtOAc. The combined organic phases were washed with NaCl solution, dried 
over MgSO4 and concentrated under reduced pressure. The crude product was purified by 
flash chromatography (PE : EA = 5 : 1 to 2 : 1) providing the product 150b (259 mg, 0.9 
mmol, 50%, d.r. syn : anti = 7 : 1) as a colorless oil. 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 5.02 – 5.00 (m, 1H, H-1a), 4.93 – 
4.90 (m, 1H, H-1b), 3.93 (d, J = 6.8 Hz, 1H, H-3), 3.61 – 3.57 (m, 2H, H-7), 3.41 (s, 3H, 
OMe), 3.27 – 3.20 (m, 1H, H-4), 2.68 (d, 1H, 3-OH), 1.74 (s, 3H, 2-Me), 1.62 – 1.44 (m, 2H, 
H-5), 1.62 – 1.44 (m, 2H, H-6), 0.88 (s, 9H, Sit-Bu), 0.03 (s, 6H, SiMe); 13C 
NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 144.4 (s, C-2), 114.0 (t, C-1), 82.1 
(d, C-4), 77.4 (d, C-3), 63.2 (t, C-7), 58.0 (q, OMe), 28.2 (t, C-6), 26.4 (t, C-5), 26.1 (q, Sit-
Bu), 18.5 (s, Sit-Bu), 18.0 (q, 2-Me), -5.2 (q, SiMe); HRMS-ESI (m/z): [M+H]
+
 calcd for 
[C15H33O3Si]
+
: 289.2199, found: 289.2203; [α]20D = −30.1° (c = 1.25, CH2Cl2). 
 (R)-7-(tert-Butyldimethylsilyloxy)-4-methoxy-2-methylhept-1-en-3-one (183) 
 
The alcohol 150b (220 mg, 0.76 mmol, 1.0 eq.) was dissolved under nitrogen atmosphere in 
CH2Cl2 (40 mL), cooled down to 0 °C and treated with NaHCO3 (77 mg, 0.92 mmol, 1.2 eq.) 
and DMP reagent (388 mg, 0.92 mmol, 1.2 eq.). After stirring for 1 h at RT the reaction was 
terminated by addition of an aqueous Na2SO3 solution. The phases were separated and the 
146 
 
aqueous phase was extracted three times with CH2Cl2. The combined organic phases were 
washed with an aqueous NaCl solution, dried over MgSO4 and concentrated under reduced 
pressure providing the ketone 183 (188 mg, 0.66 mmol, 86%) as a colorless solid.  
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 6.10 (s, 1H, H-1a), 5.83 (s, 1H, H-
1b), 4.32 (dd, J = 8.1, 4.5 Hz, 1H, H-4), 3.65 – 3.51 (m, 2H, H-7), 3.29 (s, 3H, OMe), 1.88 (s, 
3H, 2-Me), 1.84 – 1.54 (m, 2H, H-5), 1.84 – 1.54 (m, 2H, H-6), 0.86 (s, 9H, Sit-Bu), 0.02 (s, 
6H, SiMe); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 202.2 (s, C-3), 143.0 
(s, C-2), 125.7 (t, C-1), 83.2 (d, C-4), 62.6 (t, C-7), 57.7 (q, OMe), 30.0 (t, C-6), 28.8 (t, C-5), 
26.0 (q, Sit-Bu), 18.4 (s, Sit-Bu), 18.2 (q, 2-Me), -5.2 (q, SiMe); HRMS-ESI (m/z): [M+Na]
+
 
calcd for [C15H30O3NaSi]
+
: 309.1862, found: 309.1862. 
(3S,4R)-7-(tert-Butyldimethylsilyloxy)-4-methoxy-2-methylhept-1-en-3-ol (150a) 
 
The ketone 183 (144 mg, 0.5 mmol, 1.0 eq.) was dissolved under nitrogen atmosphere in THF 
(70 mL), cooled down to −78 °C and treated with (S)-CBS (0.83 g, 3.0 mmol, 6.0 eq.). After 
10 min BH3·SMe2 (2.0 M in THF) (6.3 mL, 12.6 mmol, 25.0 eq.) was added and the reaction 
mixture was stirred at −78 °C for 24 h. The reaction was terminated by addition of MeOH, the 
mixture was warmed up to RT and diluted with water. The phases were separated and the 
aqueous phase was extracted three times with EtOAc. The combined organic phases were 
washed with NaCl solution, dried over MgSO4 and concentrated under reduced pressure. The 
crude product (a mixture of diastereomers 1 : 1) was purified by flash chromatography  
(PE : EA = 10 : 1 to 5 : 1) providing the desired anti-diastereomer 150a (32 mg, 0.11 mmol, 
22%) as a colorless oil. 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 5.08 (s, 1H, H-1a), 4.93 – 4.92 (m, 
1H, H-1b), 4.28 (d, J = 3.8 Hz, 1H, H-3), 3.66 – 3.54 (m, 2H, H-7), 3.41 (s, 3H, OMe), 3.30 – 
3.23 (m, 1H, H-4), 2.23 (s, 1H, 3-OH), 1.72 (s, 3H, 2-Me), 1.56 – 1.45 (m, 2H, H-5), ), 1.56 – 
1.45 (m, 2H, H-6), 0.88 (s, 9H, Sit-Bu),0.04 (s, 6H, SiMe); 
13
C NMR (100 MHz, CDCl3, 
CDCl3 = 77.16 ppm) δ (ppm): 143.7 (s, C-2), 111.9 (t, C-1), 82.6 (d, C-4), 74.1 (d, C-3), 63.3 
(t, C-7), 57.6 (q, OMe), 29.2 (t, C-6), 26.1 (q, Sit-Bu), 24.5 (t, C-5), 19.5 (q, 2-Me), 18.5 (s, 
147 
 
Sit-Bu), -5.2 (q, SiMe); HRMS-ESI (m/z): [M+H]
+
 calcd for [C15H33O3Si]
+
: 289.2199, found: 
289.2198; [α]20D = −11.0° (c = 1.0, CH2Cl2). 
(R)-2,5-Bis(tert-butyldimethylsilyloxy)-1-(4-methoxybenzyloxy)pentane (185) 
 
The alcohol 175b (2.50 g, 10.4 mmol, 1.0 eq.) was dissolved under nitrogen atmosphere in 
CH2Cl2 (60 mL), cooled down to 0 °C and treated with 2,6-lutidine (4.20 mL, 36.3 mmol, 3.5 
eq.) followed by TBSOTf (5.30 mL, 22.9 mmol, 2.2 eq.). The reaction mixture was warmed 
up to RT and stirred at RT for additional 2.5 h. The reaction was terminated by addition of an 
aqueous NH4Cl solution. The phases were separated and the aqueous phase was extracted 
three times with CH2Cl2. The combined organic phases were washed with aqueous NaCl 
solution, dried over MgSO4 and concentrated under reduced pressure. The crude product was 
purified by flash chromatography (PE : EA = 50 : 1 to 10: 1) to give the protected alcohol 185 
(4.0 g, 8.53 mmol, 82%) as a colorless foam. 
The analytical data are in accordance with the reported in the literature.
[135]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.26 (d, J = 8.9 Hz, 2H, PMB), 
6.87 (d, J = 8.7 Hz, 2H, PMB), 4.45 (s, 2H, PMB), 3.90 – 3.81 (m, 1H, H-2), 3.81 (s, 3H, 
PMB), 3.62 – 3.59 (m, 2H, H-5), 3.42 – 3.32 (m, 2H, H-1), 1.63 – 1.43 (m, 2H, H-4), 1.63 – 
1.43 (m, 2H, H-3), 0.89 (s, 9H, Sit-Bu), 0.88 (s, 9H, Sit-Bu), 0.05 (s, 6H, SiMe), 0.04 (s, 6H, 
SiMe); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 159.2 (s, PMB), 130.8 (s, 
PMB), 129.3 (d, PMB), 113.8 (d, PMB), 74.6 (d, C-1), 73.1 (t, PMB), 71.5 (t, C-2), 63.5 (t, C-
5), 55.4 (q, PMB), 31.2 (t, C-3), 28.8 (t, C-4), 26.1 (q, Sit-Bu), 18.5 (s, Sit-Bu), 18.3 (s, Sit-
Bu), -4.2 (q, SiMe), -4.6 (q, SiMe), -5.1 (q, SiMe); HRMS-ESI (m/z): [M+Na]
+
 calcd for 
[C25H48O4NaSi2]
+
: 491.2989, found: 491.2986; [α]20D = +10.0° (c = 1.0, CHCl3; Lit. [α]
20
D = 
+10.3°, c = 1.0, CHCl3).
[135] 
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(R)-2,5-Bis(tert-butyldimethylsilyloxy)pentan-1-ol (186) 
 
The alcohol 185 (2.0 g, 4.27 mmol, 1.0 eq.) was dissolved under nitrogen atmosphere in 
CH2Cl2 (130 mL, cooled down to 0 °C and treated with water (13 mL) and DDQ (1.16 g, 5.12 
mmol, 1.2 eq.). The reaction mixture was warmed up to RT and stirred for 1.5 h. The reaction 
was terminated by addition of an aqueous NaHCO3 solution. The phases were separated and 
the aqueous phase was extracted three times with CH2Cl2. The combined organic phases were 
washed with aqueous NaCl solution, dried over MgSO4 and removed under reduced pressure. 
The crude product was purified by flash chromatography (PE : EA = 15 : 1 to 5 : 1) and the 
deprotected alcohol 186 (1.2 g, 3.4 mmol, 80%) was obtained as a colorless oil. 
The analytical data are in accordance with the reported in the literature.
[135,151]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 3.79 – 3.74 (m, 1H, H-2), 3.63 – 
3.54 (m, 2H, H-5), 3.63 – 3.54 (m, 1H, H-1a), 3.48 – 3.43 (m, 1H, H-1b), 1.92 – 1.89 (m, 1H, 
OH), 1.57 – 1.47 (m, 2H, H-3), 1.57 – 1.47 (m, 2H, H-4), 0.90 (s, 9H, Sit-Bu), 0.89 (s, 9H, 
Sit-Bu), 0.09 (s, 6H, SiMe), 0.04 (s, 6H, SiMe); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 
ppm) δ (ppm): 72.9 (d, C-2), 66.4 (t, C-1), 63.3 (t, C-5), 30.5 (t, C-3), 28.7 (t, C-4), 26.1 (q, 
Sit-Bu), 18.5 (s, Sit-Bu), 18.3 (s, Sit-Bu), ), -4.3 (q, SiMe), -4.4 (q, SiMe), -5.2 (q, SiMe); 
HRMS-ESI (m/z): [M+Na]
+
 calcd for [C17H40O3NaSi2]
+
: 371.2414, found: 371.2413; [α]20D = 
−13.0° (c = 2.0, CHCl3; Lit. [α]
20
D = −13.3°, c = 2.0, CHCl3).
[135]
 
 (R)-2,5-Bis(tert-butyldimethylsilyloxy)pentan-1-al (157c) 
 
The alcohol 186 (50.0 mg, 0.14 mmol, 1.0 eq.) was dissolved under nitrogen atmosphere in 
CH2Cl2 (10 mL), cooled down to 0 °C and treated with NaHCO3 (14.5 mg, 0.172 mmol, 1.2 
eq.) and DMP reagent (73 mg, 0.172 mmol, 1.2 eq.). After stirring at RT for 1 h the reaction 
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was terminated by addition of an aqueous Na2SO3 solution. The phases were separated and 
the aqueous phase was extracted three times with CH2Cl2. The combined organic phases were 
washed with an aqueous NaCl solution, dried over MgSO4 and concentrated under reduced 
pressure providing the aldehyde 157c (49 mg, 0.14 mmol, 99%) as a colorless solid. The 
product was used for the next step without further characterization. 
(3S,4R)-4,7-Bis(tert-butyldimethylsilyloxy)-2-methylhept-1-en-3-ol (151) 
 
The aldehyde 157c (49 mg, 0.14 mmol, 1.0 eq.) was dissolved under nitrogen atmosphere in 
Et2O (15 mL), cooled down to −78 °C and treated with isopropenylmagnesium bromide (0.5 
M in THF, 0.35 mL, 0.17 mmol, 1.2 eq.). After 30 min the reaction was terminated by 
addition of an aqueous NH4Cl solution. The phases were separated and the aqueous phase was 
extracted three times with EtOAc. The combined organic phases were washed with NaCl 
solution, dried over MgSO4 and concentrated under reduced pressure. The crude product was 
purified by flash chromatography (PE : EA = 20 : 1) providing the product 151 (27.7 mg, 
0.071 mmol, 50%, d.r. anti : syn = 8 : 1) as a colorless oil. 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 5.07 (s, 1H, H-1a), 4.90 (s, 1H, H-
1b), 4.09 (d, J = 3.1 Hz, 1H, H-3), 3.84 – 3.78 (m, 1H, H-4), 3.63 – 3.55 (m, 2H, H-7), 2.51 
(s, 1H, 3-OH), 1.71 (s, 3H, 2-Me), 1.66 – 1.42 (m, 2H, H-5), 1.66 – 1.42 (m, 2H, H-6), 0.91 
(s, 9H, Sit-Bu), 0.88 (s, 9H, Sit-Bu), 0.1 (s, 6H, SiMe), 0.03 (s, 6H, SiMe); 
13
C 
NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 143.1 (s, C-2), 111.8 (t, C-1), 77.6 
(d, C-3), 74.0 (d, C-4), 66.4 (t, C-7), 29.3 (t, C-6), 26.9 (t, C-5), 26.1 (q, Sit-Bu), 26.0 (q, Sit-
Bu), 19.6 (q, 2-Me), 18.5 (s, Sit-Bu), 18.2 (s, Sit-Bu), -4.3 (q, SiMe), -4.4 (q, SiMe), -5.1 (q, 
SiMe); HRMS-ESI (m/z): [M+H]
+
 calcd for [C20H45O3Si2]
+
: 389.2907, found: 389.2901. 
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(R)-Mosher ester (187a) 
 
The alcohol 151 (13 mg, 33.4 µmol, 1.0 eq.) was dissolved under nitrogen atmosphere in 
CH2Cl2 (1.5 mL), cooled down to 0 °C and treated with Et3N (18.6 µL, 133.8 µmol, 4.0 eq.) 
and DMAP (0.4 mg, 3.34 µmol, 0.1 eq.) followed by (S)-Mosher acid chloride (10.1 mg, 40.1 
µmol, 1.2 eq.). The reaction mixture was warmed up to RT and stirred for 3 h. The reaction 
was terminated by addition of an aqueous NH4Cl solution. The phases were separated and the 
aqueous phase was extracted three times with CH2Cl2. The combined organic phases were 
washed with NaCl solution, dried over MgSO4 and concentrated under reduced pressure. The 
crude product was purified by flash chromatography (PE : EA = 20 : 1) to give the ester (R)-
187a (16 mg, 26.5 µmol, 79%) as a colorless oil. 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.58 – 7.50 (m, 2H, Ph), 7.39 – 
7.37 (m, 3H, H-Ph), 5.38 (d, J = 4.7 Hz, 1H, H-3), 5.02 (s, 1H, H-1a), 5.00 (s, 1H, H-1b), 3.91 
– 3.80 (m, 1H, H-4), 3.64 – 3.57 (m, 1H, H-7a), 3.54 (s, 3H, 2’-OMe), 3.48 – 3.43 (m, 1H, H-
7b), 1.78 (s, 3H, 2-Me), 1.57 – 1.45 (m, 2H, H-5), 1.57 – 1.45 (m, 2H, H-6), 0.87 (s, 9H, Sit-
Bu), 0.85 (s, 9H, Sit-Bu), 0.04 (s, 6H, SiMe), 0.01 (s, 6H, SiMe); HRMS-ESI (m/z): [M+H]
+
 
calcd for [C30H52O5F3Si2]
+
: 605.3305, found: 605.3307. 
 (S)-Mosher ester (187b) 
 
The alcohol 151 (12.5 mg, 32.2 µmol, 1.0 eq.) was dissolved under nitrogen atmosphere in 
CH2Cl2 (1.5 mL), cooled down to 0 °C and treated with Et3N (18 µl, 128.6 µmol, 4.0 eq.) and 
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DMAP (0.4 mg, 3.21 µmol, 0.1 eq.) followed by (R)-Mosher acid chloride (9.75 mg, 38.6 
µmol, 1.2 eq.). The reaction mixture was warmed up to RT and stirred for 3 h. The reaction 
was terminated by addition of an aqueous NH4Cl solution. The phases were separated and the 
aqueous phase was extracted three times with CH2Cl2. The combined organic phases were 
washed with an aqueous NaCl solution, dried over MgSO4 and concentrated under reduced 
pressure. The crude product was purified by flash chromatography (PE : EA = 20 : 1) to give 
the ester (S)-187b (13.1 mg, 21.7 µmol, 67%) as a colorless oil. 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.64 – 7.57 (m, 2H, Ph), 7.39 – 
7.34 (m, 3H, H-Ph), 5.45 (d, J = 3.1 Hz, 1H, H-3), 4.86 (s, 1H, H-1a), 4.74 (s, 1H, H-1b), 3.91 
– 3.88 (m, 1H, H-4), 3.61 (s, 3H, 2’-OMe), 3.58 – 3.52 (m, 2H, H-7), 1.69 (s, 3H, 2-Me), 1.65 
– 1.43 (m, 2H, H-5), 1.65 – 1.43 (m, 2H, H-6), 0.87 (s, 9H, Sit-Bu), 0.86 (s, 9H, Sit-Bu), 0.09 
(s, 6H, SiMe), 0.01 (s, 6H, SiMe); HRMS-ESI (m/z): [M+H]
+
 calcd for [C30H52O5F3Si2]
+
: 
605.3305, found: 605.3312. 
(3S,4R)-4,7-Bis(tert-butyldimethylsilyloxy)-2-hept-1-en-3-ol (152) 
 
The aldehyde 157c (0.98 g, 2.82 mmol, 1.0 eq.) was dissolved under nitrogen atmosphere in 
Et2O (200 mL), cooled down to −90 °C and treated with vinylmagnesium bromide (0.7 M in 
THF) (5 mL, 3.4 mmol, 1.2 eq.). After 30 min the reaction was terminated by addition of an 
aqueous NH4Cl solution. The phases were separated and the aqueous phase was extracted 
three times with EtOAc. The combined organic phases were washed with an aqueous NaCl 
solution, dried over MgSO4 and concentrated under reduced pressure. The crude product was 
purified by flash chromatography (PE : EA = 20 : 1) providing the product 152 (0.64 g, 1.7 
mmol, 60%, d.r. anti : syn = 7 : 1) as a colorless oil. 
The analytical data are in accordance with the reported in the literature.
[151]
 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 5.90 – 5.80 (m, 1H, H-2), 5.29 (dd, 
J = 17.3, 1.5 Hz, 1H, H-1a), 5.19 (dd, J = 10.5, 1.4 Hz, 1H, H-1b), 4.09 – 4.13 (m, 1H, H-3), 
3.74 – 3.70 (m, 1H, H-4), 3.64 – 3.55 (m, 2H, H-7), 2.27 (d, J = 2.8 Hz, 1H, 3-OH), 1.66 – 
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1.45 (m, 2H, H-5), 1.66 – 1.45 (m, 2H, H-6), 0.90 (s, 9H, Sit-Bu), 0.88 (s, 9H, Sit-Bu), 0.09 
(s, 6H, SiMe), 0.04 (s, 6H, SiMe); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ 
(ppm): 136.5 (d, C-2), 116.5 (t, C-1), 75.8 (d, C-3), 75.2 (d, C-4), 63.2 (t, C-7), 28.9 (t, C-6), 
28.0 (t, C-5), 26.0 (q, Sit-Bu), 25.9 (q, Sit-Bu), 18.3 (s, Sit-Bu), 18.1 (s, Sit-Bu), -4.4 (q, 
SiMe), -5.3 (q, SiMe); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C19H42O3Si2Na]
+
: 397.2570, 
found: 397.2570. 
3.7 Synthesis of Progeldanamycin Derivatives 
Metathesis product 195 
 
The western fragment 148 (63 mg, 0.1 mmol, 1.0 eq.) was dissolved under nitrogen 
atmosphere in CH2Cl2 (3 mL) and treated with the eastern fragment 152 (112 mg, 0.3 mmol, 
3.0 eq.) and Hoveyda-Grubbs II catalyst (6.2 mg, 0.01 mmol, 0.1 eq.). The reaction mixture 
was stirred at 40 °C for 48 h. After 10 h an additional portion of the catalyst (6.2 mg, 0.01 
mmol, 0.1 eq.) was added. After 48 h the mixture was cooled down to RT and concentrated 
under reduced pressure. The crude product was purified by flash chromatography (PE : EA = 
10 : 1 to 4 :1) and preparative HPLC (solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t [min]/solvent B [%]): 
0/20; 5/20; 80/100; 100/100; tR = 90.0 min) providing the product 195 (39 mg, 39.8 µmol, 
40%) as a colorless oil. 
The analytical data are in accordance with the reported in the literature.
[135]
 
1
H NMR (400 MHz, C6D6, C6D5H = 7.16 ppm) δ (ppm): 7.90 – 7.84 (m, 4H, SiPh), 7.23 – 
7.17 (m, 6H, SiPh), 7.10 (s, 1H, H-17), 6.78 (m, 1H, H-15), 6. 48 (s, 1H, H-19), 5.92 (bs, 1H, 
NH), 5.70 (dd, J = 15.6, 8.2 Hz, 1H, H-7), 5.60 (dd, J = 15.6, 6.4 Hz, 1H, H-6), 4.14 (bs, 1H, 
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H-5), 3.76 – 3.69 (m, 1H, H-4), 3.62 – 3.56 (m, 1H, H-9), 3.62 – 3.56 (m, 1H, H-1), 3.27 – 
3.23 (m, 1H, H-10), 3.04 (s, 3H, 10-OMe), 2.40 (dd, J = 13.3, 5.9 Hz, 1H, H-13a), 2.44 – 2.39 
(m, 1H, H-8), 2.12 (dd, J = 13.1, 8.4 Hz, 1H, H-13b), 1.96 (bs, 1H, 9-OH), 1.99 – 1.90 (m, 
1H, H-12), 1.78 – 1.68 (m, 1H, H-2a), 1.78 – 1.68 (m, 1H, H-3a), 1.78 – 1.68 (m, 1H, H-11a), 
1.63 – 1.56 (m, 1H, H-2b), 1.63 – 1.56 (m, 1H, H-3b), 1.38 (s, 9H, t-Bu), 1.32 (d, J = 6.6 Hz, 
3H, 8-Me), 1.20 (s, 9H, Sit-Bu), 1.14 – 1.10 (m, 1H, H-11b), 1.00 (s, 9H, Sit-Bu), 0.97 (s, 9H, 
Sit-Bu), 0.77 (d, J = 6.5 Hz, 3H, 12-Me), 0.11 (s, 6H, SiMe), 0.09 (s, 6H, SiMe); 
13
C 
NMR (100 MHz, C6D6, C6D6 = 128.06 ppm) δ (ppm): 156.4 (s, C-Ar), 152.4 (s, NHCOO), 
143.4 (s, C-Ar), 140.1 (d, C-Ar), 136.0 (s, C-Ar), 134.2 (d, C-7), 133.6 (d, C-Ar), 130.1 (s, C-
Ar), 129.4 (d, C-6), 115.7 (d, C-19), 112.6 (d, C-15), 107.9 (d, C-17), 80.5 (d, C-10), 79.6 (s, 
t-Bu), 76.1 (d, C-4), 75.4 (d, C-5), 73.8 (d, C-9), 63.5 (t, C-1), 56.7 (q, 10-OMe), 45.0 (t, C-
13), 39.3 (d, C-8), 35.3 (t, C-11), 31.4 (d, C-12), 29.4 (t, C-2), 29.0 (t, C-3), 28.3 (q, t-Bu), 
26.8 (q, Sit-Bu), 26.2 (q, Sit-Bu), 19.8 (s, Sit-Bu), 19.2 (q, 12-Me), 18.6 (s, Sit-Bu), 18.4 (s, 
Sit-Bu), 17.5 (q, 8-Me), -4.2 (q, SiMe), -5.1 (q, SiMe); HRMS-ESI (m/z): [M+Na]
+
 calcd for 
[C55H91NO8Si3Na]
+
: 1000.5950, found: 1000.5946; [α]20D = −20.0° (c = 0.5, CHCl3; Lit. 
[α]20D = −18.2°, c = 0.33, CHCl3).
[135]
 
Silylated polyol 211 
 
The metathesis product 195 (50 mg, 51.1 µmol, 1.0 eq.) was dissolved under nitrogen 
atmosphere in CH2Cl2 (10 mL), cooled down to 0 °C and treated with 2,6-lutidine (30 µL, 256 
µmol, 5.0 eq.) and TBSOTf (35 µL, 153.3 µmol, 3.0 eq.). The reaction mixture was warmed 
up to RT and stirred for 3 h. The reaction was terminated by addition of an aqueous NH4Cl 
solution. The phases were separated and the aqueous phase was extracted three times with 
CH2Cl2. The combined organic phases were washed with an aqueous NaCl solution, dried 
over MgSO4 and concentrated under reduced pressure. The crude product was purified by 
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flash chromatography (PE : EA = 10 : 1 to 5 : 1) providing the product 211 (40 mg, 36.3 
µmol, 71%) as a colorless oil. 
1
H NMR (400 MHz, C6D6, C6D5H = 7.16 ppm) δ (ppm): 7.88 – 7.82 (m, 4H, SiPh), 7.24 – 
7.18 (m, 6H, SiPh), 7.05 (s, 1H, H-17), 6.81 (s, 1H, H-15), 6. 50 (s, 1H, H-19), 5.87 (bs, 1H, 
NH), 5.65 (dd, J = 15.6, 6.8 Hz, 1H, H-6), 5.46 (dd, J = 15.6, 8.2 Hz, 1H, H-7), 4.11 – 4.09 
(m, 1H, H-5), 3.81 – 3.73 (m, 1H, H-4), 3.66 – 3.63 (m, 2H, H-1), 3.60 – 3.57 (m, 1H, H-9), 
3.30 – 3.27 (m, 1H, H-10), 3.13 (s, 3H, 10-OMe), 2.43 (dd, J = 13.1, 6.5 Hz, 1H, H-13a), 2.38 
– 2.32 (m, 1H, H-8), 2.16 (dd, J = 13.1, 8.7 Hz, 1H, H-13b), 2.05 – 1.99 (m, 1H, H-12), 1.97 
(bs, 1H, 9-OH), 1.82 – 1.72 (m, 2H, H-2), 1.71 – 1.67 (m, 2H, H-3), 1.65 – 1.63 (m, 1H, H-
11a), 1.38 (s, 9H, t-Bu), 1.33 (d, J = 6.6 Hz, 3H, 8-Me), 1.20 (s, 9H, Sit-Bu), 1.14 – 1.09 (m, 
1H, H-11b), 1.05 (s, 9H, Sit-Bu), 1.04 (s, 9H, Sit-Bu), 1.00 (s, 9H, Sit-Bu), 0.79 (d, J = 6.5 
Hz, 3H, 12-Me), 0.21 (s, 3H, SiMe), 0.17 (s, 3H, SiMe), 0.16 (s, 3H, SiMe), 0.14 (s, 3H, 
SiMe), 0.10 (s, 6H, SiMe); 
13
C NMR (100 MHz, C6D6, C6D6 = 128.06 ppm) δ (ppm): 156.4 
(s, C-Ar), 152.3 (s, NHCOO), 143.4 (s, C-Ar), 140.1 (d, C-Ar), 136.0 (s, C-Ar), 134.2 (d, C-
7), 133.6 (d, C-Ar), 131.0 (s, C-6), 130.1 (d, C-Ar), 115.7 (d, C-19), 112.6 (d, C-15), 108.0 (d, 
C-17), 80.6 (d, C-10), 79.6 (s, t-Bu), 78.2 (d, C-5), 77.2 (d, C-4), 73.6 (d, C-9), 63.5 (t, C-1), 
56.8 (q, 10-OMe), 45.0 (t, C-13), 39.2 (d, C-8), 35.1 (t, C-11), 31.3 (d, C-12), 30.3 (t, C-3), 
29.5 (t, C-2), 28.3 (q, t-Bu), 26.8 (q, Sit-Bu), 26.4 (q, Sit-Bu), 26.2 (q, Sit-Bu), 25.9 (q, Sit-
Bu), 19.8 (s, Sit-Bu), 19.2 (q, 12-Me), 18.7 (s, Sit-Bu), 18.6 (s, Sit-Bu), 18.6 (q, 8-Me), 17.4 
(s, Sit-Bu), -3.3 (q, SiMe), -3.6 (q, SiMe), -3.7 (q, SiMe), -4.2 (q, SiMe), -4.3 (q, SiMe), -5.1 
(q, SiMe); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C61H105NO8Si4Na]
+
: 1114.6815, found: 
1114.6814. 
Boc-deprotected polyol 212 
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The metathesis product 195 (50 mg, 51.1 µmol, 1.0 eq.) was dissolved under nitrogen 
atmosphere in CH2Cl2 (10 mL), cooled down to 0 °C and treated with 2,6-lutidine (30 µL, 256 
µmol, 5.0 eq.) and TBSOTf (35 µL, 153.3 µmol, 3.0 eq.). The reaction mixture was warmed 
up to RT and stirred for 3 h. After that time an additional portion of TBSOTf (17 µL, 77 
µmol, 1.5 eq.) was added at 0 °C and the reaction mixture was stirred at RT for 12 h. The 
reaction was terminated by addition of an aqueous NH4Cl solution. The phases were separated 
and the aqueous phase was extracted three times with CH2Cl2. The combined organic phases 
were washed with an aqueous NaCl solution, dried over MgSO4 and concentrated under 
reduced pressure. The crude product was purified by flash chromatography (PE : EA = 100 : 1 
to 50 : 1) providing the product 212 (15 mg, 13.6 µmol, 26%) as a colorless oil. 
1
H NMR (400 MHz, C6D6, C6D5H = 7.16 ppm) δ (ppm): 7.97 – 7.94 (m, 4H, SiPh), 7.33 – 
7.31 (m, 6H, SiPh), 6.63 (s, 1H, H-17), 6.57 (s, 1H, H-15), 6.15 (s, 1H, H-19), 5.73 (dd, J = 
15.5, 7.0 Hz, 1H, H-6), 5.55 (dd, J = 15.5, 8.8 Hz, 1H, H-7), 4.21 (dd, J = 6.9, 2.1 Hz, 1H, H-
5), 3.90 – 3.88 (m, 1H, H-4), 3.78 – 3.69 (m, 1H, H-9), 3.78 – 3.69 (m, 2H, H-1), 3.40 – 3.35 
(m, 1H, H-10), 3.33 (s, 3H, 10-OMe), 2.49 (dd, J = 13.2, 6.6 Hz, 1H, H-13a), 2.36 (dd, J = 
15.3, 8.4 Hz, 1H, H-8), 2.27 (dd, J = 13.6, 5.7 Hz, 1H, H-13b), 2.07 (bs, 1H, 5-OH), 1.98 – 
1.93 (m, 1H, H-12), 1.92 – 1.83 (m, 2H, H-2), 1.81 – 1.77 (m, 2H, H-3), 1.74 – 1.71 (m, 1H, 
H-11a), 1.29 (s, 9H, Sit-Bu), 1.20 (d, J = 6.0 Hz, 3H, 8-Me), 1.17 (s, 9H, Sit-Bu), 1.13 – 1.11 
(m, 1H, H-11b), 1.15 (s, 9H, Sit-Bu), 1.10 (s, 9H, Sit-Bu), 1.06 (s, 9H, Sit-Bu), 0.89 (d, J = 
6.6 Hz, 3H, 12-Me), 0.33 (s, 3H, SiMe), 0.30 (s, 3H, SiMe), 0.29 (s, 3H, SiMe), 0.27 (s, 3H, 
SiMe), 0.26 (s, 6H, SiMe), 0.19 (s, 6H, SiMe); 
13
C NMR (100 MHz, C6D6, C6D6 = 128.06 
ppm) δ (ppm): 156.5 (s, C-Ar), 143.3 (s, C-Ar), 139.8 (d, C-Ar), 136.0 (s, C-Ar), 135.1 (d, C-
7), 133.6 (d, C-Ar), 130.7 (s, C-6), 130.1 (d, C-Ar), 116.0 (d, C-19), 113.8 (d, C-15), 110.7 (d, 
C-17), 81.5 (d, C-10), 78.5 (d, C-5), 77.5 (d, C-4), 76.1 (d, C-9), 63.5 (t, C-1), 57.2 (q, 10-
OMe), 45.2 (t, C-13), 41.3 (d, C-8), 35.7 (t, C-11), 31.4 (d, C-12), 30.3 (t, C-3), 29.7 (t, C-2), 
26.9 (q, Sit-Bu), 26.6 (q, Sit-Bu), 26.4 (q, Sit-Bu), 26.4 (q, Sit-Bu), 26.2 (q, Sit-Bu), 19.8 (s, 
Sit-Bu), 19.6 (q, 12-Me), 18.9 (s, Sit-Bu), 18.7 (s, Sit-Bu), 18.7 (s, Sit-Bu), 18.6 (q, 8-Me), 
18.4 (s, Sit-Bu), -3.4 (q, SiMe), -3.6 (q, SiMe), -3.6 (q, SiMe), -4.1 (q, SiMe), -4.3 (q, SiMe), 
-4.4 (q, SiMe), -4.5 (q, SiMe), -5.1 (q, SiMe). 
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TBS-deprotected polyol 197 
 
The metathesis product 195 (40 mg, 40.9 µmol, 1.0 eq.) was dissolved in MeOH (1 mL) and 
treated with PPTS (0.61 g, 2.45 mmol, 60.0 eq.). The reaction mixture was heated to 40 °C 
and stirred for 48 h. The reaction was terminated by addition of an aqueous NH4Cl solution 
and MeOH was removed under reduced pressure. The residue was extracted three times with 
EtOAc, the combined organic phases were dried over MgSO4 and concentrated under reduced 
pressure. The crude product was purified by preparative HPLC (solvent A: water + 0.1% (v/v) 
formic acid, solvent B: MeOH + 0.1% (v/v) formic acid; flow rate = 15.0 mL/min; gradient (t 
[min]/solvent B [%]): 0/30; 5/30; 50/60; 90/100, 100/100; tR = 74.0 min) providing the 
product 197 (28 mg, 36.8 µmol, 90%) as a colorless oil. 
1
H NMR (400 MHz, CD3OD, CHD2OD = 3.31 ppm) δ (ppm): 7.76 – 7.73 (m, 4H, SiPh), 
7.48 – 7.39 (m, 6H, SiPh), 6.93 (s, 1H, Ph), 6.73 (s, 1H, Ph), 6.13 (s, 1H, Ph), 5.60 – 5.58 (m, 
1H, H-6), 5.60 – 5.58 (m, 1H, H-7), 3.92 – 3.87 (m, 1H, H-5), 3.60 – 3.57 (m, 2H, H-1), 3.55– 
3.48 (m, 1H, H-9), 3.55 – 3.48 (m, 1H, H-4), 3.37 – 3.35 (m, 1H, H-10), 3.28 (s, 3H, 10-
OMe), 2.38 (dd, J = 13.2, 5.6 Hz, 1H, H-13a), 2.27 – 2.24 (m, 1H, H-8), 2.08 (dd, J = 13.2, 
8.8 Hz, 1H, H-13b), 1.79 – 1.73 (m, 1H, H-12), 1.72 – 1.54 (m, 2H, H-2), 1.72 – 1.54 (m, 2H, 
H-3), 1.51 (s, 9H, t-Bu), 1.45 – 1.38 (m, 1H, H-11a), 1.28 – 1.25 (m, 1H, H-11b), 1.11 (d, J = 
6.5 Hz, 3H, 8-Me), 1.11 (s, 9H, Sit-Bu), 0.64 (d, J = 6.5 Hz, 3H, 12-Me); 
13
C NMR (100 
MHz, CD3OD, CD3OD = 49.0 ppm) δ (ppm): 157.1 (s, C-Ar), 155.2 (s, NHCOO), 143.9 (s, 
C-Ar), 141.2 (s, C-Ar), 136.7 (d, C-Ar), 136.3 (d, C-7), 134.3 (s, C-Ar), 131.1 (d, C-Ar), 
130.8 (d, C-6), 128.9 (d, C-Ar), 116.1 (d, C-Ar), 113.8 (d, C-Ar), 109.2 (d, C-Ar), 81.4 (d, C-
10), 80.7 (s, t-Bu), 76.9 (d, C-4), 75.6 (d, C-5), 75.2 (d, C-9), 63.1 (t, C-1), 57.1 (q, 10-OMe), 
45.7 (t, C-13), 40.7 (d, C-8), 36.6 (t, C-11), 32.3 (d, C-12), 30.1 (t, C-3), 30.1 (t, C-2), 28.7 (q, 
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t-Bu), 27.1 (q, Sit-Bu), 20.2 (s, Sit-Bu), 19.3 (q, 12-Me), 17.5 (q, 8-Me); HRMS-ESI (m/z): 
[M+Na]
+
 calcd for [C43H63NO8SiNa]
+
: 772.4221, found: 772.4221. 
Polyol 198 
 
TBS-Deprotected polyol 197 (26 mg, 34.7 µmol, 1.0 eq.) was dissolved in THF (4 mL) under 
nitrogen atmosphere, cooled down to −78 °C and treated with TBAF·3H2O (55 mg, 173.3 
µmol, 5.0 eq.). The reaction mixture was stirred at −78 °C for 20 h. After that time the 
reaction was terminated by addition of an aqueous NH4Cl solution, the phases were separated 
and the aqueous phase was extracted three times with EtOAc. The combined organic phases 
were dried over MgSO4 and concentrated under reduced pressure. The crude product was 
purified by semi-preparative HPLC (solvent A: water + 0.1% (v/v) formic acid, solvent B: 
MeOH + 0.1% (v/v) formic acid; flow rate = 2.5 mL/min; gradient (t [min]/solvent B [%]): 
0/30; 5/30; 50/60; 90/100, 100/100; tR = 26.0 min) providing the product 198 (15 mg, 29.3 
µmol, 80%) as a colorless oil. 
The analytical data are in accordance with the reported in the literature.
[135]
 
1
H NMR (400 MHz, CD3OD, CHD2OD = 3.31 ppm) δ (ppm): 6.82 (s, 1H, Ph), 6.63 (s, 1H, 
Ph), 6.29 (s, 1H, Ph), 5.64 – 5.53 (m, 1H, H-6), 5.64 – 5.53 (m, 1H, H-7), 3.92 – 3.89 (m, 1H, 
H-5), 3.58 – 3.55 (m, 2H, H-1), 3.58– 3.55 (m, 1H, H-9), 3.48 – 3.45 (m, 1H, H-4), 3.37 – 
3.35 (m, 1H, H-10), 3.33 (s, 3H, 10-OMe), 2.49 (dd, J = 13.1, 6.5 Hz, 1H, H-13a), 2.33 (dd, J 
= 13.5, 7.9 Hz, 1H, H-13a), 2.27 – 2.21 (m, 1H, H-8), 2.01 – 1.96 (m, 1H, H-12), 1.73 – 1.61 
(m, 2H, H-2), 1.73 – 1.61 (m, 2H, H-3), 1.51 (s, 9H, t-Bu), 1.43 – 1.37 (m, 1H, H-11a), 1.25 – 
1.19 (m, 1H, H-11b), 1.10 (d, J = 6.6 Hz, 3H, 8-Me), 0.87 (d, J = 6.5 Hz, 3H, 12-Me); 
13
C 
NMR (100 MHz, CD3OD, CD3OD = 49.0 ppm) δ (ppm): 158.6 (s, C-Ar), 155.2 (s, NHCOO), 
143.9 (s, C-Ar), 141.3 (s, C-Ar), 136.3 (d, C-7), 130.8 (d, C-6), 112.3 (d, C-Ar), 111.7 (d, C-
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Ar), 104.6 (d, C-Ar), 81.4 (d, C-10), 80.7 (s, t-Bu), 76.8 (d, C-4), 75.6 (d, C-5), 75.2 (d, C-9), 
63.1 (t, C-1), 57.0 (q, 10-OMe), 45.9 (t, C-13), 40.8 (d, C-8), 36.3 (t, C-11), 32.3 (d, C-12), 
30.1 (t, C-3), 30.1 (t, C-2), 28.8 (q, t-Bu), 19.7 (q, 12-Me), 17.7 (q, 8-Me); HRMS-ESI (m/z): 
[M+Na]
+
 calcd for [C27H45NO8Na]
+
: 534.3043, found: 534.3040. 
TES-protected polyol 199 
 
Polyol 198 (5 mg, 9.8 µmol, 1.0 eq.) was dissolved in CH2Cl2 (5 mL) under nitrogen 
atmosphere, cooled down to −78 °C and treated with 2,6-lutidine (9 µL, 78 µmol, 8.0 eq.) and 
TESOTf (13 µL, 59 µmol, 6.0 eq.). The reaction mixture was stirred at −78 °C for 1 h and 
warmed up to RT. The reaction was terminated by addition of an aqueous NH4Cl solution, the 
phases were separated and the aqueous phase was extracted three times with CH2Cl2. The 
combined organic phases were dried over MgSO4 and concentrated under reduced pressure. 
The crude product was purified by purified by flash chromatography (PE : EA = 100 : 1 to  
20 : 1) providing the product 199 (8.6 mg, 8.0 µmol, 82%) as a colorless oil. 
The analytical data are in accordance with the reported in the literature.
[135]
 
1
H NMR (400 MHz, C6D6, C6D5H = 7.16 ppm) δ (ppm): 7.46 (s, 1H, Ph), 6.63 (s, 1H, Ph), 
6.38 (s, 1H, Ph), 6.38 (s, 1H, NH), 5.75 (dd, J = 15.5, 7.3 Hz, 1H, H-6), 5.75 (dd, J = 15.5, 8.9 
Hz, 1H, H-7), 4.07 (dd, J = 7.2, 1.9 Hz, 1H, H-5), 3.87 – 3.83 (m, 1H, H-4), 3.74 – 3.62 (m, 
2H, H-1), 3.74 – 3.62 (m, 1H, H-9), 3.41 (d, J = 10.4 Hz, 1H, H-10), 3.30 (s, 3H, 10-OMe), 
2.61 (dd, J = 13.2, 6.5 Hz, 1H, H-13a), 2.44 – 2.37 (m, 1H, H-13b), 2.36 – 2.32 (m, 1H, H-8), 
2.23 – 2.16 (m, 1H, H-12), 2.04 – 1.98 (m, 2H, H-11a), 1.90 – 1.80 (m, 1H, H-2a), 1.72 – 
1.65 (m, 2H, H-3), 1.72 – 1.65 (m, 1H, H-2b), 1.43 (s, 9H, t-Bu), 1.25 (d, J = 6.6 Hz, 3H, 8-
Me), 1.22 – 1.18 (m, 1H, H-11b), 1.14 – 1.02 (m, 45H, SiCH2CH3), 0.92 – 0.97 (m, 3H, 12-
Me), 0.82 – 0.61 (m, 30H, SiCH2CH3); 
13
C NMR (100 MHz, C6D6, C6D6 = 128.06 ppm)  
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δ (ppm): 156.7 (s, C-Ar), 152.4 (s, NHCOO), 143.4 (s, C-Ar), 140.1 (s, C-Ar), 135.0 (d, C-7), 
130.9 (d, C-6), 115.9 (d, C-Ar), 112.2 (d, C-Ar), 107.8 (d, C-Ar), 81.4 (d, C-10), 79.5 (s,  
t-Bu), 78.4 (d, C-5), 77.5 (d, C-4), 76.1 (d, C-9), 63.3 (t, C-1), 57.3 (q, 10-OMe), 45.4 (t, C-
13), 41.5 (d, C-8), 35.7 (t, C-11), 31.6 (d, C-12), 30.6 (t, C-2), 30.1 (t, C-3), 28.4 (q, t-Bu), 
19.7 (q, 12-Me), 18.6 (q, 8-Me), 7.5 (q, SiCH2CH3), 7.3 (q, SiCH2CH3), 7.2 (q, SiCH2CH3), 
7.0 (q, SiCH2CH3), 6.9 (q, SiCH2CH3), 5.7 (t, SiCH2CH3), 5.5 (t, SiCH2CH3), 4.9 (t, 
SiCH2CH3); HRMS-ESI (m/z): the compound is not detectable by mass spectrometry. 
Silylated aldehyde 200 
 
A solution of DMSO (0.9 µL, 12.1 µmol, 2.2 eq.) in CH2Cl2 (0.5 mL) was slowly added to a 
cooled to −78 °C solution of oxalyl chloride (0.5 µL, 6.0 µmol, 1.1 eq.) in CH2Cl2 (0.5 mL) 
After 30 min TES-protected polyol 199 (6.0 mg, 5.5 µmol, 1.0 eq.) dissolved in CH2Cl2 (0.5 
mL) was slowly added. The reaction mixture was stirred at −78 °C for 1.5 h, followed by 
addition of DIPEA (5.0 µL, 27.5 µmol, 5.0 eq). The mixture was allowed to warm up to RT 
and stirred for additional 3 h. The reaction was terminated by addition of an aqueous NH4Cl 
solution. The phases were separated and the aqueous phase was extracted three times with 
CH2Cl2. The combined organic phases were washed with an aqueous NaCl solution, dried 
over MgSO4 and concentrated under reduced pressure. The crude product was purified by 
flash chromatography (PE : EA = 50 : 1 to 10 : 1) providing the aldehyde 200 (4.3 mg, 4.4 
µmol, 80%) as a colorless oil. 
The analytical data are in accordance with the reported in the literature.
[135]
 
1
H NMR (400 MHz, C6D6, C6D5H = 7.16 ppm) δ (ppm): 9.45 (s, 1H, H-1), 7.46 (s, 1H, Ph), 
6.64 (s, 1H, Ph), 6.40 (s, 1H, Ph), 6.06 (s, 1H, NH), 5.64 (dd, J = 15.5, 7.4 Hz, 1H, H-6), 5.37 
(dd, J = 15.7, 9.0 Hz, 1H, H-7), 3.97 – 3.89 (m, 1H, H-5), 3.72 – 3.70 (m, 1H, H-9), 3.72 – 
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3.70 (m, 1H, H-4), 3.41 – 3.31 (m, 1H, H-10), 3.31 (s, 3H, 10-OMe), 2.64 (dd, J = 13.2, 6.3 
Hz, 1H, H-13a), 2.42 – 2.38 (m, 1H, H-13b), 2.38 – 2.35 (m, 1H, H-8), 2.33 – 2.29 (m, 1H, 
H-2a), 2.21 – 2.16 (m, 2H, H-2b), 2.15 – 2.10 (m, 1H, H-12), 2.02 – 1.97 (m, 1H, H-11a), 
1.80 – 1.75 (m, 1H, H-3a), 1.67 – 1.63 (m, 1H, H-3b), 1.43 (s, 9H, t-Bu), 1.23 (d, J = 6.6 Hz, 
3H, 8-Me), 1.19 – 1.17 (m, 1H, H-11b), 1.10 – 1.03 (m, 36H, SiCH2CH3), 0.97 (d, J = 6.5 Hz, 
3H, 12-Me), 0.78 – 0.69 (m, 24H, SiCH2CH3); 
13
C NMR (100 MHz, C6D6, C6D6 = 128.06 
ppm) δ (ppm): 206.1 (d, C-1), 156.7 (s, C-Ar), 152.5 (s, NHCOO), 143.2 (s, C-Ar), 139.9 (s, 
C-Ar), 135.2 (d, C-7), 130.3 (d, C-6), 115.9 (d, C-Ar), 110.0 (d, C-Ar), 107.7 (d, C-Ar), 81.4 
(d, C-10), 79.5 (s, t-Bu), 78.4 (d, C-5), 76.5 (d, C-4), 76.1 (d, C-9), 57.3 (q, 10-OMe), 45.4 (t, 
C-13), 41.7 (d, C-8), 40.7 (t, C-2), 35.7 (t, C-11), 31.6 (d, C-12), 28.4 (q, t-Bu), 26.1 (t, C-3), 
19.6 (q, 12-Me), 18.6 (q, 8-Me), 7.5 (q, SiCH2CH3), 7.4 (q, SiCH2CH3), 7.3 (q, SiCH2CH3), 
7.0 (q, SiCH2CH3), 5.7 (t, SiCH2CH3), 5.6 (t, SiCH2CH3); HRMS-ESI (m/z): the compound 
is not detectable by mass spectrometry. 
S-(2-Acetamidoethyl)-2-(triphenyl-λ5-phosphanylidene)propanethioate (202) 
 
The reagent was prepared according to the Hahn’s procedure[155]: 
2-Bromopropanoic acid (213) (1.5 g, 9.8 mmol, 1.1 eq.) was dissolved in CH2Cl2 (25 mL) 
under nitrogen atmosphere, cooled down to 0 °C and treated with N-acetylcysteamine (0.95 
mL, 8.9 mmol, 1.0 eq.) and DMAP (0.109 g, 0.891 mmol, 0.1 eq.). EDC hydrochloride (1.88 
g, 9.8 mmol, 1.1 eq.) was added to the mixture portionwise. The reaction mixture was stirred 
at 0 °C for 1 h, warmed up to RT and stirred for another 16 h. The reaction was terminated by 
addition of an aqueous NaHCO3 solution. The phases were separated and the organic phase 
was washed with H2O and NaCl solution and dried over MgSO4. The solvent was 
concentrated under reduced pressure to give the product 214 (2.36 g, 9.3 mmol, 94%) as a 
pale yellow oil which was used in the next step without further purification. 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 6.09 (bs, 1H, NH), 4.50 (q, J = 6.9 
Hz, 1H, CHBr), 3.46 – 3.39 (m, 2H, CH2NH), 3.13 – 2.98 (m, 2H, CH2S), 1.95 (s, 3H, 
CH3CO), 1.81 (d, J = 6.9 Hz, 3H, CH3CHBr); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 
ppm) δ (ppm): 196.8 (s, C(=O)S), 170.5 (s, C(=O)N), 47.9 (d, CHBr), 39.2 (t, CH2NH), 29.4 
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(t, CH2S), 23.3 (q, CH3CO), 22.0 (q, CH3CHBr); HRMS-ESI (m/z): [M+Na]
+
 calcd for 
[C7H12NO2SBrNa]
+
: 275.9670, found: 275.9669. 
S-(2-Acetamidoethyl) 2-bromopropanethioate (214) (2.3 g, 9.0 mmol, 1.1 eq.) was suspended 
in H2O (12 mL) and treated with triphenylphosphine (2.15 g, 8.2 mmol, 1.0 eq.). The reaction 
mixture was stirred at 70 °C for 11 h. After that time the solution was cooled down to RT, 
treated with NaOH (0.66 g, 16.5 mmol, 2.0 eq.) dissolved in H2O (20 mL) and the mixture 
was stirred for 5 min. The aqueous phase was extracted three times with CH2Cl2, the 
combined organic phases were dried over MgSO4 and concentrated under reduced pressure. 
The crude product was recrystallized from toluene and washed with cold solvent to give 
colorless crystalline product 202 (1.9 g, 4.5 mmol, 50%). 
1
H NMR (400 MHz, CDCl3, CHCl3 = 7.26 ppm) δ (ppm): 7.60 – 7.47 (m, 15H, Ar), 3.34 – 
3.31 (m, 2H, CH2NH), 3.02 – 2.99 (m, 2H, CH2S), 1.68 (d, J = 6.9 Hz, CH3CP), 1.54 (s, 3H, 
CH3CO); 
13
C NMR (100 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 180.5 (s, C(=O)S), 
170.5 (s, C(=O)N), 133.7 , 133.6 (d, 6C, C-Ar), 132.3 (d, 3C, C-Ar), 129.1 (d, 6C, C-Ar), 
125.4 (s, 3C, C-Ar), 53.7, 52.4 (s, C=PPh3), 43.4 (t, CH2NH), 26.9 (t, CH2S), 23.2 (q, 
CH3CO), 13.3 (q, CH3CP); HRMS-ESI (m/z): [M+H]
+
 calcd for [C25H27NO2SP]
+
: 436.1500, 
found: 436.1495. 
Silylated SNAc ester 201 
 
The aldehyde 200 (4.0 mg, 4.14 µmol, 1.0 eq.) was dissolved in CHCl3 (0.5 mL), treated with 
phosphonium ylide 202 (9.0 mg, 20.7 µmol, 5.0 eq.) and the reaction mixture was stirred at  
40 °C for 2 days. After that time the solvent was removed under reduced pressure and the 
crude product was purified by flash chromatography (PE : EA = 7 : 1 to 1 : 1) providing the 
SNAc ester 201 (4.0 mg, 3.56 µmol, 86%) as a colorless oil. 
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1
H NMR (500 MHz, CDCl3, CDCl3 = 7.26 ppm) δ (ppm): 6.79 (s, 1H, Ph), 6.74 – 6.72 (m, 
1H, H-3), 6.70 (s, 1H, Ph), 6.45 (s, 1H, Ph), 5.91 (s, 1H, NH), 5.49 (dd, J = 15.5, 7.1 Hz, 1H, 
H-9), 5.38 (dd, J = 15.5, 8.7 Hz, 1H, H-8), 3.92 (dd, J = 7.0, 2.4 Hz, 1H, H-7), 3.68 – 3.61 (m, 
1H, H-6), 3.56 (dd, J = 9.0, 1.4 Hz, 1H, H-11), 3.42 (dd, J = 12.3, 6.1 Hz, 2H, H-2’), 3.25 (s, 
3H, 12-OMe), 3.19 (d, J = 10.6 Hz, 1H, H-12), 3.05 (t, J = 6.4 Hz, 2H, H-1’), 2.53 (dd, J = 
13.3, 5.9 Hz, 1H, H-15a), 2.39 – 2.31 (m, 1H, H-4a), 2.35 (dd, J = 13.3, 5.9 Hz, 1H, H-15b), 
2.22 – 2.18 (m, 1H, H-10), 2.16 – 2.09 (m, 1H, H-4b), 1.95 (s, 3H, H-4’), 1.92 – 1.86 (m, 1H, 
H-14), 1.85 (s, 3H, 2-Me), 1.70 – 1.67 (m, 1H, H-13a), 1.66 – 1.63 (m, 1H, H-5a), 1.54 – 1.52 
(m, 1H, H-5b), 1.57 (s, 9H, t-Bu), 1.09– 1.06 (m, 1H, H-13b), 1.05 (d, J = 6.7 Hz, 3H,  
10-Me), 1.00 – 0.92 (m, 36H, SiCH2CH3), 0.79 (d, J = 6.5 Hz, 3H, 14-Me), 0.75 – 0.56 (m, 
24H, SiCH2CH3);
 13
C NMR (125 MHz, CDCl3, CDCl3 = 77.16 ppm) δ (ppm): 194.1 (s, C-1), 
170.4 (s, C-3’), 156.0 (s, C-Ar), 152.7 (s, NHCOO), 143.5 (d, C-3), 142.1 (s, C-Ar), 139.2 (s, 
C-Ar), 136.0 (d, C-9), 134.9 (s, C-2), 130.3 (d, C-8), 115.7 (d, C-Ar), 112.5 (d, C-Ar), 108.7 
(d, C-Ar), 81.1 (d, C-7), 77.9 (d, C-12), 77.4 (s, t-Bu), 76.5 (d, C-6), 75.9 (d, C-11), 57.4 (q, 
12-OMe), 45.0 (t, C-15), 40.9 (t, C-2’), 40.0 (d, C-10), 35.7 (t, C-13), 32.3 (t, C-5), 31.2 (d, 
C-14), 28.5 (q, t-Bu), 28.5 (t, C-1’), 25.6 (t, C-4), 23.4 (q, C-4’), 19.2 (q, 14-Me), 18.0 (q, 10-
Me), 12.6 (q, 2-Me), 7.2 (q, SiCH2CH3), 7.0 (q, SiCH2CH3), 6.8 (q, SiCH2CH3), 5.3 (t, 
SiCH2CH3), 5.2 (t, SiCH2CH3); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C58H110N2O9SSi4Na]
+
: 
1145.6907, found: 1145.6904. 
SNAc ester 137 
 
The silylated SNAc ester 201 (3.5 mg, 3.1 µmol, 1.0 eq.) was dissolved in CH2Cl2 (3.0 mL) 
under nitrogen atmosphere, cooled down to 0 °C and treated with TFA (300 µL). After 3 h the 
reaction was terminated by addition of an aqueous NaHCO3 solution, the phases were 
separated and the aqueous phase was extracted three times with EtOAc. The combined 
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organic phases were washed with an aqueous NaCl solution, dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by semi-preparative 
HPLC (solvent A: water + 0.1% (v/v) formic acid, solvent B: MeOH + 0.1% (v/v) formic 
acid; flow rate = 2.5 mL/min; gradient (t [min]/solvent B [%]): 0/30; 5/30; 85/60; 90/85, 
100/100; tR = 20 min) providing the SNAc ester 137 (1.3 mg, 2.2 µmol, 73%) as a colorless 
oil. 
1
H NMR (500 MHz, CD3OD, CHD2OD = 3.31 ppm) δ (ppm): 6.81 – 6.78 (m, 1H, H-3), 6.72 
(s, 1H, Ph), 6.65 (m, 1H, Ph), 6.62 (s, 1H, Ph), 5.60 – 5.59 (m, 1H, H-9), 5.60 – 5.59 (m, 1H, 
H-8), 3.94 – 3.92 (m, 1H, H-7), 3.60 (d, J = 3.0 Hz, 1H, H-11), 3.58 (d, J = 3.0 Hz, 1H, H-6), 
3.51 – 3.48 (m, 2H, H-2’), 3.35 (s, 3H, 12-OMe), 3.20 – 3.16 (s, 1H, H-12), 3.04 – 3.01 (t,  
J = 6.9 Hz, 2H, H-1’), 2.57 (dd, J = 13.4, 7.1 Hz, 1H, H-15a), 2.46 (dd, J = 13.4, 7.5 Hz, 1H, 
H-15b), 2.36 – 2. 19 (m, 1H, H-4a), 2.36 – 2. 19 (m, 1H, H-4b), 2.36 – 2. 19 (m, 1H, H-10), 
2.00 – 1.97 (m, 1H, H-14), 1.94 (s, 3H, H-4’), 1.88 (s, 3H, 2-Me), 1.71 – 1.64 (m, 1H, H-13a), 
1.71 – 1.64 (m, 1H, H-5a), 1.57 – 1.52 (m, 1H, H-5b), 1.24 – 1.22 (m, 1H, H-13b), 1.12 (d, J 
= 6.7 Hz, 3H, 10-Me), 0.89 (d, J = 6.4 Hz, 3H, 14-Me); 
13
C NMR (125 MHz, CD3OD, 
CD3OD = 49.0 ppm) δ (ppm): 194.5 (s, C-1), 173.5 (s, C-3’), 156.0 (s, C-Ar), 153.7 (s, C-Ar), 
146.4 (d, C-3), 142.4 (s, C-Ar), 137.4 (s, C-2), 136.4 (d, C-9), 130.9 (d, C-8), 108.4 (d, C-Ar), 
107.2 (d, C-Ar), 103.0 (d, C-Ar), 81.4 (d, C-7), 76.9 (d, C-12), 75.0 (d, C-6), 74.8 (d, C-11), 
57.1 (q, 12-OMe), 45.3 (t, C-15), 41.1 (t, C-2’), 40.3 (d, C-10), 35.9 (t, C-13), 32.5 (t, C-5), 
32.3 (d, C-14), 29.0 (t, C-1’), 26.1 (t, C-4), 22.5 (q, C-4’), 19.7 (q, 14-Me), 18.1 (q, 10-Me), 
12.5 (q, 2-Me); HRMS-ESI (m/z): [M+Na]
+
 calcd for [C29H46N2O7NaS]
+
: 589.2923, found: 
589.2924. 
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4 Appendix 
4.1 NMR Spectra 
Rifamycin S (9) 
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Rifamycin W (24) 
 
 
 
 
166 
 
Tetraketide 42 
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Tetraketide 67  
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Tetraketide 68 
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Tetraketide 87 
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Tetraketide 88 
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Tetraketide 89 
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Tetraketide 90 
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Tetraketide 91 
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Tetraketide 92 
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Tetraketide 93 
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Tetraketide 96 
 
 
 
 
 
177 
 
Tetraketide 102 
 
 
 
 
178 
 
3-Acetamido-2-hydroxybenzamide (103) 
 
 
 
 
 
179 
 
3-Azido-2-hydroxybenzamide (104) 
 
 
 
 
 
180 
 
Methyl 3-(bromomethyl)-5-hydroxybenzoate (49) 
 
 
 
 
 
181 
 
Methyl 3-[(1,3-dioxoisoindolin-2-yl)methyl]-5-hydroxybenzoate (52) 
 
 
 
 
 
182 
 
Methyl 3-[(tert-butyldiphenylsilyl)oxy]-5-[(1,3-dioxoisoindolin-2-yl)methyl]benzoate (51) 
 
 
 
 
 
183 
 
3-(Aminomethyl)-5-hydroxybenzoic acid (53) 
 
 
 
 
 
184 
 
Methyl 3-(bromomethyl)-5-(tert-butyldiphenylsilyloxy)benzoate (50) 
 
 
 
 
 
185 
 
3-Amino-2-fluorobenzoic Acid (55) 
 
 
 
 
186 
 
Methyl 3-azido-2-hydroxybenzoate (62) 
 
 
 
 
 
187 
 
3-Azido-2-hydroxybenzoic acid (63) 
 
 
 
 
 
188 
 
(3S,4R,5S,7R)-8-[3-(tert-Butoxycarbonylamino)-5-(tert-butyldiphenylsiloxy)-phenyl]-4-
hydroxy-5-methoxy-3,7-dimethyl-oct-2-en (148) 
 
 
 
 
189 
 
(3S,4S)-7-(tert-Butyldimethylsilyloxy)-4-methoxy-2-methylhept-1-en-3-ol (149) 
 
 
 
 
 
190 
 
(R)-Mosher Ester (180a) 
 
(S)-Mosher Ester (180b) 
 
 
 
191 
 
(3R,4R)-7-(tert-Butyldimethylsilyloxy)-4-methoxy-2-methylhept-1-en-3-ol (150b) 
 
 
 
 
 
192 
 
(R)-7-(tert-Butyldimethylsilyloxy)-4-methoxy-2-methylhept-1-en-3-one (183) 
 
 
 
 
 
193 
 
(3S,4R)-7-(tert-Butyldimethylsilyloxy)-4-methoxy-2-methylhept-1-en-3-ol (150a) 
 
 
 
 
 
194 
 
Silylated polyol 211 
 
 
 
 
 
195 
 
TBS-deprotected polyol 197 
 
 
 
 
 
196 
 
Polyol 198 
 
 
 
 
 
197 
 
TES-protected polyol 199 
 
 
 
 
 
198 
 
Silylated aldehyde 200 
 
 
 
 
 
199 
 
Silylated SNAc ester 201 
 
 
 
 
 
200 
 
SNAc ester 137 
 
 
 
 
 
201 
 
4.2 MS Data of Detoxification Products 
In most fermentations formation of “detoxification” products occurred. Either the 
(amino)benzoic acids were N-acylated or the carboxylic acid was transformed into the amide. 
 
Mutasynthons Detoxification Products HRMS data 
 
 
 
 
 
[M+H]+  
calcd for [C9H10NO4]
+: 196.0610 
found: 196.0612 
tR = 1.23 min 
 
 
 
 
 
 
 
 
 
 
 
 
[M+H]+ 
calcd for [C9H10BrN2O2]
+: 
256.9926 
found: 256.9932 
tR = 1.9 min 
 
 
 
 
[M+H]+ 
calcd for [C7H8BrN2O]
+: 214.9820 
found: 214.9820 
tR = 2.1 min 
 
 
 
 
 
 
[M+H]+  
calcd for [C10H13N2O3]
+: 209.0926 
found: 209.0929 
tR = 1.35 min 
 
 
 
 
 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C9H10FN2O2]
+: 197.0726 
found: 197.0733 
tR = 1.83 min 
 
 
 
 
202 
 
 
 
 
 
[M+H]+  
calcd for [C7H8FN2O]
+: 155.0621 
found: 155.0629 
tR = 1.57 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[M-H]
−
 
calcd for [C9H9N2O3]
-: 193.0619 
found: 193.0605 
tR = 1.9 min 
 
 
 
 
[M-H]
−
 
calcd for [C9H8NO4]
-: 194.0459 
found: 194.0454 
tR = 2.1 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[M-H]
−
 
calcd for [C9H9N2O3]
-: 193.0619 
found: 193.0612 
tR = 1.9 min 
 
 
 
 
 
 
 
 
[M+H]+ 
calcd for [C7H7N4O2]
+: 179.0569 
found: 179.0560 
[M-H]
−
 
calcd for [C7H5N4O2]
-: 177.0418 
found: 177.0410 
tR = 1.92 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C7H8NO2]
+: 138.0555 
found: 138.0565 
tR = 1.62 min 
 
 
 
 
203 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C9H11N2O3]
+: 179.0821 
found: 179.0825 
tR = 1.26 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C7H8N3O3]
+: 182.0566 
found: 182.0570 
tR = 2.17 min 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C7H8N3O3]
+: 182.0566 
found: 182.0567 
tR = 1.85 min 
 
 
 
 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C7H9N2O]
+: 137.0715 
found: 137.0716 
tR = 0.35 min 
 
 
 
 
[M+H]+  
calcd for [C9H11N2O2]
+: 179.0821 
found: 179.0821 
tR = 0.93 min 
 
 
 
 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C7H8N3O3]
+: 182.0566 
found: 182.0565 
tR = 1.84 min 
 
204 
 
 
 
 
 
 
[M+H]+  
calcd for [C9H10FN2O2]
+: 197.0726 
found: 197.0723 
tR = 1.85 min 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C7H8N3O3]
+: 182.0566 
found: 182.0563 
tR = 1.83 min 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C10H12N5O2]
+: 234.0991 
found: 234.0990 
tR = 2.0 min 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C9H10FN2O2]
+: 197.0726 
found: 197.0722 
tR = 2.0 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
[M+H]+  
calcd for 
[C10H10F3N2O2]
+: 247.0694 found: 
247.0688 
tR = 2.4 min 
 
 
 
 
[M+H]+  
calcd for [C8H8F3N2O]
+: 205.0589 
found: 205.0592 
tR = 2.2 min 
205 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C10H10N3O2]
+: 204.0773 
found: 204.0770 
tR = 1.9 min 
 
 
 
[M+H]+  
calcd for [C10H9N2O3]
+: 205.0613 
found: 205.0610 
tR = 2.0 min 
 
 
 
 
 
[M+H]+  
calcd for [C11H12N2O4]
+: 237.0875 
found: 237.0881 
tR = 2.1 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C10H13N2O3]
+: 209.0926 
found: 209.0921 
tR = 1.05 min 
 
 
 
 
 
 
[M+H]+  
calcd for [C10H12NO4]
+: 210.0766 
found: 210.0775 
tR = 1.12 min 
 
 
 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C9H10FN2O2]
+: 197.0726 
found: 197.0721 
tR = 1.8 min 
206 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C9H9FNO3]
+: 198.0566 
found: 198.0570 
tR = 2.0 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C7H8NO3]
+: 154.0504 
found: 154.0508 
tR = 1.21 min 
 
 
 
 
 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C9H11N2O3]
+: 195.0770 
found: 195.0768 
[M-H]-  
calcd for [C9H9N2O3]
-: 193.0619 
found: 193.0610 
tR = 1.6 min 
 
 
 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C7H7N4O2]
+: 179.0569 
found: 179.0559 
tR = 2.1 min 
 
 
 
 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C7H7N2O4]
+: 183.0406 
found: 183.0405 
tR = 2.0 min 
 
 
 
 
 
 
207 
 
 
 
 
 
 
 
 
[M+H]+  
calcd for [C7H8N3O3]
+: 182.0566 
found: 182.0567 
tR = 1.8 min 
 
 
 
 
[M+H]+  
calcd for [C9H10N3O4]
+: 224.0671 
found: 224.0670 
tR = 2.1 min 
 
 
 
 
[M+H]+  
calcd for [C9H9N2O5]
+: 225.0511 
found: 225.0518 
tR = 2.4 min 
 
 
 
 
 
 
 
 
 
 
 
208 
 
 
209 
 
4.3 List of Abbreviations 
[α]20D   specific optical rotation 
Å   angstrom 
Ac   acetyl 
ACP   acyl carrier protein 
AHBA   3-amino-5-hydroxybenzoic acid 
AminoDAHP  3,4-dideoxy-4-amino-D-arabino-heptulosinic acid 7-phosphate 
AminoDHQ  5-deoxy-5-amino-3-dehydroquinic acid 
AminoDHS  5-deoxy-5-amino-3-dehydroshikimic acid 
Ar   aryl 
AT   acyltransferase 
ATP   adenosine triphosphate 
b   NMR: broad 
Boc   tert-butoxycarbonyl 
t-Bu   tert-butyl 
CBS   Corey-Bakshi-Shibata 
c   concentration 
ca   circa 
calcd   calculated 
CHCl3   chloroform 
CoA   coenzyme A 
COSY   homonuclear correlation spectroscopy 
CSA   camphorsulfonic acid 
DDQ   2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
dest.   distilled 
DET   diethyl tartrate 
DH   dehydratase 
DIPEA  N,N-diisopropylethylamine 
DIBAL  diisobutylaluminium hydride 
DMAP  4-dimethylaminopyridine 
DMDARSV  demethyl-deacetyl-rifamycin SV 
DMF   N,N-dimethylformamide 
DMP   Dess-Martin periodinane 
DMRSV  27-O-demethylrifamycin SV 
DMSO  dimethylsulfoxide 
DNA   deoxyribonucleic acid 
d.r.   diastereomeric ratio 
EDC   N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
ER   enoyl reductase 
ESI   electrospray ionization 
Et3N   triethylamine 
Et   ethyl 
Et2O   diethyl ether 
EtOAc   ethyl acetate 
EtOH   ethanol 
eq.   equivalent 
g   gram 
gdm   gene in the geldanamycin biosynthesis by Streptomyces hygroscopicus 
Gdm   enzyme in the geldanamycin biosynthesis by  
210 
 
    Streptomyces hygroscopicus 
h   hour 
HCl   hydrochloric acid 
HNO3   nitric acid 
HMBC  heteronuclear multiple bond correlation 
H3PO2   hypophosphorous acid 
HPLC   high performance liquid chromatography 
HRMS   high resolution mass spectrometry 
H2SO4   sulfuric acid 
Hsp90   heat shock protein 90 
HSQC   heteronuclear single quantum coherence 
Hz   hertz 
J   coupling constant 
KR   ketoreductase 
KS   ketosynthase 
L   liter 
LDA   lithium diisopropylamide 
LiAlH4  lithium aluminium hydride 
µ   micro 
M   molar 
mg   milligram 
Me   methyl 
MeCN   acetonitrile 
MeOH   methanol 
MHz   megahertz 
min   minute 
mL   milliliter 
mmol   millimol 
M.p.   melting point 
MS   mass spectrometry or molecular sieves 
MSMS  tandem mass spectrometry 
MTPA   α-methoxy-α-(trifluoromethyl)phenylacetyl 
m/z   MS: mass/charge 
n-BuLi  n-butyllithium 
NMR   nuclear magnetic resonance spectroscopy 
NRPS   non-ribosomal peptide synthetase 
PE   petroleum ether 
Ph   phenyl 
PKS   polyketide synthase 
PMB   para-methoxybenzyl 
PPh3   triphenylphosphine 
ppm   parts per million 
PPTS   pyridinium p-toluenesulfonate 
quant.   quantitative 
rpm   rounds per minute 
RT   room temperature 
SAR   structure-activity relationship 
SNAC   N-acetylcysteamine 
T   temperature 
t   time 
211 
 
tR   retention time 
TBAF   tetra-n-butylammonium fluoride 
TBDPS  tert-butyldiphenylsilyl 
TBS   tert-butyldimethylsilyl 
TBSOTf  tert-butyldimethylsilyl trifluoromethanesulfonate 
TES   triethylsilyl 
TESOTf  triethylsilyl trifluoromethanesulfonate 
TFA   trifluoroacetic acid 
THF   tetrahydrofuran 
TLC   thin-layer chromatography 
UDP   uridine diphosphate 
UV   ultraviolet 
δ   NMR chemical shift 
Δ   heating under refluxing conditions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
212 
 
5 References 
[1] Q. Kang, Y. Shen, L. Bai, Nat. Prod. Rep. 2012, 29, 243–263. 
[2] H. G. Floss, T.-W. Yu, Chem. Rev. 2005, 105, 621–632. 
[3] H. G. Floss, T.-W. Yu, K. Arakawa, J. Antibiot. 2011, 64, 35–44. 
[4] I. E. Wrona, V. Agouridas, J. S. Panek, C. R Chim. 2008, 11, 1483–1522. 
[5] C.-G. Kim, A. Kirschning, P. Bergon, P. Zhou, E. Su, B. Sauerbrei, S. Ning, Y. Ahn, 
M. Breuer, E. Leistner, et al., J. Am. Chem. Soc. 1996, 118, 7486–7491. 
[6] H. G. Floss, Nat. Prod. Rep. 1997, 14, 433. 
[7] C.-G. Kim, T.-W. Yu, C. B. Fryhle, S. Handa, H. G. Floss, J. Biol. Chem. 1998, 273, 
6030–6040. 
[8] O. Ghisalba, H. Fuhrer, W. J. Richter, S. Moss, J. Antibiot. 1981, 34, 58–63. 
[9] J. Kibby, R. W. Rickards, J. Antibiot. 1981, 34, 605–607. 
[10] R. W. Rickards, J. Kibby, I. A. McDonald, J. Chem. Soc., Chem. Commun. 1980, 768–
769. 
[11] W. Rickards, M. G. Anderson, J. Kibby, J. M. Rothschild, J. Chem. Soc., Chem. 
Commun. 1980, 1277–1278. 
[12] T. S. Wu, J. Duncan, S. W. Tsao, C. J. Chang, P. J. Keller, H. G. Floss, J. Nat. Prod. 
1987, 50, 108–118. 
[13] A. L. Staley, K. L. Rinehart, J. Antibiot. 1991, 44, 218–224. 
[14] J. P. Lee, S.-W. Tsao, C.-J. Chang, X.-G. He, H. G. Floss, Can. J. Chem. 1994, 72, 
182–187. 
[15] U. Hornemann, J. H. Eggert, D. P. Honor, J. Chem. Soc., Chem. Commun. 1980, 11–
13. 
[16] R. J. White, E. Martinelli, G. G. Gallo, G. Lancini, P. Beynon, Nature 1973, 243, 273–
277. 
[17] M. S. Bolhuis, P. N. Panday, A. D. Pranger, J. G. W. Kosterink, J.-W. C. Alffenaar, 
Pharmaceutics 2011, 3, 865–913. 
[18] B. P. Conlon, E. S. Nakayasu, L. E. Fleck, M. D. LaFleur, V. M. Isabella, K. Coleman, 
S. N. Leonard, R. D. Smith, J. N. Adkins, K. Lewis, Nature 2013, 503, 365–370. 
[19] M. R. K. Ali, S. R. Panikkanvalappil, M. A. El-Sayed, J. Am. Chem. Soc. 2014, 136, 
4464–4467. 
[20] E. A. Campbell, N. Korzheva, A. Mustaev, K. Murakami, S. Nair, A. Goldfarb, S. A. 
Darst, Cell 2001, 104, 901–912. 
213 
 
[21] G. Zhang, E. A. Campbell, L. Minakhin, C. Richter, K. Severinov, S. A. Darst, Cell 
1999, 98, 811–824. 
[22] A. Sippel, G. Hartmann, Biochim. Biophys. Acta 1968, 157, 218–9. 
[23] H. Umezawa, S. Mizuno, H. Yamasaki, K. Nitta, J. Antibiot. 1968, 21, 234–236. 
[24] P. R. August, L. Tang, Y. J. Yoon, S. Ning, R. Müller, T. Yu, M. Taylor, D. Hoffmann, 
C. Kim, X. Zhang, et al., Chem. Biol. 1998, 5, 69–79. 
[25] T. Schupp, FEMS Microbiol. Lett. 1998, 159, 201–207. 
[26] C. R. Hutchinson, D. Hunziker, C. Khosla, Z. Hu, Microbiology 1999, 145, 2335–
2341. 
[27] T.-W. Yu, Y. Shen, Y. Doi-Katayama, L. Tang, C. Park, B. S. Moore, C. Richard 
Hutchinson, H. G. Floss, Proc. Natl. Acad. Sci. 1999, 96, 9051–9056. 
[28] T. Schupp, L. Oberer, R. Traber, W. Schilling, C. Toupet, A. Stratmann, Microbiology 
1999, 145, 3365–3375. 
[29] H. G. Floss, T. W. Yu, Curr. Opin. Chem. Biol. 1999, 3, 592–597. 
[30] J. Xu, E. Wan, C.-J. Kim, H. G. Floss, T. Mahmud, Microbiology 2005, 151, 2515–
2528. 
[31] O. Ghisalba, P. Traxler, J. Nuesch, J. Antibiot. 1978, 31, 1124–1131. 
[32] M. G. Anderson, D. Monypenny, R. W. Rickards, J. M. Rothschild, J. Chem. Soc. 
Chem. Commun. 1989, 311, 311. 
[33] A. Stratmann, T. Schupp, C. Toupet, W. Schilling, L. Oberer, R. Traber, J. Antibiot. 
2002, 55, 396–406. 
[34] J. Xu, T. Mahmud, H. G. Floss, Arch. Biochem. Biophys. 2003, 411, 277–288. 
[35] H. Yuan, W. Zhao, Y. Zhong, J. Wang, Z. Qin, X. Ding, G. P. Zhao, Acta Biochim. 
Biophys. Sin. 2011, 43, 948–956. 
[36] O. Ghisalba, R. Roos, T. Schupp, J. Nüesch, J. Antibiot. 1982, 35, 74–80. 
[37] W. Zhao, Y. Zhong, H. Yuan, J. Wang, H. Zheng, Y. Wang, X. Cen, F. Xu, J. Bai, X. 
Han, et al., Cell Res. 2010, 20, 1096–1108. 
[38] M. C. Wilson, T. M. Gulder, T. Mahmud, B. S. Moore, J. Am. Chem. Soc. 2010, 132, 
12757–12765. 
[39] A. T. Keatinge-Clay, Nat. Prod. Rep. 2012, 29, 1050. 
[40] A. T. Keatinge-Clay, Chem. Biol. 2007, 14, 898–908. 
[41] A. T. Keatinge-Clay, R. M. Stroud, Structure 2006, 14, 737–748. 
[42] J. Zheng, C. A. Taylor, S. K. Piasecki, A. T. Keatinge-Clay, Structure 2010, 18, 913–
922. 
214 
 
[43] J. Zheng, A. T. Keatinge-Clay, J. Mol. Biol. 2011, 410, 105–117. 
[44] Y.-O. You, C. Khosla, D. E. Cane, J. Am. Chem. Soc. 2013, 135, 7406–7409. 
[45] C. R. Valenzano, Y.-O. You, A. Garg, A. Keatinge-Clay, C. Khosla, D. E. Cane, J. Am. 
Chem. Soc. 2010, 132, 14697–14699. 
[46] D. Gay, Y. O. You, A. Keatinge-Clay, D. E. Cane, Biochemistry 2013, 52, 8916–8928. 
[47] A. Kirschning, F. Hahn, Angew. Chem. Int. Ed. 2012, 51, 4012–4022. 
[48] S. Weist, R. D. Süssmuth, Appl. Microbiol. Biotechnol. 2005, 68, 141–150. 
[49] K. J. Weissman, Trends Biotechnol. 2007, 25, 139–142. 
[50] A. Kirschning, F. Taft, T. Knobloch, Org. Biomol. Chem. 2007, 5, 3245. 
[51] A. J. Birch, Pure Appl. Chem. 1963, 7, 527. 
[52] K. L. Rinehart, Pure Appl. Chem. 1977, 49, 1361–1384. 
[53] S. Eichner, H. G. Floss, F. Sasse, A. Kirschning, ChemBioChem 2009, 10, 1801–1805. 
[54] J. Hermane, I. Bułyszko, S. Eichner, F. Sasse, W. Collisi, A. Poso, E. Schax, J. G. 
Walter, T. Scheper, K. Kock, et al., ChemBioChem 2015, 16, 302–311. 
[55] F. Taft, S. Eichner, T. Knobloch, K. Harmrolfs, J. Hermane, A. Kirschning, Synlett 
2012, 23, 1416–1426. 
[56] K. Harmrolfs, L. Mancuso, B. Drung, F. Sasse, A. Kirschning, Beilstein J. Org. Chem. 
2014, 10, 535–543. 
[57] L. Mancuso, G. Jürjens, J. Hermane, K. Harmrolfs, S. Eichner, J. Fohrer, W. Collisi, F. 
Sasse, A. Kirschning, Org. Lett. 2013, 15, 4442–4445. 
[58] S. Eichner, T. Knobloch, H. G. Floss, J. Fohrer, K. Harmrolfs, J. Hermane, A. Schulz, 
F. Sasse, P. Spiteller, F. Taft, et al., Angew. Chem. Int. Ed. 2012, 51, 752–757. 
[59] T. Knobloch, G. Dräger, W. Collisi, F. Sasse, A. Kirschning, Beilstein J. Org. Chem. 
2012, 8, 861–869. 
[60] T. Knobloch, K. Harmrolfs, F. Taft, B. Thomaszewski, F. Sasse, A. Kirschning, 
ChemBioChem 2011, 12, 540–547. 
[61] K. Harmrolfs, M. Brünjes, G. Dräger, H. G. Floss, F. Sasse, F. Taft, A. Kirschning, 
ChemBioChem 2010, 11, 2517–2520. 
[62] F. Taft, M. Brünjes, T. Knobloch, H. G. Floss, A. Kirschning, J. Am. Chem. Soc. 2009, 
131, 3812–3813. 
[63] F. Taft, M. Brünjes, H. G. Floss, N. Czempinski, S. Grond, F. Sasse, A. Kirschning, 
ChemBioChem 2008, 9, 1057–1060. 
[64] T. Kubota, M. Brünjes, T. Frenzel, J. Xu, A. Kirschning, H. G. Floss, ChemBioChem 
2006, 7, 1221–1225. 
215 
 
[65] H. G. Menzella, T. Tran, J. R. Carney, J. Lau-Wee, J. Galazzo, C. D. Reeves, C. 
Carreras, S. Mukadam, S. Eng, Z. Zhong, et al., J. Med. Chem. 2009, 52, 1518–1521. 
[66] W. Kim, J. S. Lee, D. Lee, X. F. Cai, J. C. Shin, K. Lee, C.-H. Lee, S. Ryu, S.-G. Paik, 
J. J. Lee, et al., ChemBioChem 2007, 8, 1491–1494. 
[67] I. V. Hartung, M. A. Rude, N. A. Schnarr, D. Hunziker, C. Khosla, J. Am. Chem. Soc. 
2005, 127, 11202–11203. 
[68] A. Klenge, Identifikation, Isolierung Und Massen- Spektrometrische Analyse von 
Biosynthese-Nebenprodukten Bakterieller Sekundärmetabolite, Leibniz Universität 
Hannover, 2012. 
[69] I. Bułyszko, G. Dräger, A. Klenge, A. Kirschning, Chem. Eur. J. 2015, 21, 19231–
19242. 
[70] S. Eichner, Darstellung Neuer Ansamycin-Derivate Über Mutasynthese in 
Kombination Mit Semisynthese Zur Erlangung Des Grades, Leibniz Universität 
Hannover, 2011. 
[71] K. Goren, T. Kehat, M. Portnoy, Adv. Synth. Catal. 2009, 351, 59–65. 
[72] L. Ferrins, R. Rahmani, M. L. Sykes, A. J. Jones, V. M. Avery, E. Teston, B. 
Almohaywi, J. Yin, J. Smith, C. Hyland, et al., Eur. J. Med. Chem. 2013, 66, 450–465. 
[73] P. K. Mandal, J. S. McMurray, J. Org. Chem. 2007, 72, 6599–6601. 
[74] Y. Yan, B. Qin, Y. Shu, X. Chen, Y. K. Yip, D. Zhang, H. Su, H. Zeng, Org. Lett. 
2009, 11, 1201–1204. 
[75] D. Hunziker, T. W. Yu, C. R. Hutchinson, H. G. Floss, C. Khosla, J. Am. Chem. Soc. 
1998, 120, 1092–1093. 
[76] S. Eichner, T. Eichner, H. G. Floss, J. Fohrer, E. Hofer, F. Sasse, C. Zeilinger, A. 
Kirschning, J. Am. Chem. Soc. 2012, 134, 1673–1679. 
[77] S. J. Admiraal, C. T. Walsh, C. Khosla, Biochemistry 2001, 40, 6116–6123. 
[78] K. H. Almabruk, W. Lu, Y. Li, M. Abugreen, J. X. Kelly, T. Mahmud, Org. Lett. 2013, 
15, 1678–1681. 
[79] L. F. Zerilli, M. Landi, G. G. Gallo, K. H. Maurer, U. Rapp, Biol. Mass Spectrom. 
1975, 2, 307–312. 
[80] K. Vékey, D. M. F. Edwards, L. F. Zerilli, J. Chromatogr. A 1989, 474, 317–327. 
[81] W. A. Korfmacher, J. Bloom, M. I. Churchwell, T. A. Getek, E. B. Hansen, K. T. 
McManus, J. Chromatogr. Sci. 1993, 31, 498–501. 
[82] A. K. Hewavitharana, P. N. Shaw, T. K. Kim, J. A. Fuerst, J. Chromatogr. B Anal. 
Technol. Biomed. Life Sci. 2007, 852, 362–366. 
216 
 
[83] G. Jürjens, Synthese Eines Ansamycin Hybrids - Studien Zur Identifikation Der 
Ungewöhnlichen Azidreduktaseaktivität in A. pretiosum, Leibniz Universität 
Hannover, 2014. 
[84] C. Oberhauser, Studien Zur Vermuteten Azidreduktaseaktivität in A. pretiosum, 
Leibniz Universität Hannover, 2014. 
[85] H.-H. Lu, A. Raja, R. Franke, D. Landsberg, F. Sasse, M. Kalesse, Angew. Chem. 
2013, 125, 13791–13795. 
[86] R. Perez-Jimenez, A. Inglés-Prieto, Z.-M. Zhao, I. Sanchez-Romero, J. Alegre-
Cebollada, P. Kosuri, S. Garcia-Manyes, T. J. Kappock, M. Tanokura, A. Holmgren, et 
al., Nat. Struct. Mol. Biol. 2011, 18, 592–596. 
[87] Z. Xiao, L. Li, Y. Li, W. Zhou, J. Cheng, F. Liu, P. Zheng, Y. Zhang, Y. Che, Cell 
Death Dis. 2014, 5, e1241. 
[88] S. Y. Quah, M. S. Tan, Y. H. Teh, J. Stanslas, Pharmacol. Ther. 2016, 162, 35–57. 
[89] T. W. Sam, C. Sew-Yeu, S. Matsjeh, E. K. Gan, D. Razak, A. L. Mohamed, 
Tetrahedron Lett. 1987, 28, 2541–2544. 
[90] J. Hlubucek, A. Robertson, Aust. J. Chem. 1967, 20, 2199. 
[91] T. V. Hansen, Tetrahedron: Asymmetry 2002, 13, 547–550. 
[92] M. Quitschalle, M. Christmann, U. Bhatt, M. Kalesse, Tetrahedron Lett. 2001, 42, 
1263–1265. 
[93] U. Ramulu, S. Rajaram, D. Ramesh, K. Suresh Babu, Tetrahedron: Asymmetry 2015, 
26, 928–934. 
[94] A. Goel, V. J. Ram, Tetrahedron 2009, 65, 7865–7913. 
[95] J. Franke, S. Eichner, C. Zeilinger, A. Kirschning, Nat. Prod. Rep. 2013, 30, 1299. 
[96] W. Xu, L. Neckers, Clin. Cancer Res. 2007, 13, 1625–1629. 
[97] S. Chaudhury, T. R. Welch, B. S. J. Blagg, ChemMedChem 2006, 1, 1331–1340. 
[98] L. H. Pearl, C. Prodromou, Annu. Rev. Biochem. 2006, 75, 271–294. 
[99] F. U. Hartl, Science 2002, 295, 1852–1858. 
[100] K. Richter, J. Buchner, J. Cell. Physiol. 2001, 188, 281–290. 
[101] J. C. Young, I. Moarefi, F. U. Hartl, J. Cell Biol. 2001, 154, 267–274. 
[102] A. Maloney, P. Workman, Expert Opin. Biol. Ther. 2002, 2, 3–24. 
[103] M. P. Goetz, Ann. Oncol. 2003, 14, 1169–1176. 
[104] W. Luo, W. Sun, T. Taldone, A. Rodina, G. Chiosis, Mol. Neurodegener. 2010, 5, 24. 
[105] R. S. Gupta, Mol. Biol. Evol. 1995, 12, 1063–73. 
[106] A. Subbarao Sreedhar, É. Kalmár, P. Csermely, Y.-F. Shen, FEBS Lett. 2004, 562, 11–
217 
 
15. 
[107] D. Hanahan, R. A. Weinberg, Cell 2000, 100, 57–70. 
[108] M. A. Biamonte, R. Van de Water, J. W. Arndt, R. H. Scannevin, D. Perret, W.-C. Lee, 
J. Med. Chem. 2010, 53, 3–17. 
[109] S. Omura, Y. Iwai, Y. Takahashi, N. Sadakane, A. Nakagawa, O. Hithoshi, Y. 
Hasegawa, T. Ikai, J. Antibiot. 1979, 32, 255–261. 
[110] L.-Z. Lin, G. Blaskó, G. A. Cordell, J. Nat. Prod. 1988, 51, 1161–1165. 
[111] M. Muroi, K. Haibara, M. Asai, K. Kamiya, T. Kishi, Tetrahedron 1981, 37, 1123–
1130. 
[112] C. Deboer, P. A. Meulman, R. J. Wnuk, D. H. Peterson, J. Antibiot. 1970, 23, 442–447. 
[113] C. Garnier, D. Lafitte, P. O. Tsvetkov, P. Barbier, J. Leclerc-Devin, J.-M. Millot, C. 
Briand, A. A. Makarov, M. G. Catelli, V. Peyrot, J. Biol. Chem. 2002, 277, 12208–
12214. 
[114] R. R. A. Kitson, C. J. Moody, J. Org. Chem. 2013, 78, 5117–5141. 
[115] S. M. Roe, C. Prodromou, R. O’Brien, J. E. Ladbury, P. W. Piper, L. H. Pearl, J. Med. 
Chem. 1999, 42, 260–266. 
[116] J. G. Supko, R. L. Hickman, M. R. Grever, L. Malspeis, Cancer Chemother. 
Pharmacol. 1995, 36, 305–315. 
[117] Y. Fukuyo, C. R. Hunt, N. Horikoshi, Cancer Lett. 2010, 290, 24–35. 
[118] E. R. Glaze, A. L. Lambert, A. C. Smith, J. G. Page, W. D. Johnson, D. L. McCormick, 
A. P. Brown, B. S. Levine, J. M. Covey, M. J. Egorin, et al., Cancer Chemother. 
Pharmacol. 2005, 56, 637–647. 
[119] M. J. Egorin, E. G. Zuhowski, D. M. Rosen, D. L. Sentz, J. M. Covey, J. L. Eiseman, 
Cancer Chemother. Pharmacol. 2001, 47, 291–302. 
[120] J. R. Porter, J. Adams, R. Ahn, V. Ammoscato, B. Arsenault, B. C. Austad, G. Baker, 
J. Basuki, M. R. Booth, M. J. Campbell, et al., Drug Dev. Res. 2010, 71, 429–438. 
[121] M. Hollingshead, M. Alley, A. M. Burger, S. Borgel, C. Pacula-Cox, H.-H. Fiebig, E. 
A. Sausville, Cancer Chemother. Pharmacol. 2005, 56, 115–125. 
[122] S. Li, S. Ni, L. Wu, L. Li, B. Jiang, H. Wang, G. Sun, M. Gan, J. Li, W. He, et al., J. 
Nat. Prod. 2013, 76, 969–973. 
[123] X. Liu, J. Li, S. Ni, L. Wu, H. Wang, L. Lin, W. He, Y. Wang, J. Antibiot. 2011, 64, 
519–522. 
[124] L. Ling, S. Ni, L. Wu, Y. Wang, Y. Wang, P. Tao, W. He, X. Wang, Biosci. 
Biotechnol. Biochem. 2011, 75, 2042–2045. 
218 
 
[125] W. Guo, P. Reigan, D. Siegel, D. Ross, Drug Metab. Dispos. 2008, 36, 2050–2057. 
[126] R. L. Cysyk, R. J. Parker, J. J. Barchi, P. S. Steeg, N. R. Hartman, J. M. Strong, Chem. 
Res. Toxicol. 2006, 19, 376–381. 
[127] M.-Q. Zhang, S. Gaisser, M. Nur-E-Alam, L. S. Sheehan, W. A. Vousden, N. Gaitatzis, 
G. Peck, N. J. Coates, S. J. Moss, M. Radzom, et al., J. Med. Chem. 2008, 51, 5494–
5497. 
[128] S. Chandarlapaty, A. Sawai, Q. Ye, A. Scott, M. Silinski, K. Huang, P. Fadden, J. 
Partdrige, S. Hall, P. Steed, et al., Clin. Cancer Res. 2008, 14, 240–248. 
[129] L. Whitesell, E. G. Mimnaugh, B. De Costa, C. E. Myers, L. M. Neckers, Proc. Natl. 
Acad. Sci. 1994, 91, 8324–8328. 
[130] C. E. Stebbins, A. A. Russo, C. Schneider, N. Rosen, F. U. Hartl, N. P. Pavletich, Cell 
1997, 89, 239–250. 
[131] A. Rascher, Z. Hu, N. Viswanathan, A. Schirmer, R. Reid, W. C. Nierman, M. Lewis, 
C. R. Hutchinson, FEMS Microbiol. Lett. 2003, 218, 223–230. 
[132] A. Rascher, Z. Hu, G. O. Buchanan, R. Reid, C. R. Hutchinson, Appl. Environ. 
Microbiol. 2005, 71, 4862–4871. 
[133] Y.-S. Hong, D. Lee, W. Kim, J.-K. Jeong, C.-G. Kim, J. K. Sohng, J.-H. Lee, S.-G. 
Paik, J. J. Lee, J. Am. Chem. Soc. 2004, 126, 11142–11143. 
[134] S. Yuzawa, C. H. Eng, L. Katz, J. D. Keasling, Biochemistry 2013, 52, 3791–3793. 
[135] J. Hermane, Synthetische Und Mutasynthetische Zugänge Zu Neuen Hsp90 
Inhibitoren, Leibniz Universität Hannover, 2013. 
[136] M. Vogt, Umpolung von Allyl-Palladium-Komplexen Und Anwendung in Der 
Synthese von Naturstoff-Fragmenten, Leibniz Universität Hannover, 2010. 
[137] S. V. Ceylan, Entwicklung Eines Induktionsheizkonzepts Für Durchflussreaktoren Und 
Untersuchungen Zur Palladium-Katalysierten Umpolungsallylierung, Leibniz 
Universität Hannover, 2011. 
[138] A. M. Becker, R. W. Rickards, R. F. C. Brown, Tetrahedron 1983, 39, 4189–4192. 
[139] F. Taft, Studien Zur Ansamitocin-Biosynthese in Actinosynnema pretiosum, Leibniz 
Universität Hannover, 2009. 
[140] M. Brünjes, Studien Zur Chemoenzymatischen Synthese Und Biosynthese von 
Maytansinoid-Analoga, 2006. 
[141] T. Frenzel, M. Brünjes, M. Quitschalle, A. Kirschning, Org. Lett. 2006, 8, 135–8. 
[142] I. E. Wrona, A. E. Gabarda, G. Evano, J. S. Panek, J. Am. Chem. Soc. 2005, 127, 
15026–15027. 
219 
 
[143] C. Herdeis, Synthesis 1986, 1986, 232–233. 
[144] G. D. Joly, E. N. Jacobsen, Org. Lett. 2002, 4, 1795–1798. 
[145] D. Ebner, J. Bagdanoff, E. Ferreira, R. McFadden, D. Caspi, R. Trend, B. Stoltz, Chem. 
Eur. J. 2009, 15, 12978–12992. 
[146] T. R. Hoye, C. S. Jeffrey, F. Shao, Nat. Protoc. 2007, 2, 2451–2458. 
[147] J. Leonard, G. Ryan, Tetrahedron Lett. 1987, 28, 2525 – 2528. 
[148] E. J. Corey, C. J. Helal, Angew. Chem. Int. Ed. 1998, 37, 1986 – 2012. 
[149] E. J. Corey, C. J. Helal, Angew. Chem. 1998, 110, 2092 – 2118. 
[150] F. Yang, L. Feng, N. Wang, X. Liu, J. Li, Y. Shen, Tetrahedron 2013, 69, 9463–9468. 
[151] T. Hirose, T. Sunazuka, S. Tsuchiya, T. Tanaka, Y. Kojima, R. Mori, M. Iwatsuki, S. 
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